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Background
Global ageing
Our population is ageing.1-3 Over the next 30 years, the number of people aged 65 years 
and older is expected to double from 506 million (7% of the world’s population) to 1.3 
billion people (14% of the world’s population).4 During the same time period the number 
of older adults aged 80 years and over (i.e. the oldest old) is projected to increase by 
233%.4 By 2050, 80% of older adults will be living in low- and middle income countries.5 
Improvements in healthcare, hygiene and sanitation, and better living standards, in 
combination with declining fertility rates, are perhaps the main factors behind the 
observed trend of population ageing.6 
While people are living longer in all parts of the world, evidence suggests that these 
years are spent in poorer health.7 8 Over the past decades, the main causes of death 
have transitioned from infectious to age-related non-communicable diseases (NCDs), a 
phenomenon which is also referred to as the epidemiologic transition.9 Ischemic heart 
disease, stroke, and diabetes are among the leading causes of premature death today.1 
Disability-adjusted life years (DALYs) are a widely used measure reflecting the combined 
burden of years of life lost due to premature mortality and years lived with disability. 
The total number of DALYs due to NCDs increased from 1.1 billion to 1.5 billion globally 
between 1990 and 2015, whereas the burden of infectious diseases decreased over 
time.10 In 2015, the total DALY burden of NCDs increased mostly because of a rise in 
cardiovascular diseases, cancer, and mental disorders, among other causes.10 The burden 
of NCDs extends beyond morbidity and mortality as it exerts a growing impact on health 
systems, development, and economic circumstances at all levels of society.11-15
What is ageing? 
Though ageing and the development of disease can coincide, one should understand 
that they are not inseparably linked. Ageing is not a disease, though it is often perceived 
as such.16 Ageing is a multifactorial process characterized by the progressive loss of 
physiological integrity and decreasing fertility with advancing age, which could lead to 
impaired function and increased vulnerability to death.17 Therefore, ageing research and 
the study of disease and disability can go hand in hand but could also be viewed as two 
separate fields of work.
The pursuit of health 
The ultimate goal of health care and health systems is to provide people the opportunity 
to spend their lives in good health. However, past and current health research have 
focused mainly on risk factors, diseases, and mortality, and only marginally on health or 
protective factors. This approach may limit our overall understanding of health and the 
factors that are associated with obtaining, maintaining, and improving health. Particularly 
in the elderly, the study of disease and disability only minimally reflects the impact it may 
have on older adult’s lives.18 For example, self-perceived health can differ substantially 
from what is measured objectively in the sense that even the diseased and disabled 
can report high levels of quality of life.19 20 Furthermore, multimorbidity (suffering from 
more than 1 chronic disease at the same time) can have an unfavourable synergistic 
impact on a person’s capacity than you would expect from the summed effect of each 
separate condition.21 A better understanding of healthy ageing is becoming increasingly 
meaningful and has the potential to enhance the lives of individuals and to facilitate the 
development of adequate strategies with regard to the economic and social implications 
of ageing populations.22 So how should we define health?
Definitions of health and its operationalization
The best known definition of health was formulated by the World Health Organization 
(WHO) in 1948: “a state of complete physical, mental, and social well-being and not 
Definitions of health 
Huber et al, 201123 “Health is the ability to adapt and to self-manage in the 
face of social, physical, and emotional challenges.”
Bircher, 200524 “Health is a dynamic state of wellbeing, characterized by 
a physical, mental, and social potential, which satisfies 
the demands of life commensurate with age, culture, 
and personal responsibility. If the potential is insufficient 
to satisfy these demands the state is disease.”
Spencer, 19th century “Health is the perfect adjustment of an organism to its 
environment.”
Definitions of healthy ageing
WHO report on ageing and 
health, 201525
“Healthy ageing is the process of developing and 
maintaining the functional ability that enables well-
being in older age.”
Franco et al, 200926 The Healthy Ageing Phenotype (HAP) can be defined 
as the condition of being alive, while having highly 
preserved functioning metabolic, hormonal, and neuro-
endocrine control systems at the organ, tissue and 
molecular levels.” It is further characterized by a higher 
degree of physiological complexity which translates into 
optimal reserves and biological resilience to respond to 
and accommodate daily stressors.
Rowe and Kahn, 199727 “Successful ageing can be defined as the combination 
of a low probability of disease and disease-related 
disability, high cognitive and physical functional capacity, 
and active engagement with life.”
Table 1. Definitions of health and healthy ageing.
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merely the absence of disease and infirmity”.28 Over time, this definition has become 
unproductive for several reasons. The static nature of the definition is challenged by the 
shift from acute to chronic diseases, making an increasing number of chronically diseased 
permanently ill. Furthermore, although “complete well-being” is a desirable goal, it is 
both hard to achieve and challenging to operationalize. More recent definitions of health 
and healthy ageing have been influenced by the work of sociologist Aaron Antonovsky. 
His theory of salutogenenis (as opposed to pathogenesis) rejects the sharp distinction 
between health and disease and positions individuals along the “health-ease dis-ease 
continuum”.29 The flexibility in this way of thinking resonates in contemporary definitions 
of both health and healthy ageing today (Table 1). 
Within definitions of health, different body systems could be considered subdomains of 
health, such as cardiovascular health or sexual health (Figure 1). The complex physiological 
mechanisms within these subdomains, which can interact with both psychological as 
well as social functioning, can differ between men and women and across stages of life. 
Currently, several definitions for healthy ageing have been formulated and operationalized 
in populations.25-27 30-34 However, to date, measurement of healthy ageing is not performed 
in a standardized manner. It has been suggested that healthy ageing measurement tools 
should include assessment of mental health and self-perceived health on top of the 
Figure 1. Key health domains in men and women.
overrepresented physiological measures,35-37 and that continuum-based tools for healthy 
ageing might better capture the heterogeneity of the phenotype, as opposed to the more 
widely adopted dichotomous approaches.36 38 An example of an effort to operationalize 
health measurement is the concept of cardiovascular health, which was introduced by 
the American Heart Association in 2010.39 The concept of cardiovascular health includes 
ideal levels of 7 metrics, 3 of which are health factors (total cholesterol, fasting glucose, 
and blood pressure) and 4 of which are health behaviours (physical activity at goal, non-
smoking, normal body mass index, and a healthy diet).39 Cardiovascular health has been 
related to different risk factors and diseases of the cardiovascular system and beyond.40-50 
There is a paucity of research that effectively translates definitions of health into 
manageable measures, which could be applied to individuals and populations. Although 
the appreciation of a health-focused approach is increasingly gaining attention, it remains 
to be elucidated how the concepts of health apply to men and women, populations, and 
across stages of life and how health measurement should be operationalized.
A gender-specific perspective
Worldwide, men are outlived by women by 6 to 8 years. However, women generally spend 
these additional years with more disease and disability: ‘men die quicker, women get 
sicker’. This is also referred to as the ‘male-female disability-survival paradox’, which 
describes that women’s longer lives are not necessarily healthy lives.51-53 To date, it is 
not well understood which mechanisms underlie the male-female disability-survival 
paradox. It could be possible that sex-specific gene expression and differential effect 
of sex hormones in men and women underlie this paradox.54 Furthermore, men and 
women differ with regard to their symptom perception and attribution, patient delay 
for consulting health professionals, and over reporting of worse health outcomes in 
women.55-57 Also, less pathognomonic symptom presentation in women may lead to 
diagnostic delays and less timely treatment initiation, which could result in more severe 
consequences in terms of long-term disability.54 It may also be possible that men have 
greater severity of disease, resulting in higher mortality.57 In summary, the observed 
differences between men and women may be explained by the interaction between 
social, psychological, behavioural, and biological factors. 
Although there is enough evidence that men and women are different, by default 
studies still combine men and women in their analyses. Historically, women were even 
excluded from study to prevent biases due to hormonal differences between men and 
women. Moreover, former trials assessing the benefits and harms of medical treatments 
predominantly included men. To some extent this still happens today. For example, in the 
safety evaluations for the approval of flibanserin as a medical treatment for women with 
hypoactive sexual desire disorder, the interaction between flibanserin and alcohol was 
evaluated in 25 persons, of which 23 were men.58 Combining men and women in research 
analyses or extrapolating findings in men to women can result in delayed or wrong 
diagnoses, more severe burden of disease, and wrong treatment choices, particularly in 
women.59 Consequently, this can lead to increased health care spending and preventable 
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mortality.59 Therefore, gender-specific research is needed to adequately support health 
systems to facilitate health for men and women equally. 
A life-course approach in women’s health
Another explanation for the differences in health observed between men and women 
is embedded in the different reproductive challenges and opportunities that men and 
women encounter earlier in life.3 60 61 There is growing support that functioning, disease, 
and health in older adults share common pathways with accumulative life experiences, 
which can start as early as in utero.62 63 Specifically in women, timing of menarche and 
menopause, and number and timing of pregnancies, can greatly affect postmenopausal 
health.64 65 In addition, ovarian function and the decline of ovarian function over time exerts 
effects on long-term health in women that extend beyond the reproductive domain. 
Thus, it has been suggested that reproductive performance in women constitutes a good 
predictor for general health in later life.66 Furthermore, women today spend almost half 
of their lives in postmenopause. Menopause is defined as the permanent loss of ovarian 
function.66 67 The onset of menopause is preceded by the menopausal transition, a period 
during which substantial short and long term alterations in different domains occur. The 
importance of a life-course approach in women’s health has only recently been adopted 
in guidelines for women’s health,68 69 but studies are still scarce. To what extent earlier life 
experiences, such as reproductive performance, and the menopausal transition impact 
menopausal health remains to be elucidated.70
Conceptual framework and aims of this thesis
In our contemporary societies, where we have the prospect of living over 100 years, it is 
becoming increasingly urgent to study health in our ageing populations using a gender-
specific and life-course perspective. The conceptual framework of this thesis is presented 
in Figure 2. The y-axis of the figure represents health and the x-axis represents age. The 
two circles reflect the combination of the biological, psychological, and social functioning 
which can change while ageing. The area within the two lines contains characteristics 
that belong to an individual or to a population, and can affect healthy ageing. These 
include, among others, fertility, menopause, medication use, lifestyle, sex hormones, or 
subdomains of health such as cardiovascular health and sexual health. The area outside 
of the lines encompasses characteristics which can affect healthy ageing that lie beyond 
the individual or population. Such characteristics include the natural environment, the 
health system, working conditions, culture, and more. The combination of these aspects 
of health and ageing are integrated into the fluctuating line at the top of the figure. 
This represents healthy ageing as a dynamic state, which is shaped by biopsychosocial 
functioning and is affected by characteristics that belong to the individual or population 
and beyond. 
A better understanding of the patterns and determinants of health has the potential 
of promoting and sustaining health in men and women. Moreover, improvements in 
measuring and monitoring health can contribute to a better aligning of health systems 
with the needs of ageing populations and could facilitate the development of age-friendly 
environments. 
In this thesis, we aim to provide insights into health and ageing whilst adopting an 
integrated, gender-specific, and life-course approach. As a first step in this thesis we have 
explored how big the economic impact of NCDs was on households and impoverishment 
and on health care costs as well as in terms of national income. Thereafter, following 
the pursuit of health, we have developed a healthy ageing score. We have also applied 
the new concept of cardiovascular health to the population-based Rotterdam Study and 
investigated further gender differences and the role of sex steroids. Furthermore, in 
women, we have specifically focused on conceptualizing healthy menopause and on the 
role of reproductive experience which occurred between menarche and menopause and 
different types of ovarian dysfunction, in cardiometabolic and overall health. 
The two arrows reflect health trajectories within an individual or population. The circles represent the 
interaction between biological, psychological, and social domains of health, which can differ across 
stages of life. The words in the figure are factors within individuals, populations or in the environment 
that can affect healthy ageing. All of the above are summarized in the fluctuating line at the top of the 
figure, which represents healthy ageing as a dynamic state, which can fluctuate over time.
Figure 2. Conceptual framework of this thesis.
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General outline of this thesis
Subsequent to this general introduction, the aims of this thesis will be addressed 
in several chapters. In the second chapter, we have studied the economic impact of 
NCDs by performing two systematic reviews. The first systematic review is presented 
in Chapter 2.1, and focuses on the micro-economic impact of NCDs on households and 
impoverishment. The second systematic review is presented in Chapter 2.2, and zooms 
in on the macro-economic impact of NCDs on health care spending and national income.
In Chapter 3 we present the results of the studies on the healthy ageing score and 
cardiovascular health in the population-based Rotterdam Study. In Chapter 3.1 we 
describe the development of a healthy ageing score and evaluate age and gender 
differences. In Chapter 3.2 we explore to what extent the healthy ageing score impacts 
biological markers of ageing, including telomere length and transcriptomic ageing. While 
adopting a life-course approach in Chapter 3.3, we assess the association between 
women’s fertile lifespan characteristics and sex steroids with the healthy ageing score in 
postmenopausal women. Chapter 3.4 describes the relation between sex steroids with 
cardiovascular health and denotes differences herein between men and women.
In Chapter 4 we focus more specifically on women’s sexual, reproductive, and menopausal 
health. In Chapter 4.1 we present a conceptual framework for healthy menopause. In 
Chapter 4.2 we study androgen levels in women with various forms of ovarian dysfunction 
and the association between androgens and cardiometabolic factors. Chapter 4.3 
describes the relation between women’s fertile lifespan characteristics with all-cause 
and cause-specific mortality in postmenopausal women. Chapter 4.4 comprehensively 
summarizes the efficacy and safety of flibanserin for women with hypoactive sexual 
desire disorder, by means of a systematic review and meta-analysis.
Finally, in the general discussion (Chapter 5) we summarize the principal findings 
of this thesis and discuss the main methodological considerations. We reflect on the 
findings and implications from different perspectives, the population, clinical, and policy 
perspective and conclude with several directions for future research.
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ABSTRACT 
Background: 
The global economic impact of non-communicable diseases (NCDs) on household 
expenditures and poverty indicators remains less well understood.
Objective: 
To conduct a systematic review and meta-analysis of the literature evaluating the global 
economic impact of six NCDs (including coronary heart disease, stroke, type 2 diabetes 
mellitus (DM), cancer (lung, colon, cervical and breast), chronic obstructive pulmonary 
disease (COPD) and chronic kidney disease (CKD)) on households and impoverishment. 
Data sources: 
Medline, Embase and Google Scholar databases were searched from inception to 
November 6th 2014. To identify additional publications, reference lists of retrieved studies 
were searched.
Study selection: 
Randomized controlled trials, systematic reviews, cohorts, case-control, cross-sectional, 
modeling and ecological studies carried out in adults and assessing the economic 
consequences of NCDs on households and impoverishment. No language restrictions. 
All abstract and full text selection was done by two independent reviewers.
Data extraction: 
Data were extracted by two independent reviewers and checked by a third independent 
reviewer. 
Main outcome measures: 
Studies were included evaluating the impact of at least one of the selected NCDs and 
on at least one of the following measures: expenditure on medication, transport, co-
morbidities, out-of-pocket (OOP) payments or other indirect costs; impoverishment, 
poverty line and catastrophic spending; household or individual financial cost.
Results: 
From 3241 references, 64 studies met the inclusion criteria, 75% of which originated from 
the Americas and Western Pacific WHO region. Breast cancer and DM were the most 
studied NCDs (42 in total); CKD and COPD were the least represented (five and three 
studies respectively). OOP payments and financial catastrophe, mostly defined as OOP 
exceeding a certain proportion of household income, were the most studied outcomes. 
OOP expenditure as a proportion of family income, ranged between 2-158% across the 
different NCDs and countries. Financial catastrophe due to the selected NCDs was seen in 
all countries and at all income levels, and occurred in 6-84% of the households depending 
on the chosen catastrophe threshold. In 16 low- and middle-income countries (LMIC), 
6-11% of the total population would be impoverished at a 1.25 US dollar/day poverty line 
if they would have to purchase lowest price generic diabetes medication.
Conclusions: 
NCDs impose a large and growing global impact on households and impoverishment, 
in all continents and levels of income. The true extent, however, remains difficult to 
determine due to the heterogeneity across existing studies in terms of populations 
studied, outcomes reported and measures employed. The impact that NCDs exert on 
households and impoverishment is likely to be underestimated since important economic 
domains, such as coping strategies and the inclusion of marginalized and vulnerable 
people who do not seek health care due to financial reasons, are overlooked in literature. 
Given the scarcity of information on specific regions, further research to estimate impact 
of the separate NCDs on households and impoverishment in LMIC, especially the Middle 
Eastern, African and Latin American regions is required.
Keywords:
non-communicable diseases, impoverishment, households, systematic review
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INTRODUCTION
Improvements in healthcare, hygiene and sanitation have increased the possibility to 
live until older age. Together with a growing global population, this has meant that non-
communicable diseases (NCDs), including coronary heart disease (CHD), stroke, chronic 
obstructive pulmonary disorder (COPD), cancer, type 2 diabetes mellitus (DM) and chronic 
kidney disease (CKD), are now the leading causes of morbidity and mortality worldwide. 
The burden exerted by NCDs extends beyond morbidity and mortality and generates an 
enormous societal impact, including on households and impoverishment.1-5
Limited insurance coverage and lack of social security nets can force households of NCD 
patients to spend large amounts of money out-of-pocket (OOP). NCDs reduce family 
income, savings and consumption of non-health items, and prompt early retirement.6 7 The 
impact of NCDs on households is likely to be especially severe in low- and middle-income 
countries (LMIC) where low-income populations, many of whom already experience 
extreme absolute poverty and precarious living conditions, are especially vulnerable to 
impoverishment due to any degree of healthcare spending.1 8-10 With some exceptions, 
such vulnerable groups suffer a double burden of chronic and infectious diseases.2 10-13 
The interplay between exposure to disease and financial vulnerability among low-income 
households can drive families and societies into deeper poverty. 
Despite greater appreciation on the likely deleterious role of NCDs on households and 
impoverishment, the extent of this impact in various geographical regions, is unclear. 
While several studies have addressed the issue, they have not been systematically 
evaluated in a single comprehensive investigation. Therefore, we report a systematic 
review to investigate the economic consequences of the major NCDs on the micro-
economic indicators (i) at the level of households (such as consumption choices, coping 
strategies, OOP, direct and indirect costs) and (ii) of poverty (such as financial burden, 
catastrophic spending, impoverishment, poverty line and financial vulnerability), across 
various global regions. 
METHODS
Conceptual framework
To guide the systematic review of the literature regarding the household impact of NCDs, 
a conceptual framework was adopted. This theory, previously described by McIntyre 
and colleagues, focuses on the economic consequences of illness and paying for health 
care.14 The economic consequences that NCDs incur on the household level are preceded 
by levels of perceived illness and the resulting treatment seeking behaviour. Seeking care 
can lead to economic consequences in the form of direct (e.g. costs for hospitalization, 
medicines, transportation) and indirect costs (e.g. time costs of informal caregivers, 
time costs of the ill). The indirect costs associated with not seeking care can exert a 
similar burden on the microeconomic level. Economic consequences in combination with 
divergent coping strategies (e.g. household labour substitution, use of savings, changing 
consumption choices) can result in poverty.
Although the importance of the first two steps (perceived illness and treatment seeking 
behaviour) is conclusive, the focus of this review was on economic consequences, coping 
strategies and poverty
Search strategy and inclusion criteria
We conducted a systematic search of electronic medical databases (Medline, Embase 
and Google Scholar) from inception to November 6th 2014 to identify scientific articles 
assessing the economic consequences of NCDs on households and on impoverishment. 
Given their large burden in populations worldwide, the following NCDs were selected: 
CHD, stroke, COPD, DM, cancers (lung, colon, breast, and cervical) and CKD.1 The step-
wise inclusion and exclusion procedure outlined in Figure 1 was followed. Eligible study 
designs included randomized controlled trials (RCTs), systematic reviews (used to identify 
further references), cohort, case-control, cross-sectional, ecological studies and modeling 
studies. Studies were included evaluating the impact of at least one of the selected NCDs 
and on at least one of the measures of interest: expenditure on medication, transport, 
co-morbidities, OOP or other indirect costs; consumption choices, coping strategies, 
impoverishment, poverty line and catastrophic spending; the household or individual 
financial cost. Only studies carried out in adults (>18 years old) were included and no 
language or date restrictions were considered. The search strategy in Appendix 1 was 
applied. 
Study selection
Two independent reviewers reviewed the abstracts and selected eligible studies. Any 
disagreements between the two reviewers were resolved through consensus or 
consultation of a third reviewer. To ensure consistent application of the inclusion criteria, 
a sample of the full texts was reviewed by a third reviewer. The references of the retrieved 
studies were scanned to identify additional relevant publications that were missed by 
the initial search. Authors of included studies were contacted to retrieve missing full 
texts and to identify any missing studies.
Data extraction
A data collection form was prepared to extract the relevant information from the included 
full texts, including study design, World Health Organization (WHO) region, characteristics 
of study participants, and characteristics of the NCDs evaluated and measures included. 
Local currencies were converted to US dollars (USD) to enhance comparability between the 
eligible studies, preferably using exchange rates given by the studies, if used. If no exchange 
rate was given, a conversion rate of the publication year of the study was used. All USD 
were converted to dollars of 2013 using the consumer price index conversion factors.15
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Quality evaluation
To evaluate the quality of all studies included, the Newcastle-Ottawa Scale (NOS) was 
applied.16 NOS scale assesses the quality of the articles in three domains of selection, 
comparability and exposure. Within the selection category, four items are assessed and 
maximum one star can be awarded to each item. Two stars can be awarded to the one 
item within the comparability category. Finally, one star can be awarded to each of the 
three items in the exposure category. A score was made by adding up the number of 
stars and therefore, NOS scale can have maximum nine stars for the highest quality. 
For cross-sectional and descriptive studies, an adapted version of NOS scale was used 
(Appendix 2). 
Statistical analyses
Heterogeneity permitting, we sought to pool the results using a random effects meta-
analysis model. If pooled, results were expressed as the pooled estimate and the 
corresponding 95% confidence intervals. All costs presented are converted in USD 2013.
RESULTS
From 3.241 references initially identified, 64 studies met the inclusion criteria (Figure 
1 and Table 1).17-80 The eligible studies were published between 1999 and 2014, and 
included more than 835 million individuals.
General characteristics of the included studies
Of these 64 studies, three studies focused on multiple WHO regions, 20 studies originated 
from the WHO Western Pacific region and 25 from the WHO region of the Americas (22 
from Canada or the United States of America (USA)). Thirteen studies were from South-
East Asia (eight from India); five studies from Europe and the African region contributed 
four studies. We found three studies from the Eastern Mediterranean region.
Fifty-seven studies had an observational design, of which twelve were prospective 
cohort studies, one was retrospective and 44 cross-sectional. One study presented a 
retrospective analysis of a randomized clinical trial and six were economic modelling 
studies. Most of the studies (51) used solely self-reported NCDs and economic measures 
data. Eligible participants were mostly sampled from hospitals, from disease registries or 
the general population. The remaining thirteen studies used data from regional, national 
and international databases and insurance data. In less than half of the studies, a control 
group was present; this was either a sample of the general population or sometimes 
sought within the same environment as the patients (e.g. same insurance company, 
same registry).
Sixteen studies focused on the impact of more than one NCD on households and 
impoverishment. The most frequently studied diseases were breast cancer and DM. Of 
the studies reporting on cancers, breast cancer was included in 21 studies, followed by 
colon cancer (eleven studies), lung cancer (eight studies) and cervical cancer (four studies). 
Two studies mentioned cancer, without specifying cancer types. Diabetes mellitus was 
the NCD of interest in 21 studies, stroke in ten, CVD in eight and CKD in five studies. Three 
studies focused on COPD and three on NCDs in general terms. 
Quality of the included studies
A quality score was appointed to all except 2 of the 64 included studies (Tables 2A-G). 
In these two studies quality assessment was unfeasible due to their methodology and 
design. The median quality score over all the studies was 4.5 out of 9 (interquartile 
range 3 to 6). Two thirds of the eligible studies scored 5 points or less, indicating that the 
majority of the studies were of low or moderate quality.
Figure 1. Flowchart of studies for the global economic impact of NCDs on households and 
impoverishment. 
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Measures of economic impact on households and impoverishment
There was substantial heterogeneity among the studies in the measurement methods 
of the economic impact of NCDs on households and impoverishment. Therefore, pooling 
the outcomes of the included studies was not feasible. 
For economic consequences (i.e. direct and indirect costs), OOP cost was the most 
common measure evaluated and was reported either as absolute costs or as a percentage 
of varying income proxies (e.g. individual income, family income, monthly non-food 
expenditure or household capacity to pay). Different OOP definitions were applied and 
could include the following expense types: cost of treatment or hospitalization (direct 
medical costs) and, among others, costs for transportation, food and lodging (referred to 
as direct non-medical costs or indirect costs). For catastrophic spending, mostly defined 
as a scenario in which OOP costs exceed a certain percentage of household income, 
different thresholds ranging from 10-40% were used. Studies applying higher thresholds 
(e.g. 40%) did not necessarily find lower percentages of households that experience 
financial catastrophe when compared to studies using lower thresholds (e.g. 10%). Two 
other frequently reported measures of micro-economic burden were income loss and 
perceived financial hardship (e.g. worries about or change for the worse in financial 
situation), the latter capturing a different, more subjective perspective of the economic 
impact of NCDs on individuals and households. 
Of the 64 eligible studies, five reported on the impact of NCDs on coping strategies, 
wherein the applied definitions differed between studies. Impoverishment was reported 
in three studies and was expressed as the percentage of people dropping below the 1, 
1.25 or 2 US dollar (USD) per day poverty line due to the economic burden of treatment.
Impact of cardiovascular disease
Huffman et al. (Table 2A) reported that 14.3% of high-income families in China 
experienced some form of household income loss due to cardiovascular disease (CVD) 
hospitalization, rising to 26.3% in India, to 63.5% in Tanzania, and to 67.5% in Argentina. 
This impact was patterned by socio-economic position, as greater household CVD-
attributable income losses were reported for lower income groups.47 In the USA, 10.4% 
of CHD patients reported that OOP spending was more than 20% of the family income.69 
CVD patients in India spent 30% of their annual family income on direct CVD health care, 
where mean OOP per hospitalization increased from 364 USD in 1995 to 575 USD in 
2004.30 59 In CVD-affected households in India, >30% borrowed or sold assets to pay for 
inpatient treatment, compared to 12% in matched control households.78 Also in India, the 
risk of impoverishment due to CVD was 37% greater than for communicable diseases 
(95% confidence interval, CI, 1.2 to 1.5).59
Impact of stroke 
The average OOP burden as a percentage of income in Japan ranged between 5.1-17.2% 
(Table 2B).33 In China, OOP costs in the first three months after diagnosis of stroke was 
158% greater than the annual income. Catastrophic spending (i.e. OOP spending >30% of 
annual income) was experienced by 71%, pushing an estimated 23% of insured and 62% 
of uninsured stroke patients below the 1 USD per day poverty line.49 In the USA, 27.8% of 
stroke patients reported OOP spending at >20% of the family income.69 Among Australian 
stroke survivors, an estimated 473 USD were spent in the first year after diagnosis and 
61% perceived financial hardship after 12 months.57 61
Impact of cancer
All but five of the 28 studies reporting on cancer originated from high-income countries 
(Table 2C). OOP spending as a percentage of annual income was estimated by two different 
studies at 9.7% and 44% for breast cancer in the USA.32 72 In Canada, the percentage was 
2.3%.41 In these countries, perceived financial hardship (e.g. worries about, or change for 
the worse in, financial situation) for breast cancer was reported by 1-92% of women.40 41 
52 This perception of financial burden was experienced by 70% of breast cancer patients in 
a study from Pakistan.18 When comparing early to late expenditures for cervical cancer 
in Nigeria, the costs rose from 240 to 558 USD.34 Among Norwegian women, income 
loss for cervical, breast, colon and lung cancer was experienced by 3.8%, 5.7%, 6.2% and 
21.1%, respectively. A loss in income due to cervical cancer was reported by 39% of 
Argentinean women.71 When comparing cancer to communicable diseases in India, the 
risk of catastrophic spending, defined as OOP costs exceeding 40% of household income, 
and the risk of impoverishment was 2.7 times (95% CI 2.1 to 3.1) and 2.3 times (95% CI 1.9 
to 2.9) higher.59
Of the five studies focusing on coping strategies, all except one did so for the assessment 
of the impact of cancer.27 64 68 77 The results of a study by Chirikos and colleagues suggested 
that losses incurred by breast cancer patients were compensated by other individuals in 
the household.64 Income and savings were used to pay for health care in up to 80% of 
breast cancer patients, 10% increased credit card debt, 7% borrowed from friends or family 
and 5% left some medical bills unpaid.77
Impact of chronic obstructive pulmonary disorder 
In Australia, financial hardship (e.g. worries about, or change for the worse in, financial 
situation) was felt by 36-78% of COPD patients (Table 2D).46 58 Financial catastrophe, at 
a 10% income threshold, was experienced by 46% of COPD patients. In absolute terms, 
annual OOP expenditure among COPD sufferers was 2048 USD.58
Impact of chronic kidney disease 
57% of Australian CKD patients reported financial hardship (Table 2E). Using the same 
income threshold of 10%, financial catastrophe was experienced by 71% of CKD patients, 
which is equivalent in absolute terms to annual OOP expenditure of 3755 USD.56 In Japan, 
mean annual OOP expenditure was 2604 USD.48 OOP expenses due to CKD increased by 
60% between 2002 and 2005, and 32.6% of CKD patients spent more than 10% on income 
OOP.67 69 
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Impact of type 2 diabetes mellitus
From the 21 studies focusing on type DM, eight originated from India and showed a 
consistent impact on households (Table 2F). Mean OOP expenditure per in-patient 
hospital stay for DM increased from 134 USD to 211 USD between 1995 and 2004 and 
direct total OOP spending per year was estimated at 262-280 USD.29 50 59 The percent wise 
household consumption spent OOP ranged between 7.7-17.5%.26 30 In Japan, the average 
OOP burden for DM, as a percentage of household income, ranged from 4.8% to 11.3%.33
In the USA, the mean annual OOP diabetes care cost was 1237 USD and increased by 
23% from 2002 to 2005.28 67 Nearly 40% of DM cases in the USA experienced catastrophic 
spending (using the >10% threshold); 13% experienced catastrophic spending even above 
the 20% threshold.69 A cross-country analysis, performed by Niens et al, quantified the 
impoverishing effects of purchasing medicines for different diseases, including DM. 
Buying lowest price generic or originator brand glibenclamide would plunge either 
2 million (5%) or 3 million (10%) chronic patients below the 1.25 USD/day poverty line, 
respectively. When stratifying across the 16 countries, these percentages ranged 
between 0 and 58%.35
Impact of NCDs combined
The proportion spent OOP on NCDs increased from 31.6% to 47.3% between 1995 and 2004 
in India (Table 2G).59 In Japan, the average OOP burden was 2.1% of available income.33 
The threshold for what is considered ‘catastrophic spending’ has a large impact on the 
proportion of households who experience it. For example, in Burkina Faso, the proportion 
of households experiencing catastrophic spending gradually increased from 4.5% to 10.6% 
(and in absolute numbers from 79 to 108 USD annually) as the catastrophic threshold 
lowered, stepwise, from >60% to >40%, >30%, and >20%.24 The mean NCD expenditure as 
a proportion of household capacity to pay in Vietnam was 27.7%. When using different 
catastrophic spending thresholds, nearly 60% of the participants spent between 20-30% 
of their income on NCDs.21
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DISCUSSION
This systematic review summarizes 64 studies published worldwide of the impact of 
the major NCDs (CHD, stroke, COPD, major cancers, DM and CKD) at the micro-economic 
level on households and impoverishment. The studies show a steady global increase in 
household expenditure on NCDs between 1999 and 2014. The importance of these trends 
in global health is further underlined by the ‘WHO Global Action Plan for the Prevention of 
Non-communicable Diseases 2013-2020’, which highlights the need for further research 
into NCDs and their impact at the micro-economic level.81 
There is evidence that a substantial number of people experience financial hardship due to 
NCDs, as income losses affect patients and their caregivers and OOP medical expenditure 
for NCDs drive households into financial catastrophe and impoverishment. This rising 
burden is directly related to the global rise of NCDs, particularly in LMIC, many of which 
have under-resourced healthcare systems that impose OOP payments on individuals 
and households as a means to supplement other sources of revenue.1 As healthcare 
systems in LMIC often experience a dual burden of infectious and chronic disease, they 
are less able to allocate resources towards primary prevention of NCDs. Most eligible 
studies used OOP expenditure to quantify the magnitude of the economic impact of 
NCDs on households and for mapping the extent of financial catastrophe, in particular. 
OOP expenditure was self-reported in most of the studies, with some exceptions where 
studies used health insurance claim data. Relative to different income proxies, OOP 
expenditure ranged widely between 2 and 158% across different NCDs and countries.
The threshold for what is considered ‘catastrophic spending’ has a large impact on the 
proportion of households who experience it; depending on the income threshold taken 
by the study, the global proportion of households suffering from financial catastrophe 
ranged from 6 to 84%. Heterogeneity in the use of an income threshold in combination 
with differences in study samples (among others, related to insurance coverage levels) 
undermine comparability across the studies, although evidence does suggest that 
financial catastrophe due to NCDs is an important issue for all countries and across all 
income strata. This observation is in accordance with other reports that took a broader 
(chronic) illness perspective.8 10 14 82 Variations in OOP spending and financial catastrophe 
across and within countries depend a great deal on the triad of factors, described by Xu 
and colleagues, as poverty levels, healthcare service access and use, and the presence or 
absence of financial risk pooling mechanisms such as health insurance or taxed-based 
systems.9 Although it was outside the scope of this study to review the impact of this 
triad on catastrophic spending, these factors are very likely to be key components of the 
(varying) relation between OOP spending and catastrophic spending. Therefore, although 
OOP spending and financial catastrophe are valuable methodological approaches to 
provide insights into the impact on households, these measures cannot be interpreted 
without being placed within the specific health system perspective from which the St
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sample is drawn. Standardized definitions and thresholds would facilitate unbiased and 
cross-country comparisons.
A minority of the studies addressed the absolute impoverishing effects of NCDs. A large 
study by Niens et al, in 16 LMICs, showed that the purchase of lowest price generic 
medication rather than originator brand DM (and other) medication could reduce absolute 
impoverishment, at the 1.25 USD/day poverty line, from 11% to 6% of the total population. 
This finding reinforces the need to improve availability of low-priced generics, which for 
NCDs receives comparatively little attention compared to infectious disease treatment.83 84
The extent to which NCDs drive households into relative poverty were more difficult to 
estimate from the eligible studies, partly due to the fact that relative poverty is more 
difficult to measure and the definitions are less clear. We observed that some eligible 
studies used income losses to estimate the relative impoverishing influence of NCDs. 
For instance, for Norwegian women suffering from cervical, breast or lung cancer, the 
percent-wise income deviation compared to healthy women was 3.8%, 5.7% and 20% 
respectively.22 Household income losses after CVD diagnosis were 67.5%, 14.3%, 26.3% 
and 63.5% in high-income groups in Argentina, China, India and Tanzania respectively, 
and were even higher in the lower income groups.47 These findings are consistent with 
similar studies, which showed that poor households are less able to cope with healthcare 
costs compared to more affluent households.9 85 86 Solely five eligible studies provided 
insights in the coping strategies adopted by households to cope with a family member 
suffering from NCDs. The paucity of evidence regarding coping strategies, together with 
the significant role that illness perceiving and absence of health care seeking due to 
financial reasons play, are likely to reflect a considerable underestimation of the true 
extent to which NCDs impact households.
Findings of this systematic review generally concur with and further extend previous 
reviews on this topic. Previous work was focused on specific types of NCDs, was focused 
in specific regions of the world or provided methodological commentaries.10 87-100 A 
recent narrative review emphasized the importance of standardized definitions for out-
of-pocket spending, the use of larger sample sizes and prospective study designs and 
a better collecting of data on economic consequences of NCDs (i.e. direct and indirect 
costs).89 Kankeu and colleagues assessed financial burden of four domains of NCDs 
(cancers, CVD, COPD, and diabetes) but did not include chronic kidney disease in their 
review. In addition and interestingly, they included only studies conducted in LMICs.91 
Mahal and colleagues summarized the economic impact of NCDs for India.94 A second 
study, conducted by Engelgau and colleagues, non-systematically reviewed studies 
mostly conducted in India.10
Costs involved in cancer care, without stratifying for cancer type, were reviewed in three 
domains in a systematic review by Pearce and colleagues. The domains included cost-
effectiveness and cancer treatment, the indirect cancer costs and human costs of cancer. 
Definite conclusions were missing due to conceptual and methodological limitations of 
the included studies. Nevertheless, the complexity of the costs attached to cancer care 
was observed.95 Pisu and colleagues reviewed OOP expenses in breast cancer patients 
only.96 Tong and colleagues thematically synthesized patient and caregiver perspectives 
in CKD. Out of 26 included studies in this review, one study from Thailand focused 
on economic consequences, and found a large economic strain due to forced early 
retirement.97
Coping with out-of-pocket health payments was assessed in 15 African countries and 
showed that borrowing and selling assets was an important coping mechanism, its 
prevalence ranging from 23-68%. Unfortunately a specification of the included diseases 
was not provided.93
The strengths and limitations of our work merit careful consideration. An important 
strength of this review is the exhaustive search for relevant articles. We used extensive, 
precise search terms and applied stringent inclusion criteria, specifically the exclusion 
of studies focusing solely on ‘chronic diseases’ or ‘illness’. We believe that this specific 
approach gave rise to a comprehensive undiluted perspective of the micro-economic 
impact of NCDs, since all available evidence was gathered via the initial search and was 
supplemented by an extensive screening of reference lists for possibly missed eligible 
studies. However, we do emphasize that precisely defining included chronic illnesses 
would greatly benefit future research and the disease specific policy implications this 
research could give rise to.
The methods used by the eligible studies to measure household impact and 
impoverishment were remarkably heterogeneous which, along with a broader disease 
burden perspective than NCDs, is a recurrent challenge in similar reviews and did not allow 
us to pool the reported estimates in a meta-analysis.14 91 Furthermore, in many studies 
convenience sampling was used to assemble study samples, and the overall quality of 
the included studies was moderate to low. Therefore, country-wide and disease-specific 
implications of the results must be interpreted with caution. Given the already wide 
scope of our systematic evaluation, we were unable to explore wider impacts associated 
with NCDs such as non-economic and indirect impacts including educational dropout 
among children, healthcare utilization and costs of premature death. Estimation of the 
number and experiences of marginalized and vulnerable people who do not seek care for 
NCDs for financial reasons is currently neglected and their inclusion could give a more 
comprehensive overview of the impact of NCDs on households and impoverishment. 
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CONCLUSIONS
NCDs impose a large and growing global impact on households and impoverishment, 
in all continents and levels of income. The true extent, however, remains difficult to 
determine due to heterogeneity across existing studies in terms of populations evaluated, 
outcomes reported and measures employed. The impact that NCDs exert on households 
and impoverishment is likely to be underestimated since important economic domains, 
such as coping strategies and the inclusion of marginalized and vulnerable people who 
do not seek health care due to financial reasons, are overlooked in literature. Given 
the scarcity of information on specific regions, further research is required to estimate 
impact of the separate NCDs on households and impoverishment in LMIC, especially the 
Middle Eastern, African and Latin American regions.
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Appendix 1. 
Search strategy 6 November 2014.
(‘non communicable disease’/de OR ‘ischemic heart disease’/exp OR ‘cerebrovascular 
accident’/exp OR ‘chronic obstructive lung disease’/de OR ‘lung cancer’/exp OR ‘colon 
cancer’/exp OR ‘breast cancer’/exp OR ‘chronic kidney disease’/de OR ‘non insulin 
dependent diabetes mellitus’/de OR ‘uterine cervix cancer’/exp OR (‘non communicable’ 
OR noncommunicable OR ((heart OR cardiac OR cardial OR cardiopath* OR cardiomyopath* 
OR coronar* OR myocard*) NEAR/3 (ischem* OR ischaem* OR anoxia OR hypoxia)) OR 
(coronary NEAR/3 (insufficien* OR occlus* OR disease* OR acute OR atherosclero* 
OR arteriosclero* OR sclero* OR cardiosclero* OR constrict* OR vasoconstrict* OR 
obstruct* OR stenosis* OR thrombo*)) OR angina* OR ((heart OR myocard* OR cardiac 
OR cardial) NEAR/3 infarct*) OR ((cerebrovascul* OR brain OR ‘cerebral vascular’ OR 
‘cerebro vascular’) NEAR/3 (accident* OR lesion* OR attack OR ischem* OR ischaem* 
OR insult* OR insuffucien* OR arrest* OR apoplex*)) OR cva OR stroke OR (chronic 
AND (obstruct* NEAR/3 (lung* OR pulmonar* OR airway* OR bronch* OR respirat*))) 
OR ((lung* OR pulmonar* OR colon* OR colorect* OR breast* OR mamma*) NEAR/3 
(neoplas* OR cancer* OR carcino* OR adenocarcino* OR metasta* OR sarcom*)) OR 
(chronic NEAR/3 (kidney* OR nephropathy* OR renal)) OR ((‘adult onset’ OR ‘type 2’ OR 
‘type ii’ OR ‘non-insulin dependent’ OR ‘noninsulin dependent’ OR ‘insulin independent’) 
NEAR/3 diabet*) OR ((cervix OR cervical) NEAR/3 (cancer* OR neoplas* OR tumo* OR 
carcinom* OR malign*))):ab,ti) AND (adult/exp) AND (‘randomized controlled trial’/exp 
OR ‘cohort analysis’/de OR ‘case control study’/exp OR ‘cross-sectional study’/de OR 
‘systematic review’/de OR ‘meta analysis’/de OR ecology/exp OR ‘ecosystem health’/exp 
OR ‘ecosystem monitoring’/exp OR model/exp OR ((random* NEAR/3 (trial* OR control*)) 
OR rct* OR cohort* OR ‘case control’ OR ‘cross-sectional’ OR (systematic* NEAR/3 review*) 
OR metaanaly* OR (meta NEXT/1 analy*) OR ecolog* OR ecosystem* OR model*):ab,ti) 
NOT ([animals]/lim NOT [humans]/lim) NOT ([Conference Abstract]/lim OR [Conference 
Paper]/lim OR [Letter]/lim OR [Note]/lim OR [Conference Review]/lim OR [Editorial]/lim 
OR [Erratum]/lim)
AND (((‘cost of living’/de OR budget/de OR ‘financial deficit’/exp OR income/de OR ‘health 
care cost’/de OR ‘hospitalization cost’/de OR insurance/exp OR ‘cost of illness’/de OR 
socioeconomics/exp OR (((cost* OR econom* OR expen*) NEAR/6 (living OR individu* 
OR famil* OR personal* OR patient* OR illness* OR direct* OR indirect*)) OR budget* OR 
deficit* OR debt* OR income OR insurance* OR socioeconom* OR pover* OR impover* OR 
poor OR wealth):ab,ti) AND (family/exp OR home/de OR household/de OR (famil* OR home 
OR household* OR personal):ab,ti)) OR ‘caregiver burden’/de OR (microeconom* OR (micro 
NEXT/1 econom*) OR ‘Out of pocket’ OR ‘Willingness to pay’ OR (catastroph* NEAR/3 
(spend* OR expend*)) OR ‘Poverty line’ OR (Value* NEXT/2 ‘statistical life’)):ab,ti)
Appendix 2.  
Newcastle Ottawa Quality Assessment Scale, cross-sectional and    
descriptive studies.
Note: A study can be awarded a maximum of one star for each numbered item within the 
Selection and Exposure categories. A maximum of two stars can be given for Comparability.
Selection
1) Is definition of NCDs adequate?
a) Yes, according to a clear and widely used definition *
b) Yes, e.g. record linkage or based on self-reports
c) No description
2) Representativeness of the cases
a) Consecutive or obviously representative series of cases *
b) Excluded cases are random *
c) No description of the excluded cases or potential for selection biases or not 
stated
3) Comparison with a reference group
a) The results are compared with a reference from community or with the status 
of the cases prior to the disease *
b) The results are compared with the results from other patients
c) No description/no comparison available
4) Definition of reference
a) Individuals with no NCD or sample from general population or the same 
individuals before NCD suffering*
b) Non community comparator is described
c) No description of source
Comparability
1) Comparability of the results on the basis of the design or analysis
a) The results are described in age and sex sub groups (sex is not applicable for 
female diseases) *
b) The results are additionally adjusted for/described in different socioeconomic 
factors or disease related confounders*
Exposure (costs, productivity, households)
1) Ascertainment of exposure
a) Secure record (e.g. surgical records, hospital records, and administrative records, 
national…) *
b) Structured interview where blind to case/control status *
c) Interview not blinded to case/control status
d) Written self-report or medical record only
e) No description
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2) Same method of ascertainment for NCDs and comparators
a) Yes *
b) No
c) No comparator group exist
3) Non-response rate
a) All participants included or same rate for both groups or respondents and non-
respondents have the same characteristics*
b) Non respondents described
c) Rate different and no designation
d) Response rate not described
Manuscript based on this chapter:
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H Franco. The global impact of non-communicable diseases on healthcare spending 
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ABSTRACT
Background: 
The impact of non-communicable diseases (NCDs) in populations extends beyond ill-
health and mortality with large financial consequences.
Objective: 
To systematically review and meta-analyze studies evaluating the impact of NCDs 
(including coronary heart disease, stroke, type 2 diabetes mellitus, cancer (lung, colon, 
cervical and breast), chronic obstructive pulmonary disease (COPD) and chronic kidney 
disease) at the macro-economic level: healthcare spending and national income.
Data sources: 
Medical databases (Medline, Embase and Google Scholar) up to January 20th 2014. For 
further identification of suitable studies, we searched reference lists of included studies 
and contacted experts in the field.
Study selection: 
We included randomized controlled trials, systematic reviews, cohorts, case-control, 
cross-sectional, modeling and ecological studies carried out in adults assessing the 
economic consequences of NCDs on healthcare spending and national income without 
language restrictions. All abstracts and full text selection was done by two independent 
reviewers. Any disagreements were resolved through consensus or consultation of a 
third reviewer. 
Data extraction: 
Data were extracted by two independent reviewers using a pre-designed data collection 
form. 
Main outcome measures: 
Studies evaluating the impact of at least one of the selected NCDs on at least one of the 
following outcome measures: healthcare expenditure, national income, hospital spending, 
gross domestic product (GDP), gross national product (GNP), net national income (NNI), 
adjusted national income (NNI), total costs, direct costs, indirect costs, inpatient costs, 
outpatient costs, per capita healthcare spending, aggregate economic outcome, capital 
loss in production levels in a country, economic growth, GDP per capita (per capita 
income), percentage change in GDP, intensive growth, extensive growth, employment, 
direct governmental expenditure and non-governmental expenditure.
Results: 
From 4364 references, 153 studies met our inclusion criteria. Most of the studies were 
focused on healthcare related costs of NCDs. 30 studies reported the economic impact 
of NCDs on healthcare budgets and 13 on national income. Healthcare expenditure for 
cardiovascular disease (12-16.5%) was the highest; other NCDs ranged between 0.7%-
7.4%. NCD-related health costs vary across the countries, regions, and according to type 
of NCD. Additionally, there is an increase in costs with increased severity and years lived 
with the disease. Low- and middle-income countries were the focus of just 16 papers, 
which suggests an information shortage concerning the true economic burden of NCDs 
in these countries. 
Conclusions: 
NCDs pose a significant financial burden on healthcare budgets and nations’ welfare, 
which is likely to increase over time. However further work is required to standardize 
more consistently the methods available to assess the economic impact of NCDs and to 
involve (hitherto under-addressed) LMI populations across the globe.
Keywords:
non-communicable diseases, national income, health expenditure, systematic review
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INTRODUCTION
Due to lifestyle and environmental change, healthcare improvements and improved 
potential to survive until old age, non-communicable diseases (NCDs) (including coronary 
heart disease (CHD), stroke, chronic obstructive pulmonary disease (COPD), cancer, type 2 
diabetes mellitus (DM) and chronic kidney disease (CKD) are currently the leading cause 
of adult death and disability worldwide.1 The global burden of NCDs is expected to rise 
further as a result of an increasing global population and demographic shifts, especially 
increases in the older population. Indeed, the global population above the age of 60, the 
age group most affected by NCDs, is expected to double between 2000 and 2050.2 
Most NCDs are chronic conditions that require expensive treatment regimens and 
prolonged individual care by increasingly specialized healthcare services. NCDs also 
detrimentally impact on national income, socio-economic development and economic 
growth3 through productivity losses, prolonged disability and increases in health and 
social care expenditure. Historically, high-income countries (HIC) experience the greatest 
economic consequences of NCDs. Yet, as a result of economic growth, epidemiological 
transition, ageing populations and healthcare system development, many low- and 
middle-income countries (LMIC) are now also experiencing a greater impact of NCDs. 
LMICs also suffer a substantial burden of NCD-related risk factors such as tobacco use, 
heavy alcohol consumption or unhealthy diet among their impoverished population 
groups.4 However, policy programs that respond to the increasing burden of NCDs in 
many LMIC remain limited.5 To date, however, little work has been done to systematically 
appraise the current evidence on the economic burden of NCDs globally. Exploring the 
studies that investigate the impact of NCDs on healthcare expenditure and national 
income can help shape future healthcare plans and strategies by better informing policy 
makers and healthcare planners about the emerging costs of NCDs.
We aimed to systematically review the literature evaluating the financial burden of six 
major NCDs (CHD, stroke, cancer (lung, colon, cervical and breast), COPD, DM and CKD) 
at the macro-economic level in order to quantify: (i,) the costs related to NCDs (direct, 
indirect, aggregate, over time and by disease severity); (ii) the per capita healthcare 
expenditure on NCDs; and (iii) national economic loss due to NCDs; and (iv) the overall 
aggregate economic impact of the NCDs on national income and healthcare spending. 
METHODS
Search strategy and inclusion criteria
We conducted a systematic search of electronic medical databases (Medline, Embase 
and Google Scholar) until November 6th 2014 (date last searched) to retrieve scientific 
articles assessing the consequences of NCDs at the macro-economic level specifically 
the impact on national income and healthcare expenditure (including: health expenditure, 
national income, hospital spending, gross domestic product (GDP), gross national product 
(GNP), net national income (NNI), adjusted national income (NNI), healthcare costs, direct 
costs, indirect costs, per capita healthcare spending, medical costs, non-medical costs, 
aggregate economic outcome, capital loss in production levels in a country, economic 
growth, percent rate of increase in GDP, GDP per capita (per capita income), intensive 
growth, extensive growth, employment, direct governmental expenditure and non-
governmental expenditure) (see Appendix 1 in the Supplement). The step-wise inclusion 
and exclusion procedure outlined in Figure 1 was followed. Eligible study designs included 
randomized controlled trials (RCTs), cohort, case-control, cross-sectional, systematic 
reviews, ecological studies and modeling studies. We included studies evaluating the 
impact of at least one NCDs selected (CHD, stroke, COPD, type 2 diabetes mellitus, cancer 
(lung, colon, breast, and cervical), and CKD) on at least one measure of the impact on 
national income and healthcare expenditure (as specified above). Only studies carried out 
in adults (>18 years old) were included and we specified no language or date restrictions.
Study selection
Two independent reviewers screened the abstracts retrieved by the search strategy and 
selected eligible studies. Any disagreements between the two reviewers were resolved 
through consensus or consultation of a third independent reviewer. The references of 
the retrieved studies were scanned to identify additional relevant publications that were 
missed by the initial search strategy. Authors of the included studies were contacted in 
order to identify additional publications.
Data extraction
A predesigned data collection form was prepared to extract the relevant information 
from the included full texts, including study design, WHO region, characteristics of the 
study participants, NCDs details and economic measures reported. 
Quality evaluation
We used the Newcastle-Ottawa Scale (NOS) to evaluate the quality of cross-sectional, 
case-control and cohort studies included in this review.6 NOS scale assesses the quality 
of the articles in three domains of selection, comparability and exposure. Within the 
selection category, four items are assessed and a maximum of one star can be awarded 
to each item. Two stars can be awarded to the one item within the comparability 
category. Finally, one star can be awarded to each of the four items in the exposure 
category. A score will be made by adding up the number of stars and thus, NOS scale 
can have a maximum of nine stars in total. We used this scale for quality assessment of 
case-control and cohort studies. For cross-sectional and descriptive studies we used an 
adapted version of NOS scale (see Appendix 2 in the Supplement). No quality score was 
applied to the modeling studies.
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Statistical analyses
Heterogeneity permitting, we sought to pool the results using a random effects meta-
analysis model. If pooled, results were expressed as the pooled estimate and the 
corresponding 95% confidence intervals. All costs presented are converted in USD 2013.
RESULTS
In total, we identified 4364 potentially relevant citations (Figure 1). Based on the title and 
abstracts, full texts of 199 articles were selected for detailed evaluation. Of those, 153 
articles met our eligibility criteria and were therefore included in the analysis (Table 1).
General characteristics of the included studies
A wide geographical distribution was observed in the reviewed studies. The majority of the 
studies (n=68) were from the American WHO region (mainly USA and Canada), 57 studies 
were from the European, 19 from the Western Pacific, two from the South-East Asian, 
three and from the African WHO region and the Eastern Mediterranean respectively, 
whereas two studies were conducted in multiple regions. The majority (n=137) of the 
reviewed studies were conducted in HIC, ten in upper middle-income countries, and five 
were conducted in low-income countries whereas one study included countries from the 
three income categories. Therefore, the GDP variation across the studies reviewed was 
narrow. The studies identified were mainly observational studies, having a retrospective 
or longitudinal design; 22 studies were modeling studies and only one study was an 
RCT. Medical records were the most frequently used method to select participants. In 
many cases, these medical records were linked to socio-economic databases to extract 
employment data. Adjustment for age, gender, ethnicity, co-morbidities/existing 
conditions, and geographic regions was usually applied. 
Of the 153 studies included in this review, 40 studies focused on the economic impact of 
CHD and stroke (cardiovascular disease), 32 on COPD, five on CKD, 24 on DM, 45 on cancer 
and 7 studies provide evidence on economic impact of a combination of NCDs (Table 1). 
Most of the studies investigated the economic impact of NCDs among people aged 45 
years and over.
Per patient global healthcare costs and non-healthcare costs of NCDs
Reported healthcare costs associated with NCDs varied across countries and regions, 
and across the type of NCDs. Reported annual direct costs of NCDs were the highest 
in the Americas, followed by European and Western Pacific regions; in the region of the 
Americas, the minimum and maximum mean reported annual total direct costs for CVD 
were 6668 USD7 and 81096 USD8, respectively, whereas the average annual direct costs 
for CVD varied from 16439 USD to 69440 USD10, and from 3862 USD11 to 5693 USD12 for the 
European and Western Pacific regions, respectively (Supplemental Table 1). A detailed 
description on the variation of any type of costs of NCDs per world region is shown in 
Supplemental Table 1. 
Direct costs 
In 107 studies, mean annual total direct costs and mean directly attributable costs per 
NCDs patient (Table 2A) were estimated. Worldwide, of all the selected NCDs, cancer and 
CVD (with estimated costs up to 197772 USD13 and 81096 USD8, respectively) had the 
highest reported mean annual total direct costs, whereas DM had the lowest. Average 
CVD-related direct costs ranged from 1643 USD9 in Poland to 81096 USD8 in USA, with 
CHD having the lowest reported estimates and heart failure imposing the highest costs. 
Among cancers, the estimated mean annual total direct costs varied: from 4595 USD14 to 
82794 USD15 for breast cancer; 4964 USD16 to 161048 USD15 for lung cancer and 220817 
USD to 197722 USD17 for colorectal cancer. Only one study from Singapore reported 
annual total direct costs for cervical cancer with an average estimate of 8049 USD18. 
COPD annual direct costs varied substantially, with Norway reporting the lowest direct 
Figure 1. Flowchart of studies for the global impact of non-communicable diseases on healthcare 
spending and national income.
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costs (431 USD19) and USA reporting the highest (34101 USD20). The lowest direct costs for 
CKD were observed in Germany with an average estimate of 5439 USD21, whereas mean 
direct costs for CKD in USA were estimated to be up to 71824 USD22. DM average annual 
direct costs varied from 162 USD23 in India to 15611 USD in USA24. 
Direct attributable costs for the NCDs were available from only 18 studies. The highest 
direct attributable costs were observed for cancer (up to 190032 USD13), followed by CKD 
(up to 33585 USD25), COPD (up to 22183 USD24), CVD (up to 21152 USD24) and finally, DM 
(up to 12246 USD24) with the lowest average estimates. Some articles reported inpatient 
and outpatient costs for NCDs (Supplemental Table 2). These demonstrate that inpatient 
costs are the main source of direct costs for NCDs. Inpatient costs accounted for 47%-
58% of total direct costs of COPD26 and 63% of total direct costs for DM27. Hospital costs 
represent the main driver of stroke expenditure, accounting for 90%28 of total direct 
costs. Hospitalization charges represented the greatest economic burden (55%)29 for the 
management of colorectal cancer, followed by medical purchases (24%) and outpatient 
care (18%). 
Indirect costs
18 studies estimated mean annual indirect costs (Table 2B). Mean annual estimated 
indirect costs for NCDs patients were highest for cancer and DM, with estimates up to 
24740 USD30 and 23418 USD31, respectively. Mean annual indirect costs for breast cancer 
varied extensively, from 2109 USD32 to 24740 USD30. The lowest indirect cost for COPD 
was reported in Japan, with an average estimate of 326 USD33, and highest in USA (3393 
USD34). Mean DM indirect annual costs were estimated at 104 USD in Serbia35 compared 
to 7797 USD in China27. No study, however, reported annual indirect costs of colorectal 
cancer, lung cancer, cervical cancer or CKD.
Aggregate costs 
Mean annual total costs of NCDs per patient were reported in 17 articles (Table 2C). Cancer 
and stroke led the total costs with average estimates up to 105310 USD30 and 44937 
USD31 respectively. The mean total cost per patient for breast cancer was estimated at 
30000 USD in Belgium36 and the USA37, although the mean costs for metastatic breast 
cancer were three times higher (105310 USD30). For lung cancer, mean estimates varied 
from 4964 USD16 in Australia to 50495 USD in USA38 whereas colorectal cancer total costs 
were 52068 USD38. Mean COPD total costs were estimated around 1700 USD in the UK 
and Japan33 but exceeded the value of 15500 USD in Denmark39. DM total costs were 
estimated at an average of 12920 USD in Sweden40 whereas estimated mean total costs 
in Serbia were 1005 USD41. No study reported total costs for cervical cancer or CKD. 
Costs of NCDs over time
There was an increase in healthcare costs associated with NCDs over time. One study 
showed that, despite a 19% decline in the hospitalization rate for CHD (acute myocardial 
infarction) in USA, overall healthcare expenditure per patient increased by 17% from 1998 
to 2008 (absolute difference of 6595 USD) and use of outpatient services increased by 65% 
(absolute difference, 1000 USD)42 and similarly for heart failure43. The average treatment 
cost of colorectal cancer patients in USA increased by 73% from 2005 to 200944, mainly 
driven by the use of new regimens, higher chances of surgery, and radiation. In USA, 
COPD-related healthcare costs increased by 5-6% annually45. Further, a 29% increase in 
medical treatment costs for diabetic patients was observed from 1999 to 2001 in Israel 
(absolute difference, 771 USD)46. 
Costs according to disease severity and comorbidity
Overall healthcare costs secondary to NCDs increased with the severity of the disease, 
years lived with the condition and co-morbidity9 36 47-57. Patients with severe stroke had 
almost a 40% greater increase in costs compared to mild stroke patients47. Among cancer 
patients, given the same stage of diagnosis, those with one, two or three co-morbidities 
experienced increased costs of 3737 USD, 4188 USD and 10442 USD respectively58. Costs 
for a diabetic patient tripled between the first and seventh year59 after diagnosis. An 
increase in treatment costs of breast cancer by stage was reported, with approximately 
52% higher treatment costs for stage II as compared to stage 057. Similarly, a 29859 USD 
increase was seen with cancer progression from stage I to stage IV29. Patients with co-
existence of COPD and CVD had 135% higher annual care costs compared with patients 
without CVD, whereas COPD related total costs were 38% higher56. Some studies reported 
lifetime healthcare costs of NCDs (initial, continuing and terminal care), demonstrating 
that initial and terminal care are the most costly.13 15 60-62. 
Global healthcare expenditure on NCDs
Among the reviewed studies, 30 reported healthcare expenditure attributable to specific 
NCDs (Table 3A). CVD accounted for 12% of all healthcare expenditure in the European Union 
(EU)63. CHD healthcare-related costs accounted for 14.2-16.5% of the annual healthcare 
budget in the American region. In contrast, in the EU, mean healthcare expenditure 
on CHD was 2.6%; within the EU, Malta has the lowest share (0.6%) and Slovakia the 
highest (5.9%)63. CKD and cancer accounted for 3.2% and 3.4%, of healthcare expenditure 
respectively25 64. In the USA, 1.2% of the healthcare budget was spent exclusively on the 
treatment of breast cancer25. The proportion of national healthcare-related expenditure 
for COPD ranged from 0.7% in Norway19, 1-3% in the Netherlands65 and up to 3.8% in 
Canada64. Again in Canada, 3.8% of healthcare expenditure is attributable to DM64 whereas 
in the European Union, DM-related healthcare expenditure was an estimated 7.4%66 (the 
Netherlands having the lowest share (1.6%), and Spain the highest)67.
In absolute terms, annual CVD hospital costs in the USA reached an estimated 400 billion 
USD in 2008, doubling the 195 billion USD in 199568,69. In USA, CHD-related hospital costs 
were estimated at 59.1 million USD in 1995 whereas the CVD-related hospital costs 
were 130 USD billion in 201070. In the EU, CVD-related hospital costs were estimated at 
151 billion USD in 2003, with CHD accounting for 32.9 billion USD63. In Australia, annual 
hospital costs due to CVD were estimated at 164 million USD in 199771. In France and 
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Hungary the annual estimated colorectal cancer health related costs were 565 million 
USD and 43 million USD respectively72,73. In Iran, the minimum annual healthcare-related 
cost for colorectal cancer was estimated at 39 million USD for the period between 2005 
and 201074. For cervical cancer, the estimated costs were 1.83 million USD in Singapore18, 
18.2 million USD in Spain75, and 12.98 million USD in Malaysia76. The estimated total 
healthcare costs in the USA for lung, colorectal, cervical and breast cancer combined were 
5.2 billion77. In USA, health-related costs for COPD and CKD in 2005 were an estimated 9.2 
billion USD24. COPD costs accounted for 232 million USD in Iceland19 whereas both COPD 
and DM accounted for 162 million USD in Australia78. DM hospital-related costs varied 
from 9.7 billion USA in the African Region79, to 41.1 billion USD67 in Europe and to 160 
billion USD in USA80.
A data series of hospital expenditure on CVD was only available in the USA. This showed 
a two fold increase in healthcare share from 1995 to 2008, with estimated health costs of 
195 billion USD in 1995 to 400 billion USD in 200868 69. An increase in healthcare expenditure 
was also seen for colorectal cancer in Brazil, from 18.54 million USD in 1996 to 37.64 
million USD in 200881. Yoon, J.J et al showed a sharp increase in healthcare spending on 
most chronic diseases from 2000 to 2008, with CKD having the highest increase by more 
than 1.62 billion USD82.
Impact of NCDs on national income
In general, NCDs have a large impact on national income mainly due to loss of productivity 
as a result of absenteeism and inability to work in 13 studies (Table 3B). There was a 463 
billion USD increase in economic loss in USA due to CVD for the period 1993-200868. In 
the EU, estimated economic loss in 2003 was 92.9 billion USD for CVD, of which CHD 
accounted for 31.84 billion USD. Estimated loss in national income from CHD-related 
productivity loss in 1996 was 71 billion USD in Germany83. Economic loss from stroke in 
1997 was 51.7 million USD in Australia84 whereas CHD-related productivity loss was 2.2 
billion USD in 200485. Worldwide, economic loss from colorectal, lung, breast and cervical 
cancer at 2009 year were 13.7, 8.2, 1.7 and 8.4 billion USD respectively86. In Malaysia, 
estimated income losses from cervical cancer-related productivity loss were 4.1 million 
USD. In the Netherlands, estimated losses in national income from COPD were 388 
million USD76 87. National income losses from DM were estimated at 20.8 billion in the 
African region in 2000 and at 65.2 billion in 2007 in USA79 88. 
Combined impact of NCDs on national income and healthcare expenditure 
19 studies reported the impact of NCDs on both healthcare expenditure and national 
income (Table 3C). The total estimated cost of CVD in Germany in 1999 was 108.9 billion 
USD whereas for the entire EU, the estimate was 244.3 billion USD for the year 2003, with 
CHD accounting for 26% of this cost63 83. Stroke costs were up to 1.3 billion USD in Australia, 
3.47 billion USD in Canada and 72.4 billion USD in USA71 89 90. Worldwide, colorectal, lung, 
breast and cervical cancer made up 41% (127.8 billion USD) of the 310.15 billion USD 
aggregate cost of new cancer cases in 2009, with lung cancer posing the highest economic 
burden (57.4 billion USD)86. In the USA, colorectal cancer and lung cancer total costs were 
2.5 billion USD38 each whereas in France, the total colorectal cancer costs were estimated 
at 1.24 billion USD72. In Malaysia, the total estimated cervical cancer costs were 17.1 
million76. Total COPD costs varied from 133.7 million in the Netherlands to 1.1 billion USD 
in Sweden and 9.1 billion USD in Japan33 49 87. Total estimated costs of DM increased from 
142.5 billion USD in 1997, to 171 billion USD in 2002 and to 195.5 billion USD in 200780 88 91. 
DM imposed 30.4 billion USD in costs on the African region and 46.7 billion USD in costs 
in China27 79. 
DISCUSSION
This systematic review summarizes 153 studies published worldwide that investigate 
the impact of six major NCDs (CHD, stroke, COPD, major cancers, type 2 diabetes and CKD) 
at the macro-economic level (i.e. health-related costs, healthcare budgets and national 
income). The studies suggest a steady global increase in healthcare expenditure on NCDs 
over the years. Additionally, NCDs undermine national economic development, with 
estimated losses in national income in excess of 600 billion USD.68 
In most countries, the highest expenditure was attributable to CVD. Between 12% 
and 16.5% of the overall healthcare budget is spent on this one condition alone; the 
proportion spent on the other NCDs ranges from 0.7% to 7.4%. In the USA and Brazil 
hospital expenditure on major NCDs doubled in a decade to an estimated 200 billion 
USD. An increasing share of healthcare expenditure on major NCDs has been reported 
previously and especially so in Germany where an increase from 27-51% of total health 
expenditure was reported.92 Similarly, in the USA, CHD-related healthcare costs were five 
times higher in 2008 than in 1996. Yet, little is known about what drives current and 
future NCDs-related healthcare costs. Interesting insights come from Australia; these 
show that the introduction of new technologies and changes in treatment practices 
(volume of treatment services) are more likely to drive healthcare costs as compared 
to ageing or other factors.93 In the overall projected increase in health expenditure in 
Australia up to 2032, volume of treatment services had the largest contribution (AUD 
81.3 billion), followed by population ageing (AUD 37.8 billion) and population growth (AUD 
34.4 billion). Also, Aaron, H et al. in a summary of the current evidence reported that most 
of the anticipated increase in total health care spending in USA is attributed to growth 
of age-specific health care spending and some will be caused by population ageing.94 
However, although health care spending at a time point in time may be influenced by 
ageing and in particular by the remaining life expectancy (and increases in longevity), 
there is limited data available projecting how the health care spending curve will evolve 
as life expectancy increases 94. More research is warranted in this respect.
Further, NCDs have a large impact on national income, with estimated losses ranging 
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from 4.1 million USD due to cervical cancer in Malaysia, to 71 billion USD in Germany 
and 600 billion USD in the USA due to CHD. Large-scale productivity losses mainly due 
to absenteeism and an inability to work, caused by the debilitating physical and mental 
impact of NCDs, have a direct detrimental impact on national income. A 2005 WHO report 
indicated that estimated losses in national income due to CVD, stroke and diabetes were 
3 billion USD in Brazil, 9 billion USD in India, 11 billion USD in Russia and 18 billion USD 
in China.95 Bradley et al. demonstrated that, with the same level of colorectal cancer risk 
factors in USA, estimated economic losses due to colorectal cancer would raise from 24.2 
billion USD in 2011 to 339 billion USD in 2020.96 A macro-economic simulation presented 
at the World Economic Forum in 2011 showed that over the next two decades, NCDs 
would lead to a staggering 47 USD trillion cumulative output losses globally, representing 
75% of global GDP in 2010.97
While the current study is the most detailed systematic review on the topic, it is limited by 
the fact that the evidence on economic burden of NCDs in LMIC is generally scarce. Most 
of the evidence in this review originates from high-income countries. Limited research 
capacity, inadequate financial investment, healthcare system development, a lack of 
electronic health records, and language restrictions may contribute to this shortage.98 
Using a systematic search in Pubmed and Embase, 14 review articles99 100-112 (including 
four systematic reviews99-101 106) evaluating the economic impact of different NCDs on 
healthcare expenditure were found. The majority of these reviews were not performed 
systematically and previous systematic reviews 99-101 106 have been published on the costs 
of specific NCDs. Valtorta and colleagues100 investigated the financial consequences of 
cancers, stroke, and heart failure but did not include diabetes, CVD, COPD, or CKD. Yabroff 
and colleagues99 used only MEDLINE, were focused on recent articles in English language, 
and tackled only colorectal cancer. 
Findings of this systematic review generally concur with and further extend the previous 
reviews. This systematic review evaluates economic consequences of six major NCDs 
using a global perspective in a single comprehensive investigation. Two reviewers, 
working in tandem, screened and selected the studies, while references of the included 
studies were additionally screened for any missing evidence. This approach ensured 
that we included most of the relevant articles in our review. Similar to previous reviews, 
however, we found substantial methodological limitations. Age range or stage of disease 
at diagnosis or other patients characteristics that may influence care and costs, were 
frequently not reported. Furthermore, many studies did not clearly state the method 
used to estimate costs and among the others, different approaches were used to 
calculate the same type of costs; e.g. direct attributable costs to diabetes were calculated 
by 1) including the direct costs of the events undergoing investigation; 2) comparing the 
cost of diabetes patients to those with no diabetes history; or 3) comparing previous 
resource use to resources use after the event. It may be argued that the studies using 
the first approach may not include all the costs associated with the disease. For example, 
diabetes patients are more likely to have fractures than those without diabetes.113 
Moreover, several methodological concerns of the studies reviewed were observed, 
related to sample selection and representativeness, case definition, the nature of costs 
included (e.g. all-cause or event-related) and the analysis costs of data over time. Also, 
there are differences among countries with regard to health care/welfare system which 
may partly explain the large variation of health care spending across countries and world 
regions. In many countries, private spending accounts for three quarters of national 
health expenditure whereas in some others, there is a large burden of health care into 
the public purse. 114 115 Although, it would be of interest to compare health care spending 
and the impact of NCDs on national income based on the organization of health care/ 
welfare system, this becomes challenging because of continuing pattern changes and 
shifts in health care/ welfare system in past several decades.115 Hence, comparisons 
across studies were difficult and a meaningful quantitative pooling of the existing data 
remains unfeasible. Therefore, future studies, especially those involving economic burden 
assessment using a standardized approach and based in LMI settings, are warranted. 
In spite of data limitations, the estimates reported here show that NCDs pose a significant 
financial burden on healthcare budgets and nations’ welfare that is likely to increase 
over time. Further work is necessary to standardize the methods to consistently assess 
the economic impact of NCDs worldwide and to involve hitherto under-addressed LMI 
populations across the globe. 
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ABSTRACT 
Background: 
Given the increasing life expectancy and transition from infectious to chronic diseases, 
healthy ageing is a key public health challenge of growing importance. 
Objectives: 
To develop a healthy ageing score (HAS), to assess age and gender differences in HAS, 
and to evaluate the association of the HAS with survival.
Design: 
Prospective population-based cohort.
Setting: 
Inhabitants of Ommoord, Rotterdam, the Netherlands.
Participants: 
1405 men and 2122 women, mean (standard deviation, SD) age 75.9 (6.4) years.
Main measures:
We included 7 domains in the total score of HAS: chronic diseases, mental health, 
cognitive function, physical function, pain, social support, and quality of life; each scored 
0, 1, or 2 in each domain. A total score (range 0-14) was constructed and was assessed 
continuously and in tertiles (13-14: healthy ageing, 11-12: intermediate ageing, 0-10: poor 
ageing). Gender-specific change in the mean HAS was computed for the age categories 
of 65-69, 70-74, 75-79, 80-84, and ≥85 years. The association between HAS and mortality 
was assessed with Cox Proportional Hazards models.
Results: 
Mean follow-up was 8.6 (3.4) years. Men had poorer scores in the chronic disease domain 
than women. However, women had poorer mental health, worse physical function, more 
pain, and lower quality of life compared to men. The prevalence of healthy ageing was 
higher in men (n=396, 28.2%), than in women (n=526, 24.8%). The mean (SD) HAS was 11.1 
(2.2) in men and 10.7 (2.3) in women. Mean HAS was higher in men than in women for 
all age categories. The ß for change in mean HAS across the 5 increasing age categories 
was -0.55 (-0.65 to -0.45) in men and -0.65 (-0.73 to -0.57) in women. The age-adjusted 
hazard ratio per unit increase in HAS with mortality was 0.86 (0.83 to 0.89) in men, and 
0.89 (0.87 to 0.91) in women. 
Conclusions: 
Levels of HAS were lower in women compared to men, in all age categories. The HAS 
declined with increasing age for both genders, albeit slightly steeper in women. The 
HAS was strongly associated with mortality in both genders. A better understanding of 
population healthy ageing and gender differences in this regard could aid to implement 
strategies for sustainable healthcare in ageing populations.
Keywords:
healthy ageing, age differences, gender differences, mortality, longevity, epidemiology
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INTRODUCTION
Our population is ageing.1 2 Between 2008 and 2040, the proportion of people aged 65 
years and older is projected to increase from 7% (506 million) to 14% (1.3 billion) of the 
world’s population.3 Additionally, the number of oldest old (aged 80 and over), is expected 
to increase by 233% in this time period.3 This demographic shift can be explained by 
better living standards and improvements in both preventive and curative health care.4 
Simultaneously, the main causes of death have shifted from infectious diseases towards 
age-related chronic diseases.5 These observed trends have led to ageing, and particularly 
healthy ageing, to become one of the top public health challenges,6 7 and resulted in the 
first World Report on Ageing and Health from the World Health Organization in 2015.8 
Focusing on health as a multidimensional state could facilitate prevention and treatment 
strategies.9 Theoretical frameworks have been formulated,10-14 and various operational 
definitions have been applied to populations.15 16 For example, Rowe and Kahn introduced 
a model for successful ageing, that included avoiding disease and disability, high cognitive 
and physical function, and engagement with life.13 14 This model has been critiqued for 
being too unidimensional, with its strong focus on physiological constructs for successful 
ageing.17 Therefore, recent applications have comprehensively included psychosocial 
constructs, such as mental health, and self-perceived health.18-20 Additionally, it has been 
suggested that continuum-based measures for healthy ageing might better capture the 
heterogeneity of the phenotype, as opposed to the more widely adopted dichotomous 
approaches.19 21 However, to date, no consensus for the measurement of healthy ageing 
exists.
Worldwide, women outlive men by 6 to 8 years. However, these years are often spent 
with more disease and disability: ‘men die quicker, women get sicker’.9 22 Whereas 
the operationalization of healthy ageing measures is upcoming, no studies have 
comprehensively assessed age and gender differences. Within the population-based 
Rotterdam Study, comprehensive and detailed information on subjective and objective 
measures, which are necessary to construct a healthy ageing score, are available. In 
addition, the vital status of all participants has been precisely adjudicated in this cohort 
of middle-aged and elderly men and women. Therefore, we aimed to develop a healthy 
ageing score (HAS) within the population-based Rotterdam Study and to assess age 
and gender differences. Furthermore, for illustrative purposes, we aimed to evaluate the 
association of the HAS with survival. 
METHODS
Study population
This study was embedded within the Rotterdam Study: a prospective, population-
based cohort among subjects 55 years and older in the municipality of Rotterdam, the 
Netherlands. The rationale and study design have been described elsewhere.23 The 
baseline examination of the original cohort was completed between 1990 and 1993 
(RS-I, visit 1). In the fourth visit of RS-I (2002-2004), assessments of social support and 
quality of life were introduced. Therefore, the current study included all participants 
alive at the fourth visit of RS-I. Of the 5.008 participants available for inclusion, 1.481 
were excluded due to missing data in more than 5 domains of the HAS. Hence, 1405 
men and 2122 women were included in the current study. The Rotterdam Study has 
been approved by the Medical Ethics Review Board of Erasmus Medical Center and by 
the Ministry of Health, Welfare and Sport of the Netherlands, implementing the Wet 
Bevolkingsonderzoek: ERGO (Population Studies Act: Rotterdam Study). All participants 
provided written informed consent to participate in the study and to obtain information 
from their treating physicians.
Assessment of healthy ageing score
In line with previously defined conceptual frameworks and applications,10-21 we included 
7 biopsychosocial domains in the development and construction of the healthy ageing 
score. These domains involved: chronic diseases, mental health, cognitive function, 
physical function, pain, social support, and quality of life. In each domain, the status was 
graded as low (0, corresponding to a worse status within the domain), moderate (1), or 
high (2, corresponding to an optimal status within the domain); Scheme 1. A total score, 
ranging from 0 to 14 was constructed, by summing up the values of these 7 domains. An 
extensive description of the HAS construction can be found in Supplemental Methods 1A. 
Assessment of all-cause mortality
In order to ascertain death and cause of death for all participants of the Rotterdam Study, 
mortality data was obtained via complementary approaches.23 Data sources included 
the central registry of the Municipality of Rotterdam, records from collaborating general 
practitioners, and information from follow-up rounds. The Central Registry of Genealogy 
of the Netherlands was consulted when the vital status of participants were missing. 
All-cause mortality was available up to October 1st, 2015.
Assessment of covariates
The following socio-economic and health behaviour factors were considered for inclusion 
as covariates in multivariable adjusted models examining the association of HAS with 
mortality: baseline age, education, household income, marital status, ethnicity, smoking, 
physical activity, dietary habits, alcohol intake, and waist-hip ratio. A description of the 
data collection procedure and coding of each covariate is provided in Supplemental 
Methods 1B. 
Statistical analyses
Participant characteristics were described using means (standard deviations (SD)) and 
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proportions. All analyses were stratified for gender, given that gender-based differences 
in health conditions, functioning, behaviour, and social relations may differentially affect 
patterns of healthy ageing.8
Characteristics of healthy ageing score
The correlation between the domains was assessed with Pearson correlation coefficients, 
and was considered high if it was ≥ 0.70.24 Thereafter, the prevalence of low, moderate, 
and high categories for each of the 7 included domains was assessed. Differences 
between men and women were tested using the Chi2 statistic. 
The healthy ageing score was constructed from the 7 domains as a score ranging from 0 
to 14. The HAS was assessed continuously as well as in tertiles. The distribution of HAS 
on a continuous scale was plotted using histograms. We calculated the mean HAS for 
men and women and additionally adjusted the mean HAS for age using linear regression 
analysis. We further evaluated and plotted the change of the mean HAS, stratified for 
age categories (65-69, 70-74, 75-79, 80-84, and ≥85 years) and gender. To define HAS 
tertiles, the cut-offs 12 and 10 were used for both men and women. Based on the 
tertiles, participants were categorized into 3 categories; healthy ageing (a score of 13-
14), intermediate ageing (a score of 11-12), and poor ageing (a score of 0-10). Differences 
Domain Low (score of 0) Moderate (score of 1) High  (score of 2)
Chronic diseasesa > 1 disease, 
‘multimorbidity’
1 disease 0 diseases
Mental health
CES-D
Score of 23-60 Score of 17-22 Score of 0-16 (no 
depressive symptoms)
Cognitive functioning
MMSE
Score of 0-20 Score of 21-25 Score of 26-30
Physical functioning
bADL/iADL
Severe disability on either 
bADL or iADL
Everything in between Mild disability on bADL 
and iADL
Pain (Very) severe pain in 
hands, knees, hips or 
back for at least 1 activity
Everything in between No or mild pain in hands, 
knees, hips and back in 
all activities
Social support ‘Agree’ in 0-2 statements ‘Agree’ in 3-4 statements ‘Agree’ for all 5 
statements
Quality of life Low QoL on 5-8 items Low QoL on 1-4 items High QoL on all 8 items
a Chronic diseases included: myocardial infarction, revascularization, heart failure, stroke, Parkinson’s disease, diabetes 
mellitus, chronic obstructive pulmonary disease, cancer, chronic kidney disease.
bADL=basic activities of daily living, CES-D= Center for Epidemiologic Studies Depression Scale, iADL=instrumental 
activities of daily living, MET=metabolic equivalent, MMSE=mini mental state examination, QoL=quality of life.
Scheme 1. Definition of healthy ageing score.
between men and women were tested using the Chi2 statistic.
Survival analyses
In secondary analyses, the association between HAS with mortality was assessed. 
However, this was only done for illustrative purposes, given that the HAS was developed 
to assess health status’ that extend beyond life or death.
The proportional hazards assumption was tested by evaluating log minus log survival 
plots. We developed two Cox Proportional Hazards models; an age-adjusted model 
(model 1) and a model further adjusted for covariates (model 2). To build model 2, we 
first selected the covariates that were associated with both the exposure (HAS) and 
the outcome (mortality) with a p-value below 0.2.25 Thereafter, using the likelihood ratio 
test, covariates were eliminated from the multivariable model via a backward selection 
approach if their contribution to the model was not significant. Hence, model 2 included 
the covariates: age, smoking (current vs never), smoking (former vs never), dietary habits, 
physical activity, and waist-hip ratio. This model could be considered a conservative 
model given that these covariates antecedently affect the domains of HAS or could be an 
intermediate factor in the association between HAS with mortality. We also developed 
survival plots for tertiles of HAS for men and women. Considering the borderline 
significant interaction term for HAS*gender (p=0.082) and significant interaction term for 
HAS*age (p=0.006), we calculated age and gender-specific hazard ratio’s (HRs) for HAS 
with mortality. HRs between the youngest and oldest age categories were compared 
using a test of interaction.26
Supplementary analyses
In order to reduce bias due to selective dropout of less healthy participants, values of 
the 7 domains and covariates were imputed for everybody alive at the start of the fourth 
visit of the Rotterdam Study and had values observed in at least 2 domains. None of the 
imputed variables had more than 35% missing data. Values were imputed using fully 
conditional specification (Markov chain Monte Carlo method) with a maximum iteration 
number of 20.
In sensitivity analyses, we compared the descriptive characteristics for the observed data 
to the data after multiple imputation. Moreover, we performed a comparison between 
the included participants in the study and the ones excluded. To evaluate the influence 
of choosing tertiles for categorical analyses of HAS, a second approach using the Youden 
Index was used. The Youden Index maximizes the sum of specificity and sensitivity, 
to attain an optimal cut-off value of healthy vs non-healthy ageing for mortality. In 
this scenario, having a score of 12 to 14 was categorized as healthy ageing whilst the 
remainder of the score was divided into 2 equal groups (a score of 10-11 for intermediate 
ageing and a score of 0-9 for poor ageing). Further sensitivity analyses included ruling out 
the possibility of reversed causality by excluding participants who died within the first 3 
years after baseline and a complete case analysis.
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General characteristics Men (n=1405) Women (n=2122)
Age, years 75.3 (6.0) 76.3 (6.6)
Education, n(%)
Primary education 156 (11.1) 417 (19.7)
Lower/intermediate general or lower 
vocational education
440 (31.3) 1070 (50.4)
Intermediate vocational or 
higher general education
538 (38.3) 532 (25.1)
Higher vocational education or 
university
271 (19.3) 103 (4.8)
Household income, in /1000,- 2.6 (1.1) 2.2 (1.0)
Marital status, n(%)
Never married 36 (2.6) 181 (8.5)
Married, living together 1124 (80.0) 919 (43.3)
Widowed, divorced 245 (17.4) 1022 (48.2)
Ethnicity, Caucasian 1372 (97.7) 2088 (98.4)
BMI, kg/m2 27.0 (3.5) 27.8 (4.6)
Waist-hip ratio 0.98 (0.07) 0.86 (0.07)
Smoking, n(%)
Current 241 (17.1) 281 (13.2)
Former 1040 (74.0) 866 (40.8)
Never 124 (8.9) 975 (46.0)
Physical activity, MET-hours/week 78.6 (43.6) 94.4 (46.0)
Dutch Healthy Diet Index, score 0-100 42.3 (9.7) 47.8 (9.8)
Alcohol intake, gram/day 15.9 (16.7) 6.9 (9.7)
Values are numbers (percentages) or mean (SD) unless stated otherwise. Decimal values for numbers, originating 
from the combination of multiple imputation sets, were rounded to integer values.
BMI=body mass index, CKD=chronic kidney disease, COPD=chronic obstructive pulmonary disease, MET=metabolic 
equivalents, MI=myocardial infarction, n=number, SD=standard deviation.
Table 1. Characteristics of the study population.
All analyses were performed using IBM SPSS Statistics Version 21.0 and R statistical 
software (http://www.r-project.org), Version 3.3.1. Associations with a p-value below 
0.05 were considered statistically significant.
RESULTS
Among the total population of 3527 participants, 1405 (39.8%) subjects were men and 
2122 (60.2%) were women (Table 1). Mean (SD) age was 75.3 (6.0) years and 76.3 (6.6) 
years in men and women, respectively. Nearly all participants (>97%) were of Caucasian 
descent. Two hundred seventy-one men (19.3%) completed higher vocational education 
or university, whereas in women this number was 103 (4.8%). Furthermore, 1124 men 
were married or living with a partner (80.0%), compared to 919 women (43.3%). 
Characteristics of healthy ageing score
The correlation between the separate domains ranged from 0 (correlation between 
chronic disease and social support) to 0.55 (correlation between mental health and quality 
of life) (Supplemental Table 1). Table 2 provides the prevalence of the 3 categories (low, 
moderate, and high) for the 7 domains included in the healthy ageing score. Compared 
to men, more women were in the high category for absence of chronic disease (41.2% in 
Men (n=1405) Women (n=2122)
Low (0) Moderate (1) High (2) Low (0) Moderate (1) High (2)
Chronic disease 452 (32.2) 508 (36.2) 445 (31.6) 427 (20.1)** 820 (38.7) 875 (41.2)**
Mental health 54 (3.9) 70 (5.0) 1281 (91.1) 172 (8.1)** 204 (9.7)** 1746 
(82.2)**
Cognitive function 35 (2.5) 182 (13.0) 1188 (84.5) 81 (3.8)* 292 (13.8) 1749 (82.4)
Physical function 54 (3.8) 234 (16.7) 1117 (79.5) 116 (5.5)* 459 (21.6)** 1547 
(72.9)**
Pain 90 (6.4) 457 (32.5) 858 (61.1) 312 (14.7)** 870 (41.0)** 940 (44.3)**
Social wellbeing 124 (8.8) 369 (26.3) 912 (64.9) 184 (8.6) 508 (24.0) 1430 (67.4)
Quality of life 78 (5.6) 467 (33.2) 860 (61.2) 176 (8.3)* 837 (39.5)** 1109 
(52.2)**
Values are numbers (percentages). Decimal values, originating from the combination of multiple imputation sets, were 
rounded to integer values.
* Difference between men and women, per category of the particular domain, statistically significant at α <0.05
** Difference between men and women, per category of the particular domain, statistically significant at α <0.001
Table 2. Prevalence of low, moderate, and high categories for the 7 domains included in the healthy 
ageing score.
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women vs 31.6% in men). However, fewer women were in the high category for adequate 
mental health (82.2% in women vs 91.1% in men), good physical function (72.9% in women 
vs 79.5% in men), absence of pain (44.3% in women vs 61.1% in men), and good quality of 
life (52.2% in women vs 61.2% in men). These differences did not change after adjusting 
for age. The mean HAS was 11.1 (2.2) and 10.7 (2.3) in men and women, respectively, and 
remained the same after adjusting for age. The distribution of HAS for men and women 
was similar (Figure 1). However, the proportion of favourable healthy ageing scores was 
higher in men than in women. When looking at HAS in tertiles, the proportion of healthy 
agers was higher in men than in women (Supplemental Table 2). Furthermore, the mean 
HAS decreased linearly across age categories, with borderline significant evidence for 
parabolic decline in both men (p=0.088) and women (p=0.059) (Figure 2). The ß for change 
in mean HAS across the 5 age categories was steeper in women (-0.65 (-0.73 to -0.57)) 
compared to men (-0.55 (-0.65 to -0.45)), but did not differ significantly by gender (p=0.12). 
Within age categories, the mean HAS was significantly higher in men aged 75-79 years 
(p=0.041) and aged 80-84 years (p=0.008) compared to women in the same age category. 
Survival analyses
Overall, 793 men died during mean 8.1 years (SD 3.6) years of follow-up, and 1002 women 
died during mean 8.9 (SD 3.3) years of follow-up. Whereas cumulative survival in men 
decreased from the start of follow-up and the decline was gradual over time, in women 
cumulative survival remained high and dropped more steeply towards the end of follow-
Figure 1. Distribution of the healthy ageing score for men and women.
up in age-adjusted model 1 (Figures 3A and 3B). This was the same for survival plots 
adjusted for covariates in conservative model 2 (Supplemental Figures 1A and 1B). For 
model 1 and model 2, the HRs per unit increase in HAS with mortality were 0.86 (0.83 to 
0.89) and 0.87 (0.83 to 0.90) respectively in men, and 0.89 (0.87 to 0.91) and 0.90 (0.87 to 
0.92) in women. Analyses were repeated for age and gender-strata (Supplemental Table 
3). In women, the HR of the youngest age category was stronger than the HR of the 
oldest age category (p=0.02), whereas no differences were observed in men (p=0.77). To 
further explore this differential effect on mortality, the proportions of low, moderate, and 
high scores within each of the 7 HAS domains were stratified for gender and age groups 
(Supplemental Table 4). For the domains mental health and pain, fewer women were in 
the high category compared to men and this remained significantly different for all age 
categories. 
Supplementary analyses
The observed data and the data after multiple imputation did not substantially differ 
(Supplemental Table 5 and 6). Moreover, we compared participants included in the study 
to those excluded. The included participants were younger, slightly higher educated 
and had a lower proportion of prevalent chronic disease, compared to the excluded 
participants (Supplemental Table 7). 
Using the Youden Index, the optimal cut-off for healthy vs non-healthy ageing was 
12. Analyses were repeated using this optimal cut-off for defining the healthy ageing 
categories. The proportion of healthy agers was now 50.9% in men and 44.1% in women. 
Figure 2. Gender-specific change of the healthy ageing score across age groups.
ß for decline in men = -0.55 (-0.65 to -0.45)
ß for decline in women = -0.65 (-0.73 to -0.57)
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Figure 3B. Age-adjusted survival plots for healthy ageing score in tertiles, for women.
The light grey line indicates healthy aghhers (score of 13-14),the middle grey line intermediate agers (score of 11-12), 
and the dark grey line poor agers (score of 0-10). 
The hazard ratios for age-adjusted model 1, for healthy and intermediate ageing, compared to poor ageing, were 0.42 
(95%CI: 0.34 to 0.52) and 0.63 (95%CI: 0.53 to 0.74) for men, and 0.44 (95%CI: 0.36 to 0.54) and 0.70 (95%CI: 0.61 to 0.82) 
for women, respectively.
Cum survival=cumulative survival.
Figure 3A. Age-adjusted survival plots for healthy ageing score in tertiles, for men. The survival analysis results remained similar to the previous categorization based on 
tertiles of HAS (Supplemental Figures 2A and 2B). 
Finally, in complete case analyses and in analyses excluding people who died within the 
first 3 years of follow-up, the direction, magnitude, and significance of the association 
between continuous HAS and mortality remained the same.
DISCUSSION
Considering the growing importance of healthy ageing as a key public health challenge, 
we developed a healthy ageing score consisting of 7 biopsychosocial domains in the 
population-based Rotterdam Study. Overall, we found that the HAS was lower in women 
in all age categories. With regard to the specific domains, more men had multimorbidity 
(i.e. more than 1 chronic disease) compared to women, whereas women had worse mental 
health, more pain, more disability, and a lower quality of life compared to men. The HAS 
declined with increasing age, albeit slightly steeper in women. Additionally, a higher HAS 
was strongly associated with lower mortality in both genders. Whereas the strength of 
this effect was stable across age groups in men, the association was less strong in older 
women compared to younger women. 
Methodological considerations
This study developed a HAS in a large population-based sample and explored age and 
gender differences in great detail. Strengths of our study include the large sample size, 
availability of detailed information which led to a comprehensive definition for HAS; 
incorporating physiological constructs, social support, as well as quality of life. The latter 
two have proven to be of particular importance in the elderly, as their subjective attitudes 
towards health may differ significantly from what is measured objectively.17 Additionally, 
the multidimensionality of the score allowed us to capture other aspects of healthy ageing 
that have not been explicitly included in the score. For example, we would expect to capture 
the burden of osteoporosis and fractures in the domains of pain and physical function. 
Another strength of our study is that our defined healthy ageing score is an interesting 
tool for clinical settings, for several reasons. Importantly, our defined healthy ageing score 
is relatively easy and inexpensive to measure, since all domains can be measured using 
questionnaires. In addition, the 0-14 continuous scale makes it easier to detect changes 
in healthy ageing over time, compared to a conventional dichotomous successful vs 
non-successful ageing approach. Finally, the comprehensive definition of HAS allows for 
directed interventions targeting the domains that require attention.
Besides these strengths, the limitations also merit careful consideration. Unhealthy 
persons were less likely to be included in the current study, compared to the more healthy 
agers. Therefore, as inherent to all cohort studies, the possibility of health selection bias 
cannot be ruled out. Moreover, nearly all participants were of Caucasian descent. Therefore, 
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the generalisability of our findings may be hampered. Furthermore, severity of disease 
was not included as a separate domain. Although this could have been captured, to some 
extent, in the other domains of the HAS, we cannot rule out that this might have led to an 
underestimation of the levels of morbidity. 
Furthermore, given that there is no consensus for the definition of healthy ageing or 
uniform measurement guidelines, the cut-offs used within some of the domains and for 
the HAS were arbitrary (i.e. a score of 0, 1, or 2). Although we could have lost information 
by categorizing continuous measures, such as the Mini Mental State Examination for 
the domain of cognitive function, it prevented the use of complex statistical modelling 
strategies. Hence, the HAS in its current form allows for straightforward interpretation 
from a clinical perspective.
Each domain was given an equal weight in the total score. Although we can argue that 
there is sufficient evidence from literature for inclusion of each of these domains, we 
cannot judge whether or not all should receive the same weight. If one would want to 
assess weights of specific domains, a multivariable prediction rule should be created, with 
an outcome that can serve as an adequate gold standard measure for healthy ageing. 
Since there are different working definitions of healthy ageing, and various perspectives 
to which underlying construct is being measured, there is no consensus on the best gold 
standard for healthy ageing measurement tools. Furthermore, the most appropriate gold 
standard may depend on the objectives and context in which healthy ageing is measured. 
A possible gold standard could be resilience, and is the opposite of vulnerability: the 
underlying construct of frailty.10 27 28 How much the concepts of healthy ageing and frailty 
overlap, remains to be elucidated.29 Others have proposed vitality30 or positive health (e.g. 
flourishing)31 as underlying constructs of healthy ageing. In our study, we did not create 
such multivariable prediction rule. However, we did assess that the correlation between 
the domains did not exceed 0.55. Hence, this provides assurance that the overlap between 
the domains was sufficiently small. 
Results in relation to other studies
Both men and women scored high on the healthy ageing score, i.e. a mean score of above 
10 on a scale from 0-14. Approximately one third to half of the participants were classified 
as healthy agers, depending on the cut-off used. This finding is in line with a review 
summarizing 28 studies, in which the mean reported proportion of successful agers was 
35.8% (SD 19.8).16 In contrast, the large variation in measurement scales among studies 
resulted in large variation in proportion of successful agers in a second review that varied 
between 1 and 90%.15 
Gender differences in healthy ageing
We observed numerous gender differences in HAS at all ages. Women had a lower proportion 
of healthy agers compared to men, which was in line with a similar study from Assmann 
and colleagues.18 Despite women living longer than men, their extended life expectancy was 
accompanied by poorer scores in more domains, including worse mental health, more pain, 
and more disability. Given the weaker relation of these domains with mortality, this may 
also explain why in older women the association between the HAS and mortality became 
weaker. These findings are in line with the theory of the ‘male-female disability-survival 
paradox’, which describes that women live longer than men but with more disability.32 33 To 
explain this paradox several explanations have been proposed. Among others, sex-specific 
gene expression and differential effects of sex hormones can be related to this paradox.34 
Another explanation encompasses behavioural differences between the sexes, in such 
that men and women differ with regard to their symptom perception and attribution,35 
patient delay for consulting health care professionals,35 and over reporting of worse health 
outcomes in women.33 36 Also, less pathognomonic symptom presentation in women may 
lead to diagnostic delays and less timely treatment initiation, which could result in more 
severe consequences in terms of long-term disability.34 It may also be possible that men 
have greater severity of disease, resulting in higher mortality.33
CONCLUSIONS
In the current study, we developed a comprehensive score for healthy ageing in a 
population-based study. The score included biological, psychological and social domains, 
most of which were easy and inexpensive to measure with questionnaires. We found that 
levels of the HAS in this elderly population were high, and that considerable gender and 
age differences occurred. These included lower levels of HAS and steeper decline across 
age categories in women and the differential importance of the different health domains 
between the sexes. 
Future research is needed to further understand which factors are associated with 
healthy ageing and which interventions are effective for maintaining, improving, and 
recovering healthy ageing. In this regard, a gender-sensitive approach needs to be 
adopted. Additionally, more research is needed to assess changes in healthy ageing over 
time, within individuals and between populations. From a conceptual perspective, a better 
understanding of which gold standard underlying constructs should be used, could aid the 
establishment of a strong contemporary field of healthy ageing research.
The importance of keeping people healthy throughout their life course is evident, particularly 
when taking into account that our population is ageing. This study adds to the body of 
research by expanding the existing theoretical frameworks and incorporating experiences 
from other operational definitions, to define a practical application. The findings of our 
study have implications for researchers, clinicians, and policy makers, for all of whom a 
gender-sensitive perspective is essential.19 For researchers, this is an interesting tool to 
adopt given its theoretical and experience-based foundation. Clinicians could benefit from 
monitoring healthy ageing in their patients over time. Finally, the measurement of healthy 
ageing in populations could help policy makers to allocate funds to keeping people healthy.
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ABSTRACT
Background: 
The concept of cardiovascular health (CVH) was recently introduced. Sex steroids and 
sex hormone-binding globulin (SHBG) influence different health domains, but no studies 
assessed their role in CVH. 
Objective:
To assess the association between estradiol (E2), testosterone (T), SHBG, and free 
androgen index (FAI) with CVH.
Design, setting, and participants: 
Analyses included 1647 men (68.6 years) and 1564 naturally-postmenopausal women 
(69.6 years) with available data on sex steroids and CVH from the population-based 
Rotterdam Study.
Main exposure measures: 
E2, T, SHBG, and FAI.
Main outcome measures: 
To define CVH, 7 metrics including 3 health factors (total cholesterol, fasting glucose and 
blood pressure) and 4 health behaviours (physical activity, smoking, body mass index and 
diet) were adopted. Three category levels of each metric were added up to a total score 
ranged 0-14. Logistic regression was performed to explore the association between E2, T, 
SHBG, and FAI and optimal cardiovascular health (OCH, score 11-14).
Results: 
OCH was reached by 153 men (9.3%) and 162 women (10.4%). The prevalence of OCH was 
higher in the lowest tertile of E2 (38.9%), and of T (43.8%), and the highest tertile of SHBG 
(48.1%) in women, and the highest tertile of T (43.1%) and SHBG (47.1%) in men. After 
adjustment for confounders, OCH was associated with lower T (OR (95%CI ): 0.69 (0.48 to 
1.00)) and lower FAI (0.43  (0.32 to 0.57)) and higher levels of SHBG (4.55 (2.99 to 6.94)) 
among women and with higher levels of SHBG (2.56 (1.45 to 4.4 )) in men. 
Conclusions: 
OCH was associated with sex steroids and with SHBG in both men and women. The 
complexity and temporality of the interrelation between sex steroids, SHBG, and CVH 
requires further investigation.
Keywords: 
sex steroids, sex hormone-binding globulin, cardiovascular diseases, epidemiology
INTRODUCTION
Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality 
worldwide.1 2 To outline new directions for research and to advocate clinical and public 
health programs for health promotion and disease prevention, in 2010 the American 
Heart Association (AHA) introduced the concept of cardiovascular health.3 This new 
concept defines health as a broader construct than merely the absence of clinically 
apparent disease and is based on the levels that span the entire range of seven health 
factors and behaviours; including cholesterol, glucose, blood pressure, physical activity, 
smoking status, body mass index, and diet.3 
With the use of cut-offs for levels of health factors and behaviours that are all literature-
based or originating from clinical practice guidelines, the AHA defines the cardiovascular 
health status as poor, intermediate, or ideal.3 Ideal cardiovascular health (ICH) is defined 
as having ideal levels of 3 health factors (total cholesterol <200 mg/dL, fasting plasma 
glucose <100 mg/dL, and blood pressure <120 / <80 mm Hg) and 4 health behaviours 
(75-150 minutes of moderate and/or vigorous physical activity, non-smoking, body mass 
index <25 kg/m2, and a healthy diet).3 
ICH has been shown to be related to less severe subclinical atherosclerosis,4-6, lower 
incidence of CVD and lower cardiovascular mortality.6-10 However, the applicability and 
relevance of cardiovascular health metrics extend beyond the cardiovascular system. 
Ideal cardiovascular health is also related to better cognition,11 better psychological 
status,12 lower cancer risk,13 more favourable overall functional status,14 and lower all-
cause mortality.9 10 
Sex steroids, such as estradiol (E2) and testosterone (T), and sex hormone-binding globulin 
(SHBG), influence individual cardiovascular risk factors and cardiovascular morbidity and 
mortality,15-18 and differences between men and women have been reported.19 The pivotal 
role of sex steroids and SHBG in bodily systems, among which the cardiovascular system, 
makes them a promising interventional target. Thus far, sex steroids and SHBG have 
been mostly related to the single cardiovascular risk factors and the presence or absence 
of CVD and its related comorbidities.15 16 Nevertheless, large population-based samples, 
using gold standard measures of sex steroids and SHBG together with concurrent 
analyses in men and women are lacking. Using the recent AHA concept of cardiovascular 
health, we aimed to assess the association between sex steroids (including E2 and T), 
SHBG and free androgen index (FAI) with overall cardiovascular health among men and 
postmenopausal women from a large population-based cohort study.
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METHODS
Study population
The study was embedded within the Rotterdam Study (RS), a prospective, population-
based cohort study among subjects 55 years and older in the municipality of Rotterdam, 
the Netherlands. The rationale and study design have been described in detail elsewhere.20 
The baseline examination was completed between 1990 and 1993 (RS-I). The cohort was 
extended in 2000, to include all inhabitants who had become 55 years of age or moved 
into the research area after the start of the study (RS-II). 
The present study included 1647 men and 1564 postmenopausal women from the third 
visit of RS-I (1997-1999) and the baseline visit of RS-II (2000-2001) with written informed 
consent and available sex steroid and SHBG measurements and cardiovascular health 
metrics. Women with surgical menopause or women who reported ever using female 
steroids were excluded from the analyses. An overview of the study participant selection 
can be found in the flowchart (Figure 1). The Rotterdam Study has been approved by the 
Medical Ethics Committee of the Erasmus MC and by the Ministry of Health, Welfare and 
Sport of the Netherlands, implementing the Wet Bevolkingsonderzoek: ERGO (Population 
Studies Act: Rotterdam Study). All participants provided written informed consent to 
participate in the study and to obtain information from their treating physicians.
Measurements of E2, T, SHBG, and FAI
All blood samples were drawn in the morning (≤ 11:00 am) and were fasting.
Estradiol levels were measured with a radioimmunoassay and SHBG with the Immulite 
platform (Diagnostics Products Corporation Breda, the Netherlands). The corresponding 
intra- and interassay coefficients of variation with lower limit of detection (LLOD) of 
the assays were <11%, <11% and 18.35 pmol/L for E2 and <4%, <5% and 0.02 nmol/L for 
SHBG. Serum levels of T were measured with liquid chromatography-tandem mass 
spectrometry (LC-MS/MS), with a corresponding interassay of <5% and a lower limit of 
quantification (LLOQ) of 0.07 nmol/L. The FAI was calculated as (T/SHBG)*100 and only 
in women, since this measure performs poorly in men, and is considered a surrogate 
marker for free testosterone levels.21 
Optimal cardiovascular health
The 7 metrics of cardiovascular health included 3 health factors (total cholesterol, 
glucose and blood pressure) and 4 health behaviours (body mass index (BMI), diet, 
smoking, physical activity)3. A detailed description of the application of the 7 metrics 
to the participants of the Rotterdam Study can be found in the Supplemental Methods 
Section. We used the AHA definitions of poor, intermediate, and ideal categories for each 
of the 7 metrics. The thresholds for these categories were based on data available from 
existing guidelines and from reviews of the literature.3 
For each metric, a participant received 0 points if that metric fell into the poor category 
(i.e. BMI ≥30), 1 point for the intermediate category (i.e. BMI = 25-29.9) or 2 points for the 
ideal category (i.e. BMI <25). Every metric had the same weight. Therefore, as there are 7 
metrics in total, a maximum score of 14 could be reached. Participants with prevalent CVD 
(including CHD, stroke, and heart failure) were not excluded from the analyses; instead 
their metric scores were subtracted by 1, resulting in a maximum total cardiovascular 
health score of 7 for these subjects.3 For the metrics total cholesterol, blood pressure, 
and fasting plasma glucose, being treated for hypercholesterolemia, hypertension or 
diabetes, was accounted for by assigning a lower score on that metric to the participant 
(e.g. moving from the ideal to the intermediate category).3 None of the participants 
had ideal cardiovascular health, i.e. a score of 14. Therefore, for statistical analyses 
purposes, the total cardiovascular health score was dichotomized into 2 groups: optimal 
cardiovascular health (OCH, score of 11-14) versus non-optimal (non-OCH, score of 0-10). 
Figure 1. Flowchart for selection of study participants.
a Chronic diseases include diabetes mellitus, cardiovascular disease, chronic obstructive pulmonary 
disorder, and cancer.
RS=Rotterdam Study.
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Statistical analyses
Participant characteristics were described using means (standard deviations) and 
proportions. The prevalence of OCH in gender-specific tertiles of E2, T, SHBG, and FAI was 
determined. Thereafter, statistical significant differences between these prevalences 
were assessed using a Chi square test.
To assess the independent relationship between the exposures E2, T, SHBG, and FAI with 
the outcome OCH, logistic regression was used. Analyses were performed separately 
for men and women. Because of skewed distributions, E2, T, SHBG, and FAI were 
transformed to a natural logarithmic scale. Per exposure 3 models were created. The 
covariates were selected based on their association with both E2, T, SHBG, or FAI and 
cardiovascular health. Model 1 was adjusted for age and for years since menopause 
(only in women). Model 2, was adjusted for age, years since menopause (only in women), 
cohort (RS-I vs RS-II), ethnicity (Caucasian vs. non-Caucasian), marital status (married, 
never married/divorced, widowed), chronic disease including CVD, DM, cancer and chronic 
obstructive pulmonary disorder (absent vs present), education (continuous), and other 
sex steroids. In model 3, we additionally adjusted model 2 for waist-hip ratio. Model 3 
could be considered a conservative model, since body fat most likely intermediates in the 
association between E2, T, SHBG, and FAI and cardiometabolic factors, for instance via 
the direct increase of androgen production (both via the enzyme 17beta-hydroxysteroid 
dehydrogenase in adipose tissue as well as via stimulation of androgen production in 
the ovaries), and the stimulation of insulin and insulin-like growth factor resulting in the 
inhibition of SHBG production in the liver.22-25
Estradiol levels below 18.35 pmol/L were under the detection limit of the immunoassay 
used, which led to a truncated distribution, particularly in women. Therefore, we checked 
whether the association for tertiles of E2 and OCH in women would show the same trend 
as the continuous approach. 
In order to further explore the role of the health behaviours and the health factors, the 
total cardiovascular health score was separated into a cardiovascular behaviour (optimal 
score 7-8) and a cardiovascular factor score (optimal score 6-8) and the same models as 
described above were created.
In sensitivity analyses we restricted the analyses to the healthy population, excluding 
men and women with prevalent chronic diseases including CVD, chronic obstructive 
pulmonary disorder (COPD), and cancer. 
All analyses were performed using IBM SPSS Statistics version 21.0. Associations 
were considered statistically significant at a p-value < 0.05. In a more conservative 
approach and to take into account multiple testing, we applied a conservative Bonferroni 
corrected p-value of p<0.0125 for 4 tests (E2, T, SHBG, and FAI), since these exposures are 
interrelated.
RESULTS
Of the study population, nearly all were from Caucasian descent and 48.7% were women. 
The mean age of the study population was 68.6 years (SD 7.5) and 69.6 years (SD 8.0) 
in men and women respectively. Women were on average 20.4 years (SD 9.4) after 
menopause. An overview of the study characteristics, including cardiovascular health 
metrics as well as sex steroids and SHBG can be found in Table 1.
None of the participants adhered to the definition of ICH (i.e. a total score of 14). Optimal 
cardiovascular health (OCH, score of 11-14) was reached by 153 men (9.3%) and 162 
women (10.4%).
In men, the prevalence of OCH was non-significantly higher in the middle tertile of 
estradiol (p for the difference: 0.080) (Figure 2A). In women, the prevalence of OCH (38.9%) 
was slightly higher in the lowest tertile of E2 but the differences were not statistically 
significant (Figure 2A). For T, a differential trend was found between men and women 
(Figure 2B). The highest prevalence of OCH (43.1%) was found for the highest levels of T 
(tertile 3) in men, whereas in women the highest prevalence (43.8%) was found for the 
lowest levels of T (tertile 1). For both men and women, prevalence of OCH was the highest 
for high levels of SHBG (47.1% for men and 48.1% in women) (Figure 2C). Prevalence of OCH 
was significantly higher (52.5%) in the lowest levels of FAI (tertile 1) in women (Figure 2D).
In Table 2 the associations between per unit increase natural log transformed E2, T, 
SHBG, and FAI with OCH can be found, expressed in odds ratios (OR) and 95% confidence 
intervals (95%CI). Optimal cardiovascular health was associated with lower levels of E2 
in women (OR (95%CI): 0.66 (0.48 to 0.89)) and with higher levels of T in men (OR (95%CI): 
2.33 (1.43 to 3.80)) in model 1, but did not remain statistically significant in model 2 (after 
adjustment for all potential confounders). For women, the direction of the observed 
effect remained the same for categorized E2, indicating that the observed effect is not 
driven by the detection limit of the E2 assay. Lower T was significantly associated with 
OCH in model 2 for women (OR (95%CI): 0.69 (0.48 to 0.99)). 
Furthermore, OCH was associated with higher levels of SHBG in both men and women 
in model 2 (OR (95%CI): 2.56 (1.45 to 4.49) for men and 4.55 (2.99 to 6.94) for women). 
In women, OCH was further associated with lower levels of T (OR (95%CI): 0.69 (0.48 to 
1.00)) and FAI (OR (95%CI): 0.43 (0.32 to 0.57)). All associations mentioned above remained 
significant after applying a conservative Bonferroni correction for 4 tests, except the 
association between T and OCH in women. After additionally adjusting model 2 for 
waist-hip ratio in the conservative models (model 3), the magnitude of the associations 
between E2, T, SHBG, and FAI with OCH attenuated. Nevertheless, the odds ratio of SHBG 
in men and SHBG and FAI in women remained statistically significant.
In sensitivity analyses, restricted to the healthy population, the association between E2, 
T, SHBG, and FAI and OCH remained the same (Supplemental Table 1). When splitting up 
the total cardiovascular health score into optimal behaviours and factors, the direction 
of the observed effects in men and women remained the same and the magnitude of 
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the effects remained similar. The significance of the associations for optimal factors 
was comparable to OCH. For optimal behaviours some differences in significance were 
observed; in men the association between T and optimal behaviours and in women the 
associations for T and E2 with optimal behaviours remained significant in all models, 
which was not the case for OCH (Supplemental Table 2). 
DISCUSSION
Overall, levels of sex steroids and SHBG were associated with cardiovascular health 
including factors and behaviours, irrespective of potential confounders. Optimal 
cardiovascular health was associated with lower levels of T and FAI and with higher 
SHBG levels in women. Among men, OCH was associated with higher SHBG levels. In our 
population, none of the participants had ideal cardiovascular health (i.e. a score of 14) and 
only one tenth had optimal cardiovascular health (i.e. a score of 11-14).
Cardiovascular health has been shown to be related to different risk factors and diseases 
of the cardiovascular system and its effects extend further to other health domains.4-14 
The marked low prevalence of ideal cardiovascular health in our study is similar to 
previously published reports.6-10 Studies have shown that better cardiovascular health 
translates into lower risks for cardiovascular morbidity and mortality as well as all-
Men, n=1647 Women, n=1564
General characteristics   
Age, years 68.6 (7.5) 69.6 (8.0)
Prevalent chronic disease, yesa 606 (36.8%) 346 (22.1%)
Waist-hip ratio 0.97 (0.93 to 1.01) 0.86 (0.81 to 0.93)
Ethnicity, Caucasian 1611 (97.8%) 1531 (97.9%)
Education
Primary 147 (8.9%) 256 (16.4%)
Lower/intermediate or lower vocational 522 (31.7%) 837 (53.5%)
Intermediate vocational or higher general 640 (38.9%) 365 (23.3%)
Higher vocational or university 338 (20.5%) 106 (6.8%)
Marital status
Married, living together 1424 (86.5%) 972 (62.1%)
Never married, divorced 91 (5.5%) 221 (14.1%)
Widowed 132 (8.0%) 371 (23.7%)
Table 1. Characteristics of the study population.
Health behaviours   
BMI, kg/m2 26.5 (3.1) 27.2 (4.3)
Smoking
Current 383 (23.3%) 247 (15.8%)
Former 16 (1.0%) 9 (0.6%)
Never 1248 (75.8%) 1308 (83.6%)
Diet
Sodium intake, g/day 2192 (1900 to 2512) 2163 (1871 to 2486)
Wholegrain intake, g/day 128 (83 to 168) 117 (88 to 155)
Fish intake, g/week 73 (0.44 to 167) 69 (0.65 to 158)
Fruit & vegetable intake, g/day 372 (275 to 498) 445 (331 to 589)
SSB intake, g/week 34 (-0.50 to 479) 6 (1 to 290)
Physical activity
Moderate and vigorous activity, min/week 885 (540 to 1350) 960 (630 to 1410)
Health factors   
Diastolic blood pressure, mmHg 77.6 (11.4) 75.2 (10.7)
Systolic blood pressure, mmHg 143.3 (20.8) 142.3 (20.7)
Total cholesterol, mg/dl 213.8 (36.8) 233.4 (37.0)
Fasting blood glucose, mg/dl 108.1 (26.5) 103.4 (20.2)
Serum lipid lowering medication, yes 208 (12.6%) 185 (11.8%)
Antidiabetic therapy, yes 84 (5.1%) 51 (3.3%)
Blood pressure lowering medication, yes 345 (20.9%) 364 (23.3%)
E2, T, SHBG, and FAI   
Estradiol, pmol/L 98.7 (76.1 to 125.8) 27.5 (18.4 to 51.8)
Testosterone, nmol/L 16.7 (13.1 to 20.9) 0.9 (0.6 to 1.2)
SHBG, nmol/L 46.5 (36.0 to 59.7) 60.2 (43.7 to 83.1)
Free androgen index  NA 1.4 (1.0 to 2.2)
Women-specific variables   
Age of menopause, yearsb NA 49.1 (4.7)
Menopause type, natural menopause NA 1305 (83.4%)
Years since menopause, yearsb NA 20.4 (9.4)
a Prevalent chronic disease consists of diabetes mellitus, cardiovascular disease, chronic obstructive pulmonary 
disorder, and cancer.
b Age of menopause was not available for all women, the presented value is based on 1551 women.
Values are reported as number (percentage) for categorical variables and mean (standard deviation) or median (27th-
75th quartile) for continuous variables.
BMI=body mass index, E2= estradiol, FAI=free androgen index, n=number, NA=not applicable, RS=Rotterdam Study, 
SHBG=sex hormone-binding globulin, SSB=sugar sweetened beverages, T=testosterone.
Table 1. Continued
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Figure 2A-D. Prevalence of optimal cardiovascular health across gender-specific tertiles of E2, T, SHBG, 
and FAI.
Figure 2A-D. Prevalence of optimal cardiovascular health across gender-specific tertiles of E2, T, SHBG, 
and FAI.
E2=estradiol, FAI=free androgen index, SHBG=sex steroid-binding globulin, T=testosterone.
The values of the tertiles are as follows:
Estradiol: men (18.4-83.8 / 83.9-115.7 / 115.8-365.5), women (18.4-18.4 / 18.5-42.3 / 42.4-320.0).
Testosterone: men (0.18-14.2 / 14.3-19.4 / 19.5-41.3), women (0.07-0.7 / 0.8-1.1 / 1.2-30.1).
SHBG: men (11.3-39.6 / 39.7-55.0 / 55.1-187.8), women (10.8-48.2 / 48.3-73.2 / 73.3-200.0).
FAI: women (0.05-1.1 / 1.2-1.9 / 2.0-38.0).
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 Men Women
Estradiol OR (95%CI) OR (95%CI)
Model 1 1.33 (0.85 to 2.08) 0.66 (0.48 to 0.89)*
Model 2 1.02 (0.59 to 1.76) 0.73 (0.50 to 1.07)
Model 3 1.21 (0.70 to 2.11) 0.75 (0.51 to 1.10)
Testosterone
Model 1 2.33 (1.43 to 3.80)* 0.81 (0.58 to 1.12)
Model 2 1.41 (0.81 to 2.45) 0.69 (0.48 to 0.99)
Model 3 1.25 (0.73 to 2.14) 0.70 (0.49 to 1.02)
SHBG
Model 1 3.10 (1.94 to 4.97)* 4.25 (2.84 to 6.36)*
Model 2 2.56 (1.45 to 4.49)* 4.55 (2.99 to 6.94)*
Model 3 2.12 (1.20 to 3.73) 3.55 (2.28 to 5.52)*
FAI
Model 1 NA 0.41 (0.31 to 0.54)*
Model 2 NA 0.43 (0.32 to 0.57)*
Model 3 NA 0.49 (0.36 to 0.67)*
Bold values indicate that the association is significant at p<0.05. 
The asterisk * indicates that the association remains significant at a Bonferroni corrected p-value of p<0.0125 for 4 
tests. The reported effect estimates are for 1 unit increase in log-transformed E2, T, SHBG, and FAI. 
Model 1: adjusted for age and for years since menopause (only in women). 
Model 2: adjusted for age, years since menopause (only in women), cohort, ethnicity, education, marital status, 
prevalent cancer/COPD, and estradiol / testosterone / SHBG depending on the model.
Model 3: model 2 + waist-hip ratio.
CI=confidence interval, E2=estradiol, FAI=free androgen index, NA=not applicable, OR=odds ratio, SHBG=sex hormone-
binding globulin, T=testosterone. 
Table 2. The association between E2, T, SHBG, and FAI with optimal cardiovascular health, stratified by 
gender. cause mortality.6-10 In our population, these previously reported findings were supported. 
Each unit increase in the cardiovascular health score was significantly associated with 
a 9% and 12% decrease in incident fatal and nonfatal cardiovascular disease in men and 
women, respectively (data not shown). For all-cause mortality this decrease in incidence 
was 7% in men and 9% in women (data not shown).
The importance of androgens and of SHBG with regard to the cardiovascular system in 
both men and women is progressively becoming apparent.15 16 18 19 Sex steroids and SHBG 
have been shown to influence individual cardiovascular risk factors and cardiovascular 
morbidity and mortality.15 16 18 19 To date, most studies have focused on the absence or 
presence of single cardiovascular risk factors or diseases. By adopting the AHA metrics 
for cardiovascular health we were able to provide a comprehensive overview of the 
association between sex steroids and SHBG with cardiovascular health in the general 
population and these associations differed in terms of magnitude and direction by type 
of exposure (i.e. E2, T, SHBG, or FAI) and gender. 
Androgens & SHBG
Higher levels of T were associated with optimal cardiovascular health among men. 
However, after adjusting for confounders these findings did not remain statistically 
significant. Low endogenous T has been linked to a less favourable cardiovascular risk 
profile (e.g. dyslipidemia, blood pressure, thrombosis, endothelial dysfunction), whereas 
its role in CVD and CVD mortality is modest.16 17 The therapeutic effects of exogenous T 
have not been proven to be beneficial or have even been harmful with regard to the risk 
of CVD.16 26
In women, lower levels of T and FAI were associated with optimal cardiovascular health. An 
unfavourable cardiovascular risk profile, atherogenicity, and more severe atherosclerosis 
have been associated with higher levels of T and FAI, although the significance of these 
results was not consistent across studies and hard clinical endpoints such as CVD and 
mortality were scarce.15 18 27-29 
The FAI is calculated from total T and SHBG and only validated in women.21 It would be 
possible that the significance of FAI is driven by SHBG.18 Indeed in our data, in contrast to 
total T, high levels of SHBG were strongly associated with OCH in women.
Estradiol
For estradiol, no significant associations were found between E2 and optimal 
cardiovascular health in men. Women with OCH tended to have lower levels of E2, but 
this association did not remain significant after adjustment for potential confounders. 
Although the direction of this association seems counterintuitive, a recent study showed 
the same direction of effect, i.e. higher E2 levels were associated with stiffer vessels that 
were smaller in diameter in both men and women.29 Furthermore, the risk of CHD and 
stroke were elevated at higher levels of E2, although this effect was attenuated after 
adjustment for confounders.27 30 In metabolic studies, focusing on glucose intolerance 
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and diabetes, a similar trend was found.31-33
To date, it remains unclear which exact mechanisms underlie the relation between low 
E2 and optimal cardiovascular health. However, several potential mechanisms have 
been described. Visceral adiposity, which is associated with atherogenic dyslipidemia, 
insulin resistance/diabetes, and inflammation, is suggested to increase E2 levels via 
two pathways. Firstly, adiposity is negatively correlated with SHBG, which in turn leads 
to a higher fraction of bioactive E2. Secondly, central adiposity increases aromatase 
activity and therefore the conversion of T into E2.34 Higher levels of E2 have been shown 
to be more strongly associated with atherothrombotic stroke in older postmenopausal 
women who had greater central adiposity.30 In our study, adjusting for waist-hip ratio 
in our conservative models led to an attenuation in the observed associations for all 
exposures, although the association between SHBG and FAI with OCH in women and 
SHBG and OCH in men remained significant, suggesting that body fat may not completely 
explain the relation between E2, T, SHBG, and FAI and OCH.
Complexity of the role of sex steroids and SHBG in cardiometabolic health
Considering the complexity of the interactions and associations, which might further 
occur differently by gender, findings regarding the associations between sex steroids 
and SHBG and cardiovascular health should nevertheless be interpreted with caution. 
A point of notion for both men and women is the difference in the interpretation of 
results for free T versus total T with regard to cardiovascular endpoints.16 Although the 
magnitude of the effect for both T measurement types is similar, each could reflect a 
different effect.35 As shown in diabetes research, the longitudinal relation between free T 
and incident DM implies a direct sex steroid effect; whereas total T may in fact reflect the 
association between low SHBG and diabetes.36 37 SHBG could be related to DM via a direct 
causal pathway or indirectly via insulin resistance.15 16 36 38 Genetic studies have shown 
that polymorphisms in the SHBG gene are associated with a higher risk of diabetes, 
suggesting the existence of a direct pathway.36 39 40 In addition, it has been suggested 
that the role of SHBG in the pathophysiology of insulin resistance and diabetes, extends 
beyond the binding and transport of sex steroids.41-43 Studies have consistently shown 
that lower levels of SHBG are independently associated with higher insulin resistance and 
a higher risk of diabetes, implying that SHBG may be an important metabolic marker.41-44 
Furthermore, insulin sensitivity is associated with systemic inflammation, which has 
been shown to be related to CVD.16 Indeed, in our data for both men and women we found 
a strong association between high SHBG levels and optimal cardiovascular health, that 
were independent from estradiol and testosterone, further emphasizing the importance 
of SHBG in the cardiometabolic system. 
A second issue that warrants attention in all research focusing on E2, T, SHBG, and FAI 
and cardiometabolic health is the fact that they are all interrelated. Cholesterol (one 
of the seven metrics of cardiovascular health) is a precursor of T, T can be aromatized 
into E2 or reduced into dihydrotestosterone locally in cardiovascular tissues, and the 
activity of androgens in its turn may depend on the levels of estrogen.16 19 45 Furthermore, 
SHBG and other binding proteins play a key role in the activity of sex steroids and SHBG 
levels strongly depend on adiposity levels.34 46 Therefore, it remains elusive whether the 
observed associations reflect a true relation or an underlying unobserved process. 
Strengths and limitations
An important strength of our study is the availability of a large representative population-
based sample with detailed information on the cardiometabolic profile for each individual. 
Furthermore, androgens were measured with LC-MS/MS, which is currently considered 
the gold standard method.21 47 Our study is the first to focus on the association of E2, 
T, SHBG, and FAI with the new concept of cardiovascular health, instead of merely 
the presence or absence of cardiovascular risk or disease. Good cardiovascular health 
has been related to optimal health in other domains such as better cognition,11 better 
psychological status,12 lower cancer risk,13 more favourable overall functional status,14 
and lower all-cause mortality.9 10 Therefore, the implications of the association between 
E2, T, SHBG, and FAI and cardiovascular health may extend beyond the cardiovascular 
system. Given the increasing number of studies describing positive effects regarding the 
combination of several ideal health factors and behaviours for CVD free survival, overall 
(healthy) longevity, quality of life, and the subsequent reduction in health care costs, the 
overall cardiovascular health approach, in contrast to the individual risk factor approach, 
comprises growing clinical relevance.3
However, the limitations of our study also merit attention. Firstly, the cross-sectional 
design does not allow us to address the temporality of the observed associations. 
Therefore, we cannot draw any conclusions with regard to the causality of the 
observations. Nevertheless, the predefined definition of cardiovascular health, which 
includes both health factors and behaviours, made the application of a longitudinal study 
design unfeasible, for we would not expect E2, T, SHBG, and FAI to directly predict health 
behaviours such as physical activity or smoking habits. However, indirect pathways have 
been described. Studies suggest that the menopausal transition is accompanied by a 
decrease in energy expenditure (mainly due lower physical activity levels), a decrease 
in food intake, and an increased appetite.48 49 Furthermore, health behaviours can also 
affect levels of E2, T, SHBG, and FAI, for example a healthy diet and exercise can decrease 
estradiol levels in postmenopausal women,50 and lifestyle factors (e.g. smoking, diet, and 
physical activity) are associated with SHBG and T changes in men.51 52 The levels of E2, T, 
SHBG, and FAI might also be affected by changes in bodyweight. A study conducted by 
Wildman and colleagues suggests a unidirectional relation between body weight and sex 
steroids and SHBG, such that changes in body weight lead to changes in testosterone 
and SHBG. The relation between body weight and estradiol was bidirectional, although 
the associations in the direction of body weight predicting levels of estradiol were 
stronger than the reverse.53
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Secondly, all metrics received the same weight (i.e. a score of 0, 1 or 2), since the definition 
of cardiovascular health does not prioritize any metric above the others.3 In order 
to give insight in any differential effect of E2, T, SHBG, and FAI on health factors and 
behaviours, a sensitivity analysis separating the two was performed and is provided in 
the supplementary material. Thirdly, we performed several number of tests. However, 
in order to take into account multiple testing, a conservative Bonferroni correction was 
applied which did not materially change the significance of our findings. Free T levels 
were not measured directly in the blood and therefore have to be interpreted with 
caution. Nevertheless, free T levels in this study were derived from the ratio of T to SHBG, 
which is considered a precise proxy for bioavailable T.54 Finally, E2 was measured using 
an immunoassay with a detection limit of 18.35 pmol/L, which is considered suboptimal 
particularly in postmenopausal women. However, the direction of the observed effect 
remained the same whilst analysing E2 continuously and categorically. 
CONCLUSIONS 
In summary levels of sex steroids and SHBG were associated with optimal cardiovascular 
health. Optimal cardiovascular health was associated with lower levels of T and FAI and 
with higher SHBG levels in women. Among men, OCH was associated with higher SHBG 
levels. After additional adjustment for waist-hip ratio, the effect sizes of E2, T, SHBG, and 
FAI in both men and women attenuated, although they remained significant for FAI and 
SHBG in women and for SHBG in men.
Using the concept of cardiovascular health, instead of merely the presence or absence 
of disease or focus on separate cardiovascular risk factors, allowed us to assess the role 
of E2, T, SHBG, and FAI in the cardiovascular system in a comprehensive manner and the 
implications may extend beyond the cardiovascular system to other health domains. 
To facilitate the development of preventative and treatment strategies, the complexity 
and temporality of the interrelation between E2, T, SHBG, and FAI and the cardiometabolic 
profile, and the role of body fat distribution in particular, warrants further investigation.
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ABSTRACT 
Middle-aged and elderly women constitute a large and growing proportion of the 
population. The peri and postmenopausal period constitutes a challenging transition time 
for women’s health, and menopausal health is a crucial aspect in healthy and successful 
ageing. Currently, no framework for the concept of healthy menopause exists, despite its 
recognized importance. Therefore, we aimed to: (i) characterize healthy menopause; (ii) 
identify aspects that contribute to it; and (iii) explore potential approaches to measure it.
We propose healthy menopause as a dynamic state, following the permanent loss 
of ovarian function, which is characterized by self-perceived satisfactory physical, 
psychological and social functioning, incorporating disease and disability, allowing the 
attainment of a woman’s desired ability to adapt and capacity to self-manage. The 
concept of healthy menopause applies to all women from the moment they enter the 
menopausal transition, up until they reach early and late postmenopause and includes 
women with spontaneous, iatrogenic, and premature menopause. 
This conceptualization can be considered as a further step in the maintenance and 
improvement of health in menopausal women from different perspectives, foremost the 
woman’s own perspective, followed by the clinical, public health, and societal perspectives, 
and can be seen as a further step in delineating lines for future research. Furthermore, it 
could facilitate the improvement of adequate preventive and treatment strategies, guide 
scientific efforts, and aid education and communication to health care practitioners and 
the general public, allowing women the achievement of their potential and the fulfillment 
of their fundamental role in society.
Keywords:
health, menopause, ageing, conceptual framework, measurement
Pushing the boundaries of life 
Our population is ageing. As a result of improvements in health care and prevention 
accompanied by declining fertility rates, the proportion of people above 60 years of 
age is increasing.1 2 This is particularly the case for women, as their life expectancy is 
6-8 years longer than for men.1 Despite the advantages for women in terms of life 
expectancy, women tend to live longer suffering disease and disability: men die quicker, 
women get sicker.3 4 Disease and disability in women has been related with a key 
transitional phase women experience in midlife: menopause. The menopausal transition 
demarks dramatic changes at the hormonal, physiological, and metabolic level.5 These 
alterations, accompanied by burdensome life experiences and lifestyle changes, lead to 
an increased risk of chronic noncommunicable disorders among women.6 The peri and 
postmenopausal period constitutes a challenging transition time for women’s health, 
and good menopausal health is a crucial aspect in healthy and successful ageing, carrying 
substantial societal benefits.5 6 
Menopause and the health related aspects of menopause have been intensively 
studied.7 8 Nevertheless, a comprehensive conceptualization of healthy menopause 
and its entailment remains unclear. Until now no studies have characterized healthy 
menopause or have come up with a framework to describe the concept of menopausal 
health. Therefore we aimed to: (i) characterize healthy menopause; (ii) identify aspects 
that contribute to healthy menopause; and (iii) explore potential approaches to measure 
healthy menopause.
Health…the holy grail?
Good health can be considered both an individual’s fundamental right as well as a 
resource for individuals to be able to fulfil their personal, social, and economic roles in 
society.9 Therefore, many have attempted to define it. The best known definition of health 
was formulated by the World Health Organization in 1948: “a state of complete physical, 
mental and social well-being and not merely the absence of disease or infirmity”.10 The 
applicability of this definition is limited and has been challenged by the observed shift 
from acute to chronic disease over the last decades as the literal implementation of the 
definition would designate all chronically diseased as permanently ill. With improved 
detection, diagnosis, treatment, and survival, levels of health and the possibility of being 
characterized as healthy diminishes even further. Additionally, “complete health and 
wellbeing” although a commendable goal, is also hard to achieve and challenging to 
operationalize.11 12 
This could be a reason why past and current health research does not focus on health but 
rather on risk factors, diseases, and mortality. This approach to health research might 
limit our understanding of the overall effect of factors that are involved in the dynamics 
of obtaining, regaining, and maintaining health. Furthermore, a more general focus on 
health as a multidimensional state could facilitate prevention and treatment strategies.13 
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Contemporary approaches to health
The conceptualization of health has been influenced by sociologist Aaron Antonovsky, 
who developed the theory of salutogenesis, i.e. the origin of health characterized by the 
relation between health, stress and coping, and which can be seen as the complement 
of pathogenesis.14 The theory rejects the current separation of health and illness and 
positions individuals along the “health-ease – dis-ease continuum”. This complementary 
approach to health and disease is also reflected in the classification systems of the WHO, 
including the International Classification of Diseases and the International Classification 
of Functioning, Disability and Health.15 16
A more recent definition of health is given by Bircher and describes health as a balance 
between individual potential and faced demands: “Health is a dynamic state of wellbeing 
characterized by a physical, mental and social potential, which satisfies the demands 
of a life commensurate with age, culture, and personal responsibility. If the potential 
is insufficient to satisfy these demands the state is disease”.17 This balance can differ 
between individuals and vary across different stages of life.13 What Bircher describes 
as potential available for health, consisting of the sum of biologically given potential 
(e.g. genetic configuration) and personally acquired potential (e.g. education, developed 
abilities, healthy lifestyle), is also in line with Antonovsky’s work.
At a conference for international health experts the preferred view on health was “the 
ability to adapt and to self-manage”.11 A description of three interacting domains of health 
was given. Firstly, physical health was described as the ability to maintain physiological 
homeostasis through changing circumstances. Secondly mental health consisted of 
the successful capacity to cope and recover from psychological stress, and incorporated 
Antonovsky’s sense-of-coherence. Finally, social health included, among others, social 
participation.11 
Reflecting on previous definitions and concepts, a comprehensive approach to 
conceptualizing health would include health and disease as a continuum, reflected as 
a dynamic balance between faced demands and an individual’s capacity to adapt / self-
manage. Furthermore, it would incorporate characteristics such as physical, mental, 
and social functioning, that can differ between persons and can change across different 
life stages, allowing for an individual to optimize his or her resources in order to feel 
healthy regardless of illness or disability. How specifically these concepts can be applied 
to different individuals, populations, and stages of life, such as menopause, remains to 
be elucidated.
Menopause: accident, disease, process or relief?
With advancing age, a woman’s chance of achieving an ongoing pregnancy declines. This 
is predominantly dictated by a gradual decrease in both the quantity and the quality 
of oocytes, which reflects the process of ovarian ageing.18 In the fourth month of the 
development of the female fetus the ovaries contain approximately 6-7 million oocytes, 
which is already reduced to a remaining 1–2 million primordial follicles at birth as a result 
of apoptosis.19 The number of oocytes further decreases throughout life until finally 
the follicle pool is nearly depleted (count < 1000 follicles) and menopause is reached.20 
Menopause is defined by the World Health Organization (WHO) as the permanent cessation 
of menstruation due to the loss of ovarian follicular activity. The final menstrual period 
is retrospectively assigned after 12 consecutive months of amenorrhea, in absence of 
other pathological or physiological causes.21 Menopause generally occurs around the age 
of 51 years, with a range between 40-60 years worldwide.21 22 Studies in human natural 
fertility populations indicate that the end of natural fertility (i.e. sterility) occurs around 
the age of 41 years, with a similar variation in age as observed for age at menopause.23 
24 A similar variation is observed for the onset of menstrual cycle irregularities preceding 
menopause, which commonly occurs around the age of 46 years.25 In 2001 the Stages 
of Reproductive Aging Workshop (STRAW) introduced specific terminology and staging 
criteria to define the various phases of reproductive ageing. Based on menstrual cycle 
pattern and qualitative follicle stimulating hormone (FSH) criteria the following phases 
were distinguished: 1. the (early, broad and late) reproductive stage, 2. the (early and 
late) menopausal transition, 3. the (early and late) postmenopause.5 The biological 
processes encompassing menopause are part of a woman’s life and should therefore not 
be regarded as a medical condition but as a natural phase of a woman’s life cycle that 
extends beyond the ovaries and reproductive capacity, generating repercussions in all 
organs, tissues and all aspects of a woman’s life. So what is healthy menopause exactly?
Healthy menopause: a conceptual framework
In order to summarize the existing body of literature regarding menopausal health, a 
search strategy with the elements “menopause” and “health” was performed in Embase.
com (February 5th 2015). The search yielded 17.516 hits, of which the titles and abstracts 
of the top 500 articles after sorting by relevance ranking were screened. None of these 
articles attended to the overall concept of healthy menopause and a little over fifteen 
percent indirectly discussed key menopausal health subdomains such as sexual health 
or bone health. Overall, we were unable to identify any conceptual framework for healthy 
menopause.
In view of literature and the conceptual gaps, we propose to characterize healthy 
menopause by means of a user-based conceptual framework, positioning women and 
their needs at the center. This conceptualization can be seen as a further step in the 
maintenance, recovery, and improvement of health in middle-aged and elderly women 
from different perspectives, foremost the woman’s own perspective, followed by the 
clinical, public health, and societal perspectives, and can be considered as a further step 
in delineating lines for future research. 
We propose healthy menopause as (Figure 1): 
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A dynamic state, following the permanent loss of ovarian function, which is characterized 
by self-perceived satisfactory physical, psychological and social functioning, incorporating 
disease and disability, allowing the attainment of a woman’s desired ability to adapt and 
capacity to self-manage.
The concept of healthy menopause applies to all women from the moment they enter the 
menopausal transition, up until they reach early and late postmenopause and includes 
women with spontaneous, iatrogenic, and premature menopause. Current evidence 
delineates the menopausal transition in particular as a period during which substantial 
short and long term alterations occur in different domains of women’s health and quality 
of life.5 8 Temporal health consequences include, among others, the manifestation of 
vasomotor symptoms, depression, and sleep disturbances.26 27 Potential long term health 
risks include, among others, the development of osteoporosis, urogenital complaints, 
dyslipidemia, insulin resistance, and weight gain.28-30 Furthermore, health-related quality 
of life (HRQoL) is a dimension of menopause as well as functioning, whereas overall quality 
of life (QoL) could be considered one of the dimensions of a woman’s ability to adapt and 
capacity to self-manage, recognizing the importance of the distinction between HRQoL 
Figure 1. Illustration of the proposed conceptual framework for healthy menopause. The terms physical, psychological, 
and social refer to self-perceived satisfactory physical, psychological, and social functioning. as opposed to overall QoL.31 Therefore, the transitional phase provides a unique window 
of opportunity to improve the future health status of women.
The conceptual framework emphasizes self-perceived satisfactory functioning and a 
woman’s desired ability to adapt and her capacity to self-manage, hereby enabling her 
to determine and gain control over her health. It incorporates disease and disability, not 
necessarily implying that this will affect her sense of wellbeing and quality of life. Healthy 
menopause can be seen as a combination of obtained and developed resources utilized 
by a woman in order to maintain, revisit, adjust, recover, and improve the dynamic 
balance between every day opportunities and challenges. These resources expand at 
all levels and encompass women as a whole beyond their hormonal, reproductive, or 
physiological health.
Beyond the sum of all elements?
The cascade of hormonal changes through the menopausal transition can affect different 
body systems. In particular, changes in estradiol, FSH, and free androgen index coincide 
with an increase in cardiovascular risk, mood disorders, deteriorated mental and sexual 
functioning, and decreased bone density.32 Within the concept of healthy menopause, 
different body systems could be considered subdomains of health related to physical, 
psychological, and social functioning.8 It is beyond the scope of this paper to discuss 
each subdomain of health in detail. Nevertheless, a brief description of four major health 
subdomains is given below.
Cardiovascular risk. The incidence of cardiovascular disease (CVD), the leading single 
cause of death among women, increases substantially after menopause.33-35 Adverse 
changes in cardiovascular risk factors during the menopausal transition may account 
for this increase in CVD risk. While proatherogenic changes in lipid profile seem to be 
specifically related to ovarian ageing, unfavourable changes in other cardiovascular 
risk factors may be more influenced by chronologic ageing.36 Irrespective of the relative 
contributions of ovarian versus chronologic ageing to the increased CVD risk, the pre and 
perimenopausal period remains a critical time period in women’s lifespan when increased 
attention to risk factor modification could reduce the risk for subsequent CVD events. 
Mood and cognitive functioning. In general, women have a 2-fold greater risk for 
depression compared to men.37 During the menopausal transition, an increased risk 
of depressed mood and experiencing a major depressive episode have been reported. 
Hormonal changes during menopause might partly account for the increased risk of 
depression.38 While longitudinal studies of cognitive performance during the menopausal 
transition are scant, the impact of perimenopause on cognition appears to be subtle and 
transient.39 Estrogen effects on serotonergic function may be a key mechanism relating 
mood and cognitive symptoms in the menopausal transition.40
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Bone loss. While the results for the impact of menopausal transition on bone density 
are inconsistent, data from the Study of Women’s Health across the Nation (SWAN) 
suggests that there is no to little change in bone mineral density at midlife in pre or early 
perimenopausal women. Bone loss increases substantially in the later perimenopause 
and remains rapid in the first few postmenopausal years.41 In addition to estrogen 
deficiency, other risk factors such as low body weight and smoking also contribute to the 
pathogenesis of postmenopausal osteoporosis.41
Sexual functioning. The progressive decline of sex hormones together with psychosocial 
factors modulate vulnerability to sexual symptoms in menopause including low sexual 
desire, poor arousal and lubrication, dyspareunia, orgasmic dysfunction, and lack sexual 
pleasure.42 43 The close link between sexual satisfaction and general physiological well-
being of women makes sexuality an important element of healthcare for women at 
menopause.44 45
Beyond the aforementioned aspects, healthy menopause is characterized as an 
overarching concept at the intersection of multiple domains of health that could be 
measured in individuals and populations.
The numbers tell the tale?
 A multidimensional concept asks for multidimensional measurements. Consequently 
there may be various approaches to measuring menopausal health. These approaches 
can be consolidated following the conceptual framework and could be subdivided into 
objective and subjective measures, of which a non-exhaustive overview can be found in 
Table 1. The choice of measurement instruments depends on the purpose of use, such 
as the evaluation of preventative or treatment interventions, research tools, and the 
needed perspective including the clinical, public health, societal, or individual perspective.
Objective measures only do not suffice in measuring healthy menopause for several 
reasons. Firstly, risk assessment is not the same as health assessment,46 an example 
is the American Heart Association’s concept of cardiovascular health that includes ideal 
health behaviour and health factor metrics.47
Secondly, although disease and disability are incorporated into the conceptual framework 
of healthy menopause, disease and disability will not necessarily affect an individual’s 
sense of wellbeing and quality of life. This phenomenon is known as the disability 
paradox.48-51 Health, disease, and disability can coexist at different degrees changing 
dynamically over time and across the life course. Thirdly, objective measures do not 
incorporate the woman-centered perspective of this framework for healthy menopause, 
i.e. self-perceived satisfactory functioning and desired ability to adapt and self-manage. 
Nevertheless, objective measures may influence, although not necessarily, how a 
woman perceives her own health. Therefore, a comprehensive approach for measuring 
menopausal health may be a combination of both objective and subjective measures. 
Such a battery of comprehensive measurement methods could provide valuable 
information about aspects of menopausal health. However, the vast majority of 
these measurements fail to account for the multidimensional concept of healthy 
menopause as a whole and would need to be complemented by additional tools. The 
conceptualization of healthy menopause could be an initial step in designing tools to 
assess this multidimensional concept.
Putting things to practice
This unifying conceptual framework could facilitate the improvement of adequate 
preventative and treatment strategies, guide scientific efforts, and aid education and 
communication to health care practitioners and the general public. The menopausal 
Element Measurement tool examples References
Menopause WHO definition 21
STRAW criteria 5
Age-based 21 22
Functioning, disease and disability 36-item short-form 52  
EQ-5D 53
Health-related (i.e. menopause related) QoL 54-62
ADL / IADL 63 64
COOP/WONCA charts 65
Walking speed, grip strength 66-68
Health domain specific diagnostic toolsa
Productivity 69
QALY/DALY 70-72
Ability to adapt and self-manage None, thus partly via overall QoLb 73-75
a Examples of such diagnostic tools include, but are not limited to, the guideline on the assessment of cardiovascular 
risk,76 the 6-minute walking test,77 or the CESD/HADS depression and/or anxiety scales.78 79
b We are not aware of any available instrument to measure objective and subjective ability to adapt and self-manage. 
Nevertheless, overall quality of life might be valid as one of the dimensions of the ability to adapt and to self-manage.
ADL=activities of daily living, CESD=Center for Epidemiologic Studies Depression Scale, COOP/WONCA=Dartmouth 
Primary Care Cooperative Information Project/World Organization of Family Doctors, DALY=disability-adjusted life 
year, EQ-5D=EuroQol-5D, HADS=hospital anxiety and depression scale, IADL=instrumental activities of daily living, 
QALY=quality-adjusted life year, QoL=quality of life, SEIQoL=schedule for the evaluation of individual quality of life, 
STRAW=Stages of Reproductive Aging Workshop, WHO=World Health Organization.
Table 1. Non-exhaustive overview of measurement tools depicted per element of the overall concept of 
healthy menopause.
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transition is an opportune time for general education, recognition of signs and 
symptoms, promotion of healthy lifestyle, individualized counseling, and evaluation and 
possible treatment of modifiable risk factors. Recognizing this overarching, gradual, and 
comprehensive impact that the menopausal transition has in women, could aid women, 
professionals, and policy makers in their approach towards the realization of healthy 
menopause. 
Experiences from other fields that have made important transitions from a disease 
reduction to a health promotion perspective, such as sexual and cardiovascular health, 
could well serve as an example for successful implementation of the concept of healthy 
menopause.43 47 Taking into account the user-based framework, a coordinated bottom-
up approach is warranted. To significantly improve healthy menopause, professionals 
and policy makers should enhance women’s abilities to optimally cope with menopausal 
changes at midlife, and first embrace the overarching concept of healthy menopause and 
consider women as individuals rather than specific organs or domains. This approach 
could further contribute to improve women’s conditions and health, allowing the 
achievement of their potential and the fulfillment of their fundamental role in society.
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ABSTRACT
Background: 
Sex steroid hormones play important roles in the development of cardiovascular 
diseases (CVD). Extremes in low as well as high androgen levels have been associated 
with increased CVD risk in both men and women.
Objectives: 
To assess whether differences in androgen levels in women with various forms of ovarian 
dysfunction are associated with cardiometabolic abnormalities.
Design, setting, and participants: 
Cross-sectional study in 680 women with polycystic ovary syndrome (PCOS), premature 
ovarian insufficiency (POI), natural postmenopausal women (NM), or regular menstrual 
cycles (RC) (170 women per group). 
Main measures: 
Measurements of serum testosterone, androstenedione and dehydroepiandrosterone 
sulfate using liquid chromatography-tandem mass spectrometry. Assessments were 
taken of body mass index (BMI), blood pressure, lipid profiles, glucose, insulin, and SHBG, 
and the bioactive fraction of circulating testosterone was calculated using the free 
androgen index (FAI). 
Results: 
PCOS women were hyperandrogenic (median FAI = 4.9 (IQR 3.6 to 7.4)), and POI women 
were hypoandrogenic (FAI = 1.2 (0.8 to 1.7)) compared with RC women (FAI = 1.7 (1.1 to 
2.8)) after adjustment for age, ethnicity, smoking, and BMI (p<0.001). After adjustment 
for age, there were no significant differences in androgens between POI and NM (p=0.15) 
and between NM and RC (p=0.27) women, the latter indicating that chronological ageing 
rather than ovarian ageing influences the differences between pre-and postmenopausal 
women. A high FAI was associated with elevated triglycerides (ß log FAI for PCOS: 0.45, 
p<0.001, POI: 0.25, p<0.001, NM: 0.20, p=0.002), insulin (ß log FAI for PCOS: 0.77, POI: 0.44, 
NM: 0.40, all p<0.001), HOMA-IR (ß log FAI for PCOS: 0.82, POI: 0.46, NM: 0.47, all p<0.001), 
and mean arterial pressure (ß log FAI for PCOS: 0.05, p=0.002, POI: 0.07, p<0.001, NM: 0.04, 
p=0.04) in all women, with increased glucose (ß log FAI for PCOS: 0.05, p=0.003, NM: 0.07, 
p<0.001) and decreased high-density lipoprotein (ß log FAI for PCOS: -0.23, P < 0.001, 
NM: -0.09, p=0.03) in PCOS and NM, and with increased low-density lipoprotein (ß log 
FAI for POI: 0.083, p=0.041) in POI women. Adjustment for BMI attenuated the observed 
associations. Associations between FAI and cardiometabolic features were the strongest 
in PCOS women, even after adjustment for BMI
Conclusions: 
Androgen levels differed substantially between women with and without ovarian 
dysfunction, and increased androgen levels were associated with impaired 
cardiometabolic features in all women irrespective of their clinical condition. This study 
affirms the potent effect of androgens on cardiometabolic features, indicating that 
androgens should indeed be regarded as important denominators of women’s health. 
Future research regarding the role of androgens in the development of CVD and potential 
modulatory effects of BMI is required.
Keywords: PCOS, POI, menopause, androgens, cardiovascular risk factors
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INTRODUCTION
Sex steroid hormones are recognized to play a crucial role in the development of 
cardiovascular disease (CVD) in men and women.1 Although CVD is more prevalent 
amongst men, the incidence of CVD in women increases steadily beyond 50 years of 
age.2 Consequently, CVD currently represents the world’s leading cause of death in 
women.3 This rise in CVD incidence in women has been previously attributed to a decline 
in premenopausal estrogen levels following the menopausal transition.4 More recently, 
research has extended our understanding of the potential role of androgens in the 
development of CVD both in men and women.
Various studies in both sexes have proposed that extremes of low as well as high 
androgen concentrations are associated with increased CVD risk.5-7 In men, low androgens 
have been associated with dyslipidemia, increased body mass index (BMI), diabetes, 
hypertension and CVD mortality.8 9 Several studies in postmenopausal women have 
also reported an inverse relation between endogenous androgen levels, dyslipidemia 
and atherosclerosis.10-12 Furthermore, improvements in lipid profiles following estradiol/
testosterone replacement therapy have been reported in postmenopausal women.13 14 
In contrast, increased androgen concentrations have been shown to impair cardiovascular 
health in both men and women.15 16 Women with polycystic ovary syndrome (PCOS), 
especially those with hyperandrogenism, exhibit an increased prevalence of dyslipidemia, 
insulin resistance, obesity and CVD.17 18 Moreover, supplementation of androgens in 
postmenopausal women has been associated with decreased insulin sensitivity and 
with dyslipidemia.19 A chronically induced hyperandrogenic state appears to cause 
atherogenicity through inflammation, as demonstrated in female to male transsexuals 
treated with testosterone.20 
In women, androgens are produced in the ovaries, in the adrenal cortex and through 
peripheral conversion of precursor hormones.21 Decreased levels of circulating androgens 
have been reported in women with premature ovarian insufficiency (POI), who experience 
menopause before the age of 40 years.22 23 POI has been identified as a risk factor for the 
development of CVD.24 
In this study, we aimed to compare androgen levels measured by liquid chromatography-
tandem mass spectrometry (LC-MS/MS) and assess their associations with 
cardiometabolic features in women under different clinical conditions: PCOS (associated 
with hyperandrogenism), POI (associated with hypoandrogenism), women who 
experienced natural menopause (NM) and women of reproductive age with regular 
menstrual cycles (RC). 
 METHODS
Study population
Four groups of women were included in this study: women previously diagnosed 
with PCOS, women previously diagnosed with POI, women who experienced natural 
menopause (NM) and women of reproductive age with regular menstrual cycles (RC). 
The included women with PCOS or POI participated in a large prospective cohort study on 
menstrual cycle disturbances within the reproductive outpatient clinic of the University 
Medical Center Utrecht between November 2004 and July 2011. Women were screened 
according to a standardized protocol consisting of medical/reproductive history, 
anthropometric measurements, transvaginal ultrasonography and an extensive fasting 
endocrine/metabolic laboratory evaluation. Spare serum samples were collected and 
stored at -20 degrees Celsius. The screening procedure has been previously described 
in detail elsewhere.25 26 This study was conducted with approval of the local institutional 
ethical review board, and all participants provided written informed consent. The study 
was registered on www.clinicaltrials.gov with trial number NCT0230904. 
PCOS was diagnosed according to the Rotterdam criteria, if at least two of the following 
characteristics were present: ovulatory dysfunction, androgen excess and/or polycystic 
ovarian morphology.27 Ovulatory dysfunction was defined as an average menstrual cycle 
length of 35 days to six months (oligomenorrhea) or absence of a menstrual bleeding for 
≥ 6 months (amenorrhea). For the current study, we selected women with an anticipated 
hyperandrogenic PCOS phenotype, based on the primary clinical and biochemical 
assessment of hyperandrogenism. Clinical and biochemical hyperandrogenism were 
defined as a Ferriman-Gallwey score>8, and/or a free androgen index (FAI)>4.5 (FAI: 
(Testosterone / SHBG) x 100)).28 POI was defined as secondary amenorrhea ≥ 4 months 
occurring before the age of 40 years with accompanying FSH levels above 40 IU/L.29 
Women with POI were excluded if they had a history of past ovarian surgery and/or 
gonadotoxic treatment such as chemotherapy or radiation therapy. 
Included NM women were selected from the Rotterdam Study. The Rotterdam Study 
is a large prospective population-based cohort study of men and women of 45 years 
of age and older, which was initiated in 1990 in Ommoord, a suburb of Rotterdam, the 
Netherlands. This study has been designed to investigate the incidence and risk factors 
for various chronic illnesses such as cardiovascular and endocrine diseases, as has been 
previously described in detail.30 For the current study, women who experienced natural 
menopause after the age of 45 years, with a history of previous regular menstrual cycles 
throughout their reproductive life were selected.  
Included RC women were participants in a preconceptional cohort study in women 
starting IVF/ICSI treatment within the reproductive outpatient clinic of the University 
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Medical Center Utrecht between October 2006 and November 2013. This study was 
registered on www.clinicaltrials.gov with trial number NCT02309073. For the current 
study we included women undergoing IVF/ICSI treatment with the indication of severe 
male infertility, since these women were clinically evaluated and exhibited no signs of 
female reproductive dysfunction. Severe male infertility was defined as a semen analysis 
with volume × concentration × motility of < 2.0 million. Included women reported a 
regular mean menstrual cycle length between 21-35 days. 
None of the women included in this study were using any form of hormonal therapy/
contraception for at least six weeks prior to the moment of blood withdrawal. The current 
study was conducted with institutional ethical review board permission and all included 
women provided written informed consent. 
Endocrine and metabolic assessment
In all women testosterone, dehydroepiandrosterone sulfate (DHEAS), and androstenedione 
were measured with LC-MS/MS in serum samples that were previously stored at -20 
degrees Celsius.
All steroid hormones were measured simultaneously with a LC-MS/MS method using the 
CHS™ MSMS Steroids Kit (Perkin Elmer, Turku, Finland).The Steroids Kit uses a combined 
solvent extraction and protein precipitation method with acetonitrile containing the 
deuterated internal standards 2H5-androstenedione, 2H8-17 α-hydroxyprogesterone and 
2H5-testosterone. The internal standards undergo processing identical to the analytes. 
The chromatographic separation was performed on a Waters® Acquity™ UPLC HSS T3 1.8 
µm column (diameter 1 mm, length10 cm) and in-line filter frit 0.2 µm with acetonitrile/
MeOH gradient. A Waters XEVO-TQ-S system (Waters, Milford, MA, USA) equipped with 
an ESI source operating in the electrospray positive mode except for DHEAS (negative 
ESI). Multiple reaction monitoring was applied for the detection of the analytes using 
both quantifiers and qualifiers. The corresponding inter-assay coefficients of variation 
and lower limit of quantification (LLOQ) are the following: androstenedione <6.5%; LLOQ 
0.20 nmol/L, DHEAS <5.9%; LLOQ 0.25 µmol/L, and testosterone <5%; LLOQ 0.07 nmol/L.
In women with PCOS or POI, serum was drawn at the outpatient clinic in which insulin, 
glucose, SHBG and lipids were directly assessed. Insulin and SHBG were assessed with 
the Immulite 1000 assay (Diagnostics Products Corporation Breda, Netherlands) until 
April 2007 and thereafter with the Roche Modular E170 (Roche Diagnostics, Almere, 
Netherlands). (Conversion formula: Roche Modular E170 = 1.10 x (Immulite 1000) - 0.7). 
Glucose and lipids were assessed with the VITROS Chemistry System (Ortho-Clinical 
Diagnostics, Strasbourg, France) until November 2006 and then with the Unicell DxC 800 
assay (Beckman Coulter, Woerden, Netherlands). 
The corresponding intra- and interassay coefficient of variation with lower limit of 
detection (LLOD) of the last used assays were insulin <2 and <4%; LLOD: 0.5 mE/L, SHBG 
<2 and <5%; LLOD: 0.35 nmol/L, glucose <4 and <4%; LLOD: 0.3 mmol/L, lipids <2 and <3%; 
LLOD: 0.1 mmol/L. 
In natural postmenopausal women, serum was drawn during their evaluation for the 
Rotterdam Study, and insulin, glucose, SHBG and lipid profiles were directly assessed. 
Insulin and SHBG were determined using Immulite 2000Xpi (Diagnostics Products 
Corporation Breda). Glucose and lipids were assessed using the COBAS 8000 system 
(Roche Diagnostics). The corresponding intra- and interassay coefficients of variation 
with the LLOD of the last used assays were insulin <6 and <8%; LLOD: 14 pmol/L, SHBG 
<4 and < 5%; LLOD: 0.02 nmol/L, glucose <0.8 and < 1.4%; LLOD: 0.11 mmol/L, lipids <1.1 
and <2.1%; LLOD: 0.1 mmol/L.                     
There were no metabolic parameters available of the women of reproductive age with 
regular menstrual cycles. In these women, SHBG was assessed in serum samples that 
were previously stored at -20 degrees Celsius. 
Hormones included in the statistical analyses were testosterone, DHEAS, androstenedione, 
SHBG and the calculated FAI. Cardiometabolic features included in the analyses were 
total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) 
cholesterol, triglycerides (TG), insulin and glucose. The calculated homeostasis model 
assessment-insulin resistance (HOMA-IR; (glucose x insulin)/22.5) and mean arterial 
pressure (MAP; (2 x diastolic+systolic)/3)) were additionally included.31 32
Statistical analyses
A power calculation was performed based on the groups in which we expected to detect 
the smallest difference in the concentration of total testosterone (i.e. women with 
POI). We expected a clinically significant lower testosterone level in the POI group of 
1.12 nmol/L (SD ± 0.58) versus a testosterone of 1.36 nmol/L in women with regular 
menstrual cycles (RC).22 To obtain a power of 0.9 with a significance level of 0.05/4=0.0125 
(applying Bonferroni correction for multiple testing), 167 patients needed to be included 
in the current study. Taking into account potential processing/measuring errors, a total 
of 170 patients were included in each group. 
The primary research aim was to assess androgen levels and cardiometabolic 
characteristics in PCOS, POI, NM and RC women. All hormone levels and cardiometabolic 
features were log-transformed to obtain normally distributed variables. Crude and 
adjusted means were calculated and stratified per group using linear regression 
analyses. Due to the large age difference between the four groups, model 1 was primarily 
adjusted for age. Model 2 was adjusted for age, ethnicity and smoking, and could be 
considered the fully adjusted model. Since BMI is most likely an intermediate in the 
causal pathway between androgens and cardiometabolic characteristics, for instance, 
through direct inhibition of SHBG production and stimulation of insulin-like growth factor 
(IGF-I) production, adjusting for BMI could potentially result in an overadjustment.33 
Nevertheless, a third model including BMI was made. Furthermore, androgen levels and 
cardiometabolic features between the four groups of women were compared. Due to 
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large differences between the four groups of women, age differences in particular, we 
were not able to assign one reference group as this would result in unequal comparisons. 
Subsequently, we chose to make 4 specific one to one comparisons in order to obtain 
the most illustrative results. For androgen levels these comparisons were: PCOS versus 
RC, POI versus RC, POI versus NM and NM versus RC. In the absence of values for the 
RC group, we compared cardiometabolic features between the following groups: PCOS 
versus POI and POI versus NM. T-tests were used to assess crude statistical differences 
and linear regression with a dichotomous class variable (e.g. PCOS 1 vs. RC 0) for (multi)
variable adjusted statistical differences. 
The secondary research aim was to assess potential associations between androgen 
levels and the cardiometabolic features for women with PCOS, POI or NM. The FAI was 
used as a proxy for the androgen concentrations since it reflects the bioactive proportion 
of circulating testosterone levels. Associations were first depicted in scatterplots and 
subsequently assessed using linear regression analyses. Cardiometabolic features were 
used as the dependent and the FAI as independent variable, and adjusted for the same 
covariates as in models 1-3 of the primary research aim. Furthermore, we assessed 
whether the association between FAI and cardiometabolic features was significantly 
different for POI versus NM and PCOS versus POI women (p-value for interaction). 
SPSS version 21.0 was used for all analyses. Associations were considered statistically 
significant at a p-value of <0.05 after applying a Bonferroni correction for the number of 
performed comparisons.
RESULTS
The baseline characteristics, median androgen concentrations and cardiometabolic 
characteristics of participating women with PCOS, POI, NM and RC are outlined in 
Table 1. Women were predominantly from Northern European descent. The majority of 
women in the PCOS and NM group were overweight (64 and 62%, respectively). Figure 1 
shows the multivariable adjusted mean FAI of each group, which was used as a proxy 
for the androgen concentrations in further analyses. After adjustment for age, ethnicity, 
smoking and BMI, the FAI remained highest in women with PCOS, followed by the RC, NM, 
and POI women (Figure 1).
The differences in androgen concentrations between the four study groups are shown in 
Table 2. Women with PCOS exhibited a 3-fold increase in absolute FAI and a 2-fold increase 
in absolute testosterone levels compared with RC women, which remained significant 
after correction for age, ethnicity, smoking and BMI (both p<0.001). Women with POI 
exhibited a 30% decrease in absolute FAI and 12% decrease in absolute testosterone 
levels compared with RC women, which remained significant after correction for age, Ge
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Figure 1. Adjusted backtransformed means and confidence interval of the free androgen index.
Square, model 1 is adjusted for age. Triangle, model 2 is adjusted for age, ethnicity, and smoking. Circle, model 3 is 
adjusted for age, ethnicity, smoking, and BMI. The upper bounds of the confidence interval of models 1 and 2 in the 
PCOS group have been truncated (10.87 and 12.83, respectively). NM=women who experienced natural menopause, 
PCOS=polycystic ovary syndrome, POI=premature ovarian insufficiency, RC=women with regular menstrual cycles.
ethnicity, smoking and BMI (p<0.001 and p=0.002, respectively). After adjustment for age, 
there were no significant differences in FAI, SHBG and androgen concentrations between 
POI versus NM and NM versus RC. Additional adjustment for other covariates did not 
alter these findings. 
The differences in cardiometabolic features between PCOS versus POI and POI versus NM 
women are outlined in Table 3. After correcting for age, ethnicity and smoking, we found 
significant differences in HDL cholesterol (p<0.001), TG (p=0.001), insulin (p<0.001) and 
HOMA-IR (p<0.001) between (hyperandrogenic) PCOS and (hypoandrogenic) POI women. 
After additional adjustment for BMI, only HDL cholesterol levels remained significantly 
decreased in PCOS compared to POI women (1.2 versus 1.7 mmol/L, respectively; 
p<0.001). When comparing POI and NM women, significant differences were found 
for MAP and insulin levels in models adjusted for age, ethnicity and smoking (p<0.001 
and p=0.013, respectively). After additional adjustment for BMI, only MAP remained 
significantly different between POI and NM women (Table 3). 
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PCOS vs. RC POI vs. RC POI vs. NM RC vs. NM
Testosterone Model 1 <0.001 0.002 0.15 0.27
Model 2 <0.001 0.001 0.24 0.35
Model 3 <0.001 0.002 0.31 0.47
Androstenedione Model 1 <0.001 <0.001 0.14 0.49
Model 2 <0.001 <0.001 0.17 0.20
Model 3 <0.001 <0.001 0.15 0.19
DHEAS Model 1 0.43 0.12 0.96 0.73
Model 2 0.49 0.06 0.91 0.51
Model 3 0.37 0.07 0.85 0.43
SHBG Model 1 <0.001 <0.001 0.60 0.35
Model 2 <0.001 <0.001 0.55 0.31
Model 3 0.16 <0.001 0.83 0.18
FAI Model 1 <0.001 <0.001 0.12 0.99
Model 2 <0.001 <0.001 0.17 0.85
Model 3 <0.001 <0.001 0.51 0.56
Model 1 is adjusted for age. 
Model 2 is adjusted for age, ethnicity and smoking. 
Model 3 is adjusted for age, ethnicity, smoking and BMI (conservative model). 
P-values in bold are significant at p=0.05 after Bonferroni correction for 4 comparisons (i.e. p<0.0125).
DHEAS=dehydroepiandrosterone sulfate, FAI=free androgen index, NM=natural menopausal women, PCOS=polycystic 
ovary syndrome, POI=premature ovarian insufficiency, RC=women with regular menstrual cycles, SHBG=sex hormone-
binding globulin. 
Table 2. P-values for differences in androgens, SHBG and FAI between groups.
PCOS vs. POI POI vs. NM
Mean arterial pressure Model 1 0.03 0.004
Model 2 0.06 <0.001
Model 3 0.56 0.009
Total cholesterol Model 1 0.28 0.84
Model 2 0.28 0.78
Model 3 0.26 0.90
HDL cholesterol Model 1 <0.001 0.03
Model 2 <0.001 0.06
Model 3 <0.001 0.19
LDL cholesterol Model 1 0.29 0.21
Model 2 0.29 0.24
Model 3 0.97 0.38
Triglycerides Model 1 0.001 0.37
Model 2 0.001 0.37
Model 3 0.53 0.87
Glucose Model 1 0.53 0.86
Model 2 0.63 0.94
Model 3 0.44 0.69
Insulin Model 1 <0.001 0.016
Model 2 <0.001 0.013
Model 3 0.04 0.06
HOMA-IR Model 1 <0.001 0.03
Model 2 <0.001 0.02
Model 3 0.07 0.10
Model 1 is adjusted for age. 
Model 2 is adjusted for age, ethnicity and smoking. 
Model 3 is adjusted for age, ethnicity, smoking and BMI (conservative model). P-values in bold are significant at p=0.05 
after Bonferroni correction for 3 comparisons (i.e. p<0.0167). 
HOMA-IR=homeostasis model assessment insulin resistance, NM=natural menopausal women, PCOS=polycystic 
ovary syndrome, POI=premature ovarian insufficiency, RC=women with regular menstrual cycles.
Table 3. P-values for differences in cardiometabolic parameters between groups.
The multivariable adjusted associations between FAI and cardiometabolic features, 
stratified for PCOS, POI, and NM women, are depicted in Supplemental Figure 1-3. Details 
regarding exact effect sizes and p-values can be found in Supplemental Table 1. 
The associations between FAI and cardiometabolic features in age-adjusted models 
(Supplemental Figure I) did not substantially change after additional adjustment for 
ethnicity and smoking (Figure 2). After adjustment for age, ethnicity and smoking, a high 
FAI was significantly associated with higher TG (ß for PCOS: 0.45, POI: 0.25, NM: 0.20), 
insulin (ß for PCOS: 0.77, POI: 0.44, NM: 0.40), HOMA-IR (ß for PCOS: 0.82, POI: 0.46, NM: 
0.47), and MAP in all women (ß for PCOS: 0.05, POI: 0.07, NM: 0.04), and with high glucose 
levels in PCOS and NM women only (ß for PCOS: 0.05, NM: 0.07). A high FAI was associated 
with lower HDL cholesterol in PCOS and NM women (ß for PCOS: -0.23, NM: -0.09), and 
with higher LDL cholesterol in POI women (ß: 0.08). No significant associations were 
found for total cholesterol in either of the study groups. All exact effect sizes (ß’s) are 
depicted in Supplemental Table I. 
When comparing the associations between androgens and cardiometabolic features in 
PCOS versus POI women, there were significant differences in P-values for interaction 
regarding HDL cholesterol (p=0.009), HOMA-IR (p=0.020) and insulin (p=0.020), indicative 
of a stronger association between FAI and cardiometabolic features in PCOS women than 
POI women. The p-values for interaction were non-significant for all cardiometabolic 
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Figure 2. Associations between log free androgen index and cardiometabolic parameters for NM, POI 
and PCOS women, adjusted for age, smoking, and ethnicity. 
Positive associations are depicted on the right side of the null line; negative associations are depicted on the left side 
of the null line. Associations are significant when the confidence interval (visualized as the horizontal line) does not 
reach the vertical null line.
HOMA-IR=homeostasis model assessment-insulin resistance, NM=natural menopausal women, MAP=mean arterial 
pressure, PCOS=polycystic ovary syndrome, P-int=p-value for interaction, POI=premature ovarian insufficiency.
Figure 3. Associations between log free androgen index and cardiometabolic parameters for NM, POI 
and PCOS women, adjusted for age, smoking, ethnicity, and BMI.
Positive associations are depicted on the right side of the null line; negative associations are depicted on the left side 
of the null line. Associations are significant when the confidence interval (visualized as the horizontal line) does not 
reach the vertical null line.
HOMA-IR=homeostasis model assessment-insulin resistance, NM=natural menopausal women, MAP=mean arterial 
pressure, PCOS=polycystic ovary syndrome, P-int=p-value for interaction, POI=premature ovarian insufficiency.
features when comparing POI versus NM, indicating that the associations between FAI 
and cardiometabolic features do not differ between these women. 
When models were additionally adjusted for BMI (Figure 3), the FAI remained associated 
with HDL cholesterol (ß: -0.09), TG (ß: 0.29), insulin (ß: 0.43) and HOMA-IR (ß: 0.46) only 
in women with PCOS. After adjustment for BMI, there were no significant associations 
between FAI and cardiometabolic features in POI women. In NM women, only glucose (ß: 
0.05), insulin (ß: 0.25), and HOMA-IR (ß: 0.30) remained significantly associated with FAI 
after adjustment for BMI.
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already approximate those of NM women although these women are nearly 20-30 years 
older. This emphasizes the importance of performing a cardiometabolic evaluation in 
women diagnosed with PCOS as well as POI.41 42
Aside testosterone, endogenous estrogen levels have also been extensively studied 
as a potential predictor of CVD risk. Circulating estradiol and testosterone are both 
bound to SHBG, although the binding affinity of SHBG for testosterone is higher than 
that for estradiol.43 Increasing SHBG levels, with steady estradiol/testosterone levels, 
therefore result in a relative increase in the bioactive fraction of estradiol compared with 
testosterone.44 Bearing this interactive relation in mind, we performed a post-hoc analysis 
in which we additionally adjusted the associations between FAI and cardiometabolic 
abnormalities for endogenous estradiol levels. We found that the observed associations 
between FAI and lipid metabolism were slightly attenuated. However, in the BMI 
adjusted models, we did not find any significant changes in the associations between 
FAI and cardiometabolic features after additional adjustment for estradiol levels (data 
not shown). These results are in line with previous reported effects of estrogens on lipid 
metabolism and body fat distribution in women. Estradiol is known to influence the size 
and number of subcutaneous adipocytes and attenuates lipolysis, which may cause 
postmenopausal women to gain body fat after menopause.45 46 
BMI exerted a distinct effect on the observed associations between FAI and 
cardiometabolic features in our study. After adjustment for BMI, FAI remained 
significantly associated with most cardiometabolic features in PCOS women. However, 
in NM women, only glucose metabolism parameters remained associated with FAI after 
adjustment for BMI, whereas in women with POI, there we no longer any significant 
associations. It has been proposed that the association between androgens and BMI is 
modulated through obesity-related changes in circulating levels of insulin and IGF-1.47 48 
Increasing BMI results in a concomitant rise in insulin levels, which inhibits the hepatic 
production of SHBG and therefore leads to higher levels of bioactive testosterone.49 
Furthermore, insulin and IGF-1 directly stimulate the ovarian synthesis of androgens.48 
Adipose tissue is also able to actively produce androgens through activity of 17beta-
hydroxysteroid dehydrogenase.50 Increased enzyme activity occurring with obesity might 
further attribute to androgen excess.
One of the strengths of this study is that we measured androgen levels with LC-MS/MS, 
which is currently considered the gold standard for androgen assessment in women.51 
52 Furthermore, by selecting four distinct groups of women, we were able to study 
associations between androgen concentrations and cardiometabolic features in women 
with contrasting endocrine profiles, which, as such, has not been previously performed. 
Since this study provided abundant data, we presented selected data based on clinical/
scientific relevance in order to restrict the number of performed comparisons.
DISCUSSION
The primary aim of the current study was to compare androgen levels assessed by LC-
MS/MS and to explore its potential association with various cardiometabolic features 
in women under different clinical conditions (i.e. PCOS, POI, NM and RC). As expected, 
we found women with PCOS to be hyperandrogenic, and women with POI to be 
hypoandrogenic, compared to RC women. Differences in androgens between NM versus 
POI and NM versus RC, were no longer significant after adjusting for age.
The second research aim of this study was to assess potential associations between 
androgen levels and cardiometabolic features in these women. We found that a higher 
FAI was associated with increased cardiovascular risk factors, i.e. elevated TG, insulin, 
HOMA-IR, and MAP in all women. A high FAI was also associated with increased glucose 
and decreased HDL levels in women with PCOS and NM, and with increased LDL in POI 
women. Adjustment for BMI substantially attenuated these associations. The strongest 
associations were observed in women with PCOS, even after adjustment for BMI. 
In women, numerous studies have been performed concerning changes in androgen 
concentrations with age and following the menopausal transition. Previous cross-
sectional studies have described lower androgen levels in postmenopausal women 
compared to premenopausal women, suggesting an association between androgen 
concentrations and menopausal status.34 35 However, most longitudinal studies 
demonstrated a continuous decline in total testosterone, DHEAS and androstenedione 
levels with age, with no or very little variation occurring in relation to the menopausal 
status.21 36 37 Our finding that androgen levels between POI vs. NM and NM vs. RC did 
not differ significantly after adjustment for age, further supports the results from these 
longitudinal studies. 
In the current study we observed that an increase in FAI is associated with various 
cardiometabolic derangements in all women, irrespective of their clinical condition. 
Previous large studies in pre-, peri and postmenopausal women also reported a positive 
correlation between circulating androgen levels and CVD risk.15 38 39 We observed a 
linear association between FAI and cardiometabolic features in all study groups. A 
linear association would indicate that women with the lowest androgen concentrations 
exhibit the most favorable cardiometabolic profile. However, in the current study, POI 
women exhibited the lowest androgen concentrations compared to other study groups, 
and POI has been repeatedly associated with an increased CVD risk.24 40 These findings 
would correspond more with a U-shaped association between androgens and CVD with 
increased risk at both ends, as previously proposed.5 7 This apparent discrepancy may be 
explained by variations in other biological factors contributing to CVD risk (e.g. circulating 
estrogen levels) or differences in study type, design and sample size. Moreover, it is 
noteworthy that the cardiometabolic characteristics of women with POI and PCOS 
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A limitation of the current study is the lack of cardiometabolic features of RC women. 
Therefore, we were unable to directly compare associations between androgens and 
cardiometabolic features between these women and the other study groups. Another 
potential limitation is that although the use of FAI to study the unbound fraction of 
testosterone in women has been validated, it might be less precise than the direct 
measurement of the unbound fraction of testosterone in serum.51 However, we solely 
used the FAI to study associations between androgens and cardiometabolic features, 
and did not attempt to establish absolute normative values of free circulating androgen 
concentrations in different groups of women for clinical usage outside the current study. 
The association between sex hormone levels, cardiometabolic abnormalities and the 
development of actual cardiovascular events in women has not been clearly established 
yet. Results from the few available long term follow-up studies in the general female 
population report either no independent relationship between endogenous sex hormone 
levels and CVD events or only suggest a potential role for testosterone.5 53 54 The potential 
association between ovarian dysfunction and future CVD events also remains partially 
unsettled. In a recent meta-analysis, POI was found to be an independent modest risk 
factor for ischemic heart disease and overall CVD, but not for stroke.24 The association 
between PCOS and cardiometabolic abnormalities (e.g. obesity, dyslipidemia, insulin 
resistance) has indeed been clearly established. However, previous reports on the 
actual development of CVD events in PCOS women have been inconsistent.55-58 Many 
of these studies suffer from several limitations, such as a retrospective design, unclear 
phenotyping, limited follow-up, all of which hinder the interpretation of reported results. 
Unfortunately, due to the cross-sectional design of our study, we were not able to 
assess the potential relation between androgen levels and the development of actual 
cardiovascular events.
CONCLUSIONS
In summary, this study demonstrates that androgens intrinsically affect the 
cardiometabolic features of women with and without various forms ovarian dysfunction. 
Increased androgen levels were strongly associated with impaired cardiometabolic 
features in all women participating in the current study. Differences in androgen levels 
between pre- and postmenopausal women were no longer significant after correcting 
for age, which indicates that predominantly chronological ageing rather than ovarian 
ageing influences variations in circulating androgen levels. Furthermore, we observed 
a substantial effect of BMI on circulating androgen levels. This study affirms the potent 
effect of androgens on cardiometabolic features, implying that androgens should indeed 
be regarded as important denominators of women’s health. Future research, regarding 
the role of androgens in the development of CVD and potential modulatory effects of 
BMI, is required. 
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ABSTRACT
Objectives: 
To characterize the relation between established and previously unexplored 
characteristics of the fertile life with all-cause and cause-specific mortality.
Design, setting, and participants:
A total of 4076 postmenopausal women of the prospective population-based Rotterdam 
Study, the Netherlands.
Main exposure measures: 
Women’s fertile lifespan (age at menarche to menopause), number of children, maternal 
age at first and last child, maternal lifespan (interval between maternal age at first and last 
child), post-maternal fertile lifespan (interval between age at last child and menopause), 
lifetime cumulative number of menstrual cycles, and unopposed cumulative endogenous 
estrogen exposure.
Main outcome measures: 
Registry-based all-cause and cause-specific mortality.
Results:
 A total of 2754 women died during 14.8 years of follow-up. Compared to women with 
2-3 children, a 12% higher hazard of dying was found for women having 1 child (hazard 
ratio (95% confidence interval), 1.12 (1.01 to 1.24)), which became non-significant in 
models adjusted for confounders (1.08 (0.96 to 1.21)). Late age at first and last birth were 
associated with a 1% lower hazard of dying (0.99 (0.98 to 1.00)). Longer maternal and post-
maternal fertile lifespan (1.01 (1.00 to 1.02)), longer fertile lifespan (1.02 (1.00 to 1.05)) and 
unopposed cumulative estrogen exposure (1.02 (1.00 to 1.04)) were significantly harmful 
for all-cause mortality. Findings differed with regard to direction, size, and statistical 
significance when stratifying for CVD, cancer, and other mortality. 
Conclusions: 
Overall, we found that late first and last reproduction were protective for all-cause 
mortality, whereas a longer maternal lifespan, post-maternal fertile lifespan, and 
estrogen exposure were harmful for all-cause mortality. More research is needed in 
contemporary cohorts with larger sample sizes and more extreme ages of birth.
Keywords: 
fertility, longevity, mortality
INTRODUCTION
During the past decades there has been a major interest in the role of fertility 
characteristics, including parity and timing of childbirth, in later life health.1 This research 
area has intensified during the past twenty years given the demographic trends wherein 
couples tend to postpone childbirth to later life stages.2 Since the 1970s, the proportion 
of European women aged 30 years and older at first childbirth increased from 8 to 40% 
and the mean age hereof increased by 4 to 5 years.3 The paradigm shift in reproductive 
choices is not without risk as it could lead to involuntary childlessness and unattained 
desired family sizes.4 Moreover, pregnancy complications and maternal mortality rates 
are higher during late motherhood at advanced ages.5 Nevertheless, benefits from these 
changing fertility patterns on mortality and longevity have also been widely observed.1
Several measures of fertility potential have been suggested, some of which include late 
reproduction, parity, and age of menopause.6 The fertile lifespan (the interval between 
menarche and menopause), which has been used as a proxy for endogenous sex steroid 
exposure in cardiometabolic studies,7 could serve as physiologic index for fertility 
capacity.8 9 Additionally, since most women don’t utilize their entire reproductive period 
to bear children, it may be of interest to look at more precise measures of the child 
bearing potential via extra characteristics, which include maternal lifespan (the interval 
between age at first birth and age at last birth) and post-maternal fertile lifespan (the 
interval between age at last child and age of menopause). 
The full spectrum of fertile lifespan characteristics in association with all-cause or cause-
specific mortality has not been examined. Particularly for several characteristics such 
as age at last birth in relation to cause-specific mortality, the evidence is limited. In the 
current study we cover a range of established and previously unexplored characteristics 
of the fertile lifespan and expand the scope from all-cause to cause-specific mortality. 
Hence, we aimed to assess the associations between eight characteristics of the fertile 
lifespan (number of children, age at first birth, age at last birth, maternal lifespan, post-
maternal fertile lifespan, fertile lifespan itself, lifetime cumulative number of menstrual 
cycles, and lifetime unopposed endogenous estrogen exposure) with all-cause and cause 
specific mortality in the prospective population-based Rotterdam Study.
METHODS
Study population
The study was embedded within a prospective, population-based cohort study among 
subjects 55 years and older in the municipality of Rotterdam, the Netherlands: the 
Rotterdam Study. The rationale and study design have been described in detail 
elsewhere.10
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The baseline examination was completed between 1990 and 1993 (RS-I). Of the 4878 
women enrolled in the RS at baseline, 4076 postmenopausal women were included in 
the present study. Women without informed consent (n=187), missing data in more than 
50% of the covariates (n=123), missing age of menarche or menopause (n=473) or missing 
age at first birth, last birth or number of children (n=19) were excluded from the analyses. 
An overview of the participant flow can be found in the flowchart (Supplemental Figure 
1). The Rotterdam Study has been approved by the Medical Ethics Committee of the 
Erasmus MC and by the Ministry of Health, Welfare and Sport of the Netherlands, 
implementing the Wet Bevolkingsonderzoek: ERGO (Population Studies Act: Rotterdam 
Study). All participants provided written informed consent to participate in the study and 
to obtain information from their treating physicians.
Assessment of fertile lifespan characteristics
The self-reported number of children, age of the mother at first and last birth, and age 
at menarche and menopause were assessed during the baseline interview using a 
questionnaire. Age at menopause was defined in retrospect as the age at final menstrual 
period, after a 12-month period of amenorrhoea.11 
Maternal lifespan was defined as the interval between maternal age at first and last 
birth in women that had 2 or more children, and may be a more precise measure of the 
childbearing period compared to the fertile lifespan, considering the fact that women 
don’t utilize the entire fertile period to bear children. The post-maternal fertile lifespan 
was made by subtracting maternal age at last birth from age of menopause. Both age of 
menopause and age at last birth could be considered indirect proxies for fertility.6 Fertile 
lifespan in years was calculated by subtracting age at menarche from age at menopause. 
Lifetime cumulative number of menstrual cycles was calculated by subtracting 9 months 
for each pregnancy, 4 months of breastfeeding for every born child,12 13 and contraceptive 
use duration in months from the reproductive lifespan in months. This value, the 
cumulative endogenous estrogen exposure, was then converted to years, after which it 
was multiplied by the reported mean number of menstrual cycles per year.12 14 To get the 
unopposed cumulative endogenous estrogen exposure, the total postovulatory period 
in months (i.e. (lifetime number of menstrual cycles*2)/4), was subtracted from the 
cumulative endogenous estrogen exposure in months.12 
Assessment of all-cause and cause-specific mortality
Mortality data was obtained via several complementary approaches in order to ascertain 
(cause of) death for all participants of the Rotterdam Study. Data sources included the 
central registry of the Municipality of Rotterdam, records from collaborating general 
practitioners, and information obtained during follow-up rounds. If the vital status of 
participants was missing, the Central Registry of Genealogy of the Netherlands was 
consulted. Two research physicians independently classified the cause of death according 
to the International Classification of Diseases, 10th revision (ICD-10), 15 from which cause-
specific mortality was assessed. In case of disagreement, consensus was sought in 
a separate session. All causes of death were approved by experienced field-specific 
experts for final classification. For all-cause mortality participants were followed until 
March 3rd 2015 and for cause-specific mortality until January 1st 2013. For the study of 
cause-specific mortality, we created 3 groups: cardiovascular mortality, cancer mortality, 
and other deaths (Supplemental Methods Section).
Assessment of covariates
Socio-economic and environmental conditions and family planning can greatly impact the 
potential biological association between fertility and mortality.6 Therefore, the following 
covariates were considered for inclusion in the statistical models: baseline age, education 
level, marital status, household income, ethnicity, smoking, alcohol intake, diet, physical 
activity, hormonal contraceptive use, female hormone use, prevalent chronic disease, 
cycle regularity at age of 25 years, menopause type, and waist to hip ratio. Moreover, 
women of the same age can have different ages of menopause. Timing of menopause is 
associated both with fertile lifespan characteristics and with postmenopausal health.16 
Hence, time since menopause was included as a covariate in statistical models. All 
covariates were self-reported, except for body mass index and waist to hip ratio, which 
was measured by research assistants at the study centre. A description of the definitions 
and coding of all covariates can be found in the Supplemental Methods Section.
Statistical analysis
As a first step the distributions of all fertile lifespan characteristics was assessed. Since 
all of these variables were approximately normally distributed, no transformation was 
necessary. The correlations between the variables number of children, age of the mother 
at first and last birth, and age at menarche and menopause (the variables used to make 
the 8 fertile lifespan characteristics), were assessed using the Pearson’s correlation 
coefficient. 
The association between the eight fertile lifespan characteristics (all analysed 
continuously) and all-cause and cause-specific mortality were assessed using cox 
regression. P-splines were used to characterize the shape of the effect of each 
continuous exposures with all-cause mortality and to identify any potential non-linear 
associations.17 In addition, fertile lifespan characteristics were analysed categorically 
using categories adapted from literature; if no evidence-based categorizations were 
available, quartiles were used.18-21 The proportional hazards assumption was checked 
by testing the significance of the interaction term of each exposure with time in the cox 
models (e.g. time*number of children), and this assumption held for all exposures. 
Model 1 was adjusted for age and time since menopause. Model 2 was additionally 
adjusted for education level, marital status, household income, hormonal contraceptive 
use, smoking, alcohol intake, physical activity, menopause type, female hormone use, 
prevalent chronic disease, and waist to hip ratio. These covariates were chosen since they 
were statistically associated with both the exposure (i.e. fertile lifespan characteristic) 
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and the outcome (mortality) at α<0.2.22 The same models were created for all-cause and 
cause-specific mortality.
Covariates were imputed using fully conditional specification using the Markov chain 
Monte Carlo method (n=5 imputations). 
Two prespecified interactions were tested in model 2: age*exposure (e.g. age*age at 
last child) and number of children*exposure (e.g. number of children*age at last child). 
If the interaction term was significant, the analyses were stratified to show potential 
differential effects.
As a sensitivity analysis, a complete case analysis was performed to assess whether the 
imputation process influenced the findings. Furthermore, in a second sensitivity analysis, 
the population was restricted to women who never used hormonal contraceptives, in 
order to assess the magnitude of the effect of family planning behaviour through fertility 
control.23 Moreover, in a third sensitivity analysis, we restricted the population to 
healthy individuals by means of excluding all women with prevalent chronic disease at 
baseline or women who died within the first 3 years after baseline (these women may 
have underlying unknown chronic diseases). 
RESULTS
Descriptive statistics
An overview of the study characteristics can be found in Table 1. Women had a median 
age of 69.1 years (interquartile range (IQR) 62.2 to 76.6) and most women were of 
Northern European descent (98.4%). The median number of children women gave birth to 
was 2 (IQR 1 to 3) and the mean age at first and last birth were 26.4 (standard deviation 
(SD) 4.5) and 32.1 (SD 5.5) years, respectively. 
During the study period, 2754 women died of any cause and the median follow-up time 
was 16.6 years (IQR 9.0 to 21.0). Until January 1st, 2013, 780 women died of cardiovascular 
disease, 547 women of malignant cancers, and 1024 of other causes (Supplemental Table 
1). 
All variables from which the fertile lifespan characteristics were derived were significantly 
correlated with each other, except for age at menarche, which was only correlated with 
age at last birth (Supplemental Table 2).
Maternal characteristics
The Cox regression results for the association between fertile lifespan characteristics and 
all-cause mortality can be found in Table 2. Compared to the reference group of women 
with 2 or 3 children, a 12% higher hazard of dying was found for women having 1 child 
in model 1 (hazard ratio (HR) (95% confidence interval (95% CI)), 1.12 (1.01 to 1.24)), which 
became statistically non-significant in model 2 (1.08 (0.96 to 1.21)). A 1 year increase in 
General characteristics Value
Age, years Median (IQR) 69.1 (62.2 to 76.6)
Time since menopause, years Mean (SD) 21.2 (10.7)
Waist to hip ratio Mean (SD) 87.1 (8.9)
Body mass index Mean (SD) 26.7 (4.0)
Education Number (%)
Primary 1230 (30.2%)
Lower/intermediate or lower vocational 1873 (45.9%)
Intermediate vocational or higher general 812 (19.9%)
Higher vocational or university 161 (4.0%)
Marital status, living with partner Number (%) 2087 (51.2%)
Equivalent household income (/1000,-) Median (IQR) 1.8 (1.2 to 2.5)
Ethnicity, Caucasian Number (%) 4011 (98.4%)
Menopause type, natural Number (%) 3827 (93.9%)
Oral contraceptive use, yes Number (%) 1172 (28.7%)
Female hormone use, yes Number (%) 544 (13.3%)
Prevalent chronic disease, yes Number (%) 629 (15.4%)
 Coronary heart disease 176 (4.4%)
Heart failure 137 (3.4%)
Stroke 89 (2.2%)
Diabetes Mellitus 206 (5.1%)
Cancer 28 (2.3%)
COPD 104 (2.6%)
Smoking, current Number (%) 752 (18.4%)
Alcohol intake, glasses/day Median (IQR) 0.1 (0 to 0.7)
Physical activity, ideal levelsa Number (%) 3655 (89.7%)
 
Table 1. Characteristics of the study population (n=4076).
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Fertile lifespan characteristics Value
Number of children Median (IQR) 2 (1-3)
Number of children Number (%)
0 children 845 (20.7%)
1 child 665 (16.3%)
 2 children 1141 (28.0%)
  3 children 743 (18.2%)
  4 children 383 (9.4%)
 5 or more children 299 (7.3%)
Age at first birth, years Mean (SD) 26.4 (4.5)
Age at first birth Number (%)
 19 years or younger 166 (5.1%)
 20-24 years 1166 (36.1%)
 25-34 years 1745 (54.0%)
 35 years or older 154 (4.8%)
Age at last birth, years Mean (SD) 32.1 (5.5)
Age at last birth Number (%)
 24 years or younger 335 (10.4%)
 25-34 years 1880 (58.2%)
 35-39 years 743 (23.0%)
 40 years or older 273 (8.4%)
Maternal lifespan, years Median (IQR) 5.0 (2.0 to 9.0)
Post-maternal fertile lifespan, years Mean (SD) 16.8 (7.0)
Fertile lifespan, years Mean (SD) 35.2 (5.3)
Lifetime number of menstrual cycles Mean (SD) 331.4 (106.4)
Unopposed cumulative endogenous estrogen exposure, years Median (IQR) 16.1 (12.8 to 18.6)
a ≥150 / ≥75 minutes/week of moderate and/or vigorous activity.
COPD=chronic obstructive pulmonary disorder, IQR=interquartile range, SD=standard deviation.
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age at first birth was associated with a 1% lower hazard of dying in model 1 and 2 (0.99 
(0.98 to 1.00)). When compared to the reference group of women giving birth between 25 
to 34 years, older women (i.e. ≥35 years) had a 25% lower hazard of dying in model 2 (0.75 
(0.61-0.93)). For age at last birth, a 1 year increase was associated with a 1% lower hazard 
of dying in model 1 (0.99 (0.98 to 1.00)). A 1 year longer maternal and post-maternal 
fertile lifespan was significantly associated with a 1% higher hazard of dying in model 1 
(1.01 (1.00 to 1.02) for both), but lost significance in model 2.
Some differences were observed when comparing the association of fertile lifespan 
characteristics with cause-specific mortality to the association with all-cause mortality 
(Supplemental Table 3-5).
For number of children, having no children compared to having 2 to 3 children was 
associated with a 26% higher hazard for CVD mortality (1.26 (1.02 to 1.56)). Late age at 
first birth (25 years or older) resulted in a 16% higher hazard for cancer mortality (1.16 
(0.94 to 1.46)), whereas this was associated with a 15% lower hazard for other mortality 
(0.85 (0.73 to 0.99)). Late age at last birth (35 years or older) resulted in a 17% lower 
hazard for CVD mortality (0.83 (0.68 to 1.00)), whereas no effect was found for the other 
causes of death. 
Proxies for estrogen exposure
A 1 year longer fertile lifespan was associated with a 2% higher hazard for all-cause 
mortality in model 1and model 2 (1.02 (1.00 to 1.05)). The observed effects were similar 
for unopposed cumulative endogenous estrogen exposure. No associations were found 
between lifetime number of menstrual cycles and all-cause mortality (Table 2).
Fertile lifespan and unopposed cumulative endogenous estrogen exposure were 
associated with a 5% and 4% higher hazard for CVD mortality (1.05 (1.00 to 1.10) and 
1.04 (1.00 to 1.09), respectively), but not with cancer and other mortality (Supplemental 
Table 3-5). A larger number of lifetime number of menstrual cycles was significantly 
associated with other mortality, although the effect size reflected unity (1.00 (1.00 to 
1.00)); Supplemental Table 5. 
Linearity and interaction terms
In Figure 1 the shape of the effects for each fertile lifespan characteristic and all-cause 
mortality are shown. There was evidence against linearity only for number of children 
(p-values for each imputed set ranged from 0.0073 to 0.0192), for which the association 
was J-shaped. 
The interaction terms with baseline age were not significant for any of the fertile lifespan 
characteristics, whereas the interaction terms with number of children were significant 
for age at last birth (p-value=0.03), post-maternal fertile lifespan (p-value=0.03), and 
cumulative estrogen exposure (p-value=0.04). When stratifying the analysis for 0, 1, 2 
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or 3, and 4 or more children, we found that the associations were merely evident for the 
group of women bearing 1 child for age at last birth (0.97 (0.95 to 0.99), p-value=0.003), 
for post-maternal fertile lifespan (1.03 (1.01 to 1.05), p-value=0.003), and for endogenous 
estrogen exposure (1.08 (1.03 to 1.13), p-value=0.002), whereas no significant associations 
were found for the other 3 groups (Table 3). 
Supplemental Table 6 details the multiple imputation process. In 3 different sets of 
sensitivity analyses; the complete case analyses, the analyses restricted to the non-
diseased population, and the analyses excluding women ever using oral contraceptives, the 
direction, size, and significance of the associations remained the same (data not shown). 
Finally, since of the 4878 women enrolled in the RS at baseline, 4076 postmenopausal 
women were included in the present study, we compared the characteristics of the 
included participants to the total population of women at baseline. Compared to the total 
female population of the Rotterdam Study, women included in this study were 0.8 years 
younger, and had 0.6% less prevalent chronic disease, but did not differ for other baseline 
characteristics (Supplemental Table 7).
DISCUSSION
Given the demographic changes in reproductive choices and their relevance for mortality 
and longevity, we characterized the relation between established and previously 
unexplored characteristics of the fertile life with mortality, and therein expanded the 
scope from all-cause to cause-specific mortality. Overall, we found that late first and 
last reproduction were protective for all-cause mortality, whereas a longer maternal 
lifespan, post-maternal fertile lifespan, and estrogen exposure were harmful for all-
cause mortality. For late last reproduction, post-maternal fertile lifespan, and estrogen 
exposure, these findings were merely evident in 1-child mothers. In addition, the findings 
differed with regard to direction, size, and significance when stratifying for CVD, cancer, 
and other mortality. From a clinical perspective, the magnitude of the associations 
ranged from a 1-5% lower or higher risk of dying per year increase of each fertile lifespan 
characteristic. 
Strengths and limitations
Strengths of this study included the consideration of the full spectrum of established 
as well as previously unexplored characteristics of the fertile lifespan, and access to 
the precise adjudicated causes of death information, which allowed us to study cause-
specific mortality. Furthermore, the contemporary character of the cohort, in contrary 
to historical cohorts, provides a valuable insight into the role of fertility in longevity 
against a background of increasing reproductive choices and improved standards of 
care and therefore is applicable to the present time. Additionally, the adjustment for 
many confounders, the graphical representation of the effects using p-splines, and the 
stratified analysis for number of children, adds new information to the existing body of 
evidence in this field of work.
Several limitations merit careful consideration. Although we had information on marital 
status, no information was available on age at marriage and number of marriages. 
Furthermore, for the included women we had no information on fetal losses, abortions, 
and stillbirths. Assumptions were made for assembling the lifetime cumulative number 
of menstrual cycles and unopposed cumulative estrogen exposure. Since fertile 
lifespan characteristics were assessed when women already reached menopause, 
retrospective recall could have occurred. However, because information on fertile lifespan 
characteristics were collected before the outcome (mortality) occurred, we reasonably do 
not expect this recall to have impacted our findings. Also, the Rotterdam Study comprises 
of men and women of 55 years and older. Hence, immortal time bias could have occurred, 
given that women could have died during their reproductive life, for instance of maternal 
complications, and would therefore not be included in the studied population.24 However, 
even if occurred, this would have led to an underestimation of the true effects in our study. 
Lastly, fertility characteristics may be of different importance for disease subtypes, such 
as breast, colorectal, and lung cancer. Our study was underpowered to stratify analyses 
for different disease and cancer subtypes.
Comparison with other studies and possible explanations
When comparing our findings to other studies, it is important to consider that the 
Rotterdam Study is a contemporary cohort and therefore conclusions with regard 
to natural fertility are limited. In contrast to historical cohorts from the 18th and 19th 
century where fertility followed pre-contraceptive patterns, in the current cohort there 
could have been a larger impact of reproductive choices. Among the included women, 
the youngest women were 27 years old at the time of the introduction of the first oral 
contraceptive in the Netherlands in 1962, and only 30% of women indicated ever using 
oral contraceptives.25 (25) (24) The mean age at first birth in our study was 26 years, 
meaning that the influence of contraceptive use was probably less pronounced for age at 
first birth, compared to the consecutive births thereafter. Indeed, this may be supported 
by the large post-maternal fertile lifespan found in this study (17 years) indicating 
women stopped reproducing long before the onset of menopause. Where age of last birth 
may be influenced by family planning, economic circumstances and socially acceptable 
propagation habits, age of menopause is less subject to these external factors.6 The 
interval between the two, i.e. post-maternal fertile lifespan, could provide insight in the 
potential influence of these external factors within our study population. The age at last 
birth was on average 32 years, whereas last reproduction was nearly 10 years later in 
historical cohorts.26 In sensitivity analyses we repeated the analyses excluding women 
who ever used oral contraceptives. The results did not substantially change with regard 
to significance, direction, and size of the effect.
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Maternal characteristics
In line with our findings, for number of children, contemporary cohorts consistently 
show a nonlinear effect, with the highest mortality in nulliparous women and women 
bearing 4 or more children19 27, whereas the findings from historical cohorts have shown 
negative, neutral and positive effects.23 28 For age at first birth, the empirical results are 
inconsistent, ranging from a beneficial effect of late first birth on longevity to no effect.1 23 
In our study, we found a linear protective effect of late first reproduction on mortality, of 
which the statistical significance attenuated after adjusting for socio-economic factors 
and lifestyle. The effects of parity and first reproduction on mortality have been explained 
before by evolutionary fitness trade-off theories, balancing reproductive investment and 
somatic maintenance.29 30 Two of such theories are the antagonistic pleiotropy theory 
(i.e. the same gene could be beneficial in early life, whereas being detrimental in later 
life),31 and the disposable soma theory (i.e. the limited amount of energy has to be divided 
between reproductive activities and maintaining the soma).32 
Late first parenthood was protective for other mortality. Whereas early parenthood has 
been associated with lower socio-economic status, particularly during childhood, and 
with personality characteristics such as a tendency towards more risk taking behaviour, 
late parenthood could be characterized by less stress and better career prospects.33 We 
would have expected to find the same protective effect for cardiovascular mortality,33 
for which the observed hazard was around unity. We did find a significant protective 
effect of late last reproduction with cardiovascular mortality, which attenuated after 
adjustment for covariates.
There has been a particular interest in late last reproduction, since studies from both 
contemporary and historical cohorts consistently point towards a protective effect of 
late last childbirth on post-reproductive survival.1 23 In our study, we found this effect, but 
less pronounced than in other studies. This could be explained by the fact that only 10 of 
the included women gave birth to their last child above the age of 45, whereas in other 
studies these numbers were higher.18 The shape of the effect of age at last birth was 
linear and protective for mortality in our study. Although most studies did not comment 
on this extensively, one study by Helle and colleagues did not find any evidence against 
linearity for age at last birth, in line with our findings.1 
There have been several theories about which mechanisms could underlie the protective 
effect of late last reproduction.23 Reproductive performance, including measures such as 
late age of menopause and late last reproduction, could be viewed as a marker for later 
life health.21 23 34 35 Studies have shown that that there is a genetic link between fertility 
and longevity, that encompasses overlapping pathways and genes for telomerase 
activity, apoptosis mediated through p53/p73, Foxo transcription factors, the expression 
of APOE, and the role of the immune system, mitochondrial function, and oxidative stress 
in both processes.6 Moreover, reproductive performance and longevity have shown to be 
linked via common genetic factors related to DNA repair and maintenance. Therefore, it 
could be that the occurrence of menopause is a consequence of the ageing of the soma 
that results from the deterioration of these DNA repair mechanisms. 
Others have suggested that extended fertility and its association with a longer lifespan 
might be explained by the ‘rejuvenation theory’. This theory describes that late pregnancy, 
childbirth, and breastfeeding could be rejuvenating at the physiological level36, and 
that the presence of young children in the post-reproductive period could extend the 
lifespan.37
Early versus late child bearing
Interestingly, we found a differential effect for age at last birth when stratifying the 
analysis for number of children. After stratification, the protective effect of late last 
reproduction (>35 years) on the risk of dying, compared to last child bearing while 34 years 
or younger, was merely evident among women with one child only. A similar interaction 
was found in a study by Gagnon and colleagues in a historical context.38 
For age at first reproduction, the median age was 37.1, 29.3, and 25.4 years in 1-child, 
2-3 child and 4 or more child mothers, respectively. The ages at last reproduction were 
37.1, 37.5, and 38.7 years, respectively. Since for 1-child mothers the age at first and last 
reproduction is the same, there is a nearly 8 year difference in first reproductive event 
between 1-child and > 1 child mothers.
A possible explanation of the observed differential effect may be that 1-child mothers 
precisely planned when they wanted to have their first child but due to their age may have 
been unable to attain their desired family size with a second or third child. Some support 
for this explanation comes from the recent work performed by Habbema and colleagues, 
that found that in order to have a 90% chance of giving birth to 1 child, a woman should 
be no older than 35 years, and in order to have 2 children, women should start no later 
than 31 years.4 The social factors that caused these women to have their child late may 
have protected them from dying.24 Indeed, when looking into the characteristics of these 
women, we found that older mothers were more highly educated and less often smokers 
compared to younger mothers.
Proxies for estrogen exposure
The findings for fertile lifespan and unopposed cumulative estrogen exposure were in 
the same line, both indicating that longer estrogen exposure was hazardous for all-
cause mortality, and CVD mortality in particular, whereas no association was found 
between estrogen exposure and cancer mortality. The latter could be explained by 
the fact that various subtypes of cancer that were included in the study, including of 
both hormonal and non-hormonal cancers. Findings from other studies reporting the 
association between endogenous estrogen levels and cardiovascular outcomes have 
been inconsistent, particularly in the elderly. Estradiol is supposed to have a protective 
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role in the cardiovascular system.39 However, in line with our findings, an increasing 
number of studies suggest the opposite.40-47 
Several potential mechanisms have been described. Visceral adiposity, which is 
associated with inflammation, insulin resistance/diabetes, and atherogenic dyslipidemia 
is suggested to increase estradiol levels via two pathways. Adiposity is negatively 
correlated with sex hormone binding globulin, leading to a higher fraction of bioactive 
estradiol. Also, central adiposity increases aromatase activity, and therefore the 
conversion of testosterone into estradiol.44 Higher levels of estradiol were more strongly 
associated with atherothrombotic stroke in older postmenopausal women with greater 
central adiposity.43 In our study, adjusting for waist-hip ratio did not materially change 
the findings, indicating that pathways beyond adiposity may exist.
Another suggested explanation for this finding comes from the work of Naessen and 
colleagues.46 47 They suggest that higher levels of endogenous estrogen do not increase 
the risk of atherosclerosis, but that that the rise in endogenous estrogen is a response to 
counteract the developing atherosclerosis.46 47
CONCLUSIONS
Overall, we found associations between established and previously unexplored fertile 
lifespan characteristics and mortality that differed for different causes of death. We 
found that late first and last reproduction were protective for all-cause mortality, whereas 
a longer maternal lifespan, post-maternal fertile lifespan, and estrogen exposure were 
harmful for all-cause mortality. Furthermore, with regard to late last reproduction, 
differences were found when comparing women with different number of children that 
could partly be explained by socio-economic status and overdue initiation of family 
planning. To broaden our understanding of the effect of changing fertility patterns on 
mortality in the present time, more research is needed in contemporary cohorts with 
larger sample sizes and more extreme number of children and ages of birth. The findings 
in contemporary cohorts may differ, due to changes in women’s reproductive choices, 
including use of hormonal contraception. The implications for women with diverse 
number of children for different causes of death should be further explored, taking into 
account insights in reproductive choices, and an extensive evaluation of the role of socio-
economic status.
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Conclusions: 
Treatment with flibanserin, on average, resulted in half of one additional satisfying 
sexual event per month, while substantially increasing the risk of dizziness, somnolence, 
nausea, and fatigue. Overall, the quality of the evidence was graded as very low. Before 
flibanserin can be recommended in guidelines and clinical practice, future studies 
should include women from diverse populations, particularly women with comorbidities, 
medication use, and surgical menopause.
Keywords: 
flibanserin, hypoactive sexual desire disorder, efficacy, safety, systematic review, meta-
analysis
ABSTRACT 
Background: 
In August 2015 the US Food and Drug Administration (FDA) approved flibanserin as a 
treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women, 
despite concern about suboptimal risk-benefit trade-offs.
Objective: 
To conduct a systematic review and meta-analysis of randomized controlled trials (RCTs) 
assessing efficacy and safety of flibanserin for the treatment of HSDD in women. 
Data sources: 
Medical databases (among others, Embase, Medline, Psycinfo) and trial registries were 
searched from inception to June 17, 2015. Reference lists of retrieved studies were 
searched for additional publications.
Study selection:
RCTs assessing treatment effects of flibanserin in pre- and postmenopausal women 
were eligible. No age, language, or date restrictions were applied. Abstract and full-text 
selection was done by two independent reviewers. 
Data extraction and synthesis: 
Data were extracted by one reviewer and checked by a second reviewer. Results were 
pooled using two approaches depending on the blinding risk of bias. 
Main outcome measures: 
Primary efficacy outcomes included number of satisfying sexual events (SSE), e-Diary 
sexual desire, and Female Sexual Function Index (FSFI) desire. Safety outcomes included, 
among others, 4 common adverse events (AEs): dizziness, somnolence, nausea, and 
fatigue.
Results: 
Five published and 3 unpublished studies including 5914 women were included. Pooled 
mean differences for SSE change from baseline were 0.49 (95% confidence interval (CI), 
0.32 to 0.67) between 100mg flibanserin and placebo, 1.63 (95%CI, 0.45 to 2.82) for e-Diary 
desire, and 0.27 (95%CI, 0.17 to 0.38) for FSFI desire. The risk ratio for study discontinuation 
due AEs was 2.19 (95%CI, 1.50 to 3.20). The risk ratio for dizziness was 4.00 (95%CI, 2.56 
to 6.27) in flibanserin vs placebo, 3.97 (95%CI, 3.01 to 5.24) for somnolence, 2.35 (95%CI, 
1.85 to 2.98) for nausea, and 1.64 (95%CI, 1.27 to 2.13) for fatigue. Women’s mean global 
impression of improvement scores indicated minimal improvement no change.
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INTRODUCTION
In August 2015, the US Food and Drug Administration (FDA) approved flibanserin as 
a medical treatment for hypoactive sexual desire disorder (HSDD) in premenopausal 
women.1 Flibanserin, a 5-HT1A agonist, a 5-HT2A antagonist and a very weak partial 
agonist on dopamine D4 receptors, increases dopamine and norepinephrine and decreases 
serotonin in animal brain areas.2 3 Therefore, since dopamine and norepinephrine are 
thought to promote and serotonin is thought to inhibit sexual desire and arousal,3 4 it 
was suggested that flibanserin enhances sexual desire in HSDD. 
With prevalences from 10 to 40%, HSDD is defined as “persistently or recurrently deficient 
(or absent) sexual fantasies and desire for sexual activity” accompanied by “marked 
distress and interpersonal difficulty”, that is not accounted for by a nonsexual mental 
disorder, medication, severe relationship stress, or a general medical condition.5 6 With 
the appearance of the Diagnostic and Statistical Manual of Mental Disorders (5th 
edition), HSDD was replaced by female sexual interest/arousal disorder, merging arousal 
and desire disorders. 
The approval of flibanserin at the intersection of science, policy, and advocacy received 
considerable attention in the public domain and was accompanied by debates among 
health institutions and stakeholders.7 Some observed significant benefits without 
safety concerns,8 whereas others expressed concern about medicalization of women’s 
sexuality, questioned whether benefits outweighed risks, and expressed concern about 
pharmaceutical industry influencing FDA’s decisions.9 
Several narrative reviews and commentaries have been published, providing a complete 
or partial overview of biomedical and integrative treatment options for HSDD.8 10-17 To our 
knowledge, no studies have comprehensively summarized the evidence regarding the 
beneficial and harmful treatment effects of flibanserin for women with HSDD. Therefore, 
in view of these controversies and the availability of this new prescription drug, we 
aimed to assess efficacy and safety of flibanserin for the treatment of HSDD in women 
by performing a systematic review and meta-analysis of randomized controlled trials.
METHODS
Search strategy and inclusion criteria
We conducted a systematic search of 3 trial registries and 13 electronic databases 
(including Embase.com, Medline (Ovid), and Psycinfo) from inception to June 17, 2015, 
to identify all studies assessing efficacy and safety of flibanserin for the treatment 
of women with HSDD. The search strategy for each database was designed by an 
experienced medical information specialist (Supplemental Methods 1). 
A stepwise selection procedure was followed (Supplemental Figure 1). Eligible studies 
included interventional studies assessing efficacy and safety of flibanserin in women 
with HSDD or sexual interest/arousal disorder (Supplemental Methods 2). Studies in 
premenopausal and postmenopausal women were eligible, given the potential off-label 
use in postmenopausal women.7 Studies assessing any outcome measure were eligible; 
outcome measures included, among others, change from baseline in number of satisfying 
sexual events (SSE), sexual desire, and distress related to desire; adverse events (AEs) 
leading to study discontinuation; specific AEs including dizziness, somnolence, nausea, 
and fatigue and serious AEs. No age, language or date restrictions were applied.
Study selection
Two independent researchers reviewed all abstracts and registered trials, and selected 
potentially eligible studies. Full texts of these studies were retrieved to assess fulfilment 
of the selection criteria. Disagreements were resolved through consensus or consultation 
of a third reviewer. The references of the retrieved studies were scanned to identify 
additional publications that were missed by the initial search. 
Data extraction
A data collection form was prepared to extract all relevant information from the 
included studies. Extracted data included period of surveillance, country, funding source, 
participant characteristics (age, menopausal status, duration of HSDD, and more), dosage 
regimens, and participant flow. Furthermore, baseline and end of follow-up levels of the 
outcomes were extracted. A second researcher checked the extracted data. 
In cases of missing data, the clinicaltrials.gov website and the Advisory Committee 
Briefing Documents were consulted.18 In 5 cases, we contacted authors and in all cases 
the owner of flibanserin, Sprout Pharmaceuticals Inc.
Quality evaluation
The quality of the evidence per outcome was graded according to the recommendations 
of the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) 
Working Group, and included consideration of within-study risk of bias (methodological 
quality), directness of evidence, heterogeneity, imprecision, and risk of publication bias.19 
The within-study risk of bias was assessed by two researchers independently using the 
Cochrane Collaboration risk of bias tool.19
Since the number of eligible studies was smaller than 10, assessing publication bias with 
funnel plots was not feasible.19
Efficacy and safety outcomes
Primary efficacy outcomes included number of SSE per month, monthly sexual desire 
intensity (e-Diary desire; Invivodata Inc), and Female Sexual Function Index desire 
domain (FSFI desire).20 Five efficacy outcomes were labelled as secondary: FSFI total 
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score, Female Sexual Distress Scale-Revised Item 13 and total score,21 Patient’s Global 
Impression of Improvement, and Patient Benefit Evaluation.
Safety outcomes included any AEs, investigator defined drug-related AEs, AEs leading 
to study discontinuation, the 4 most common AEs (dizziness, somnolence, nausea, and 
fatigue), and severe and serious AEs. 
Statistical analyses
Heterogeneity permitting, we sought to pool the results of women using 100 milligrams 
(mg) of flibanserin (100mg once daily at bedtime or 50mg twice daily) vs women using 
placebo via fixed and random effects models. Heterogeneity was assessed using Cochrane 
X2 and I2 statistics. Random effects models were used in case of clinical heterogeneity 
(differences in study inclusion criteria) or statistical heterogeneity (I-squared of ≥40% or 
a significant test for heterogeneity). In all other cases, fixed effects models were used.
Adequately blinded studies (Supplemental Methods 3) were summarized using the 
inverse variance weighted mean difference and 95% confidence interval (CI) for continuous 
outcomes, and the risk difference or risk ratio and 95% CI for dichotomous outcomes. For 
inadequately blinded studies, we presented outcomes for flibanserin and placebo groups 
separately.22 23 
In case of missing data for the number in analysis or standard error (SE), for efficacy 
outcomes the number of study completers and the largest outcome-specific SE from 
the other studies were imputed, respectively; a conservative approach given its modest 
effect on study size, weighting, and precision estimates. For safety outcomes, the 
number of study starters was used, given that dropout, among other reasons, was likely 
to be related to AEs. 
We performed 3 subgroup analyses, one in premenopausal women only, a second for the 
FDA-approved dose of 100mg once daily at bedtime, and a third comparing published 
and unpublished studies.
In sensitivity analyses, the smallest outcome-specific SE was taken and the number of 
study completers and study starters were replaced by each other in efficacy and safety 
assessments, respectively. Furthermore, to detect the influence of a single study on the 
overall meta-analysis, the studies were omitted 1 by 1. 
All statistical data analyses were performed using Stata Statistical Software: Release 12 
(StataCorp LP).
RESULTS
Of 592 references and registered trials initially identified, 8 studies were included in the 
qualitative assessment and 4 to 7 studies were included in the quantitative synthesis, 
depending on how many studies reported each outcome (Supplemental Figure 1). Three 
studies were unpublished trials conducted between 2006 and 2011 (Supplemental Table 
1). The remaining 5 studies were published between 2011 and 2014.24-28 
General characteristics of the included studies
All studies were randomized, double-blind, placebo-controlled trials performed in the 
United States of America (USA) and Canada, except for 1 study, which was performed in 13 
European countries. All studies included premenopausal (6 studies) or postmenopausal 
women (2 studies) with generalized acquired HSDD according to the Diagnostic and 
Statistical Manual of Mental Disorders (Fourth Edition, Text Revision) and for whom the 
diagnosis was ascertained by a trained clinician via a diagnostic interview (Table 1). No 
studies were found for women with sexual interest/arousal disorder. Furthermore, all 
women were in stable, heterosexual, monogamous relationships for at least 1 year. Most 
studies included a dosing regimen of 100mg of flibanserin once daily at bedtime. 
Overall, at least 7914 women were assigned to any treatment arm, of which 5914 women 
completed the various trials. An overview of study participant flow and number of 
dropouts per reason is presented in Supplemental Table 2.
General characteristics of the study participants
Five studies reported characteristics of the study participants (Supplemental Table 
3). These characteristics did not differ between studies or treatment arms except 
for the mean (SD) age of 36.1 years (6.7) and 55.5 years (5.4) in premenopausal and 
postmenopausal women, respectively. Mean (SD) BMI was 26.9 (5.8), and nearly 90% of 
participants were of Caucasian descent. No information was found on level of education 
and socio-economic status. Study exclusion criteria specified an extensive list of diseases 
and medications.
Women’s mean (SD) number of baseline SSEs per month was 2.5 (2.6) (Supplemental 
Table 4). Baseline e-Diary desire (scale 0-84) was 11.5 (9.3), and FSFI desire (scale 1.2-6) 
was 1.8 0.7). 
Quality evaluation
Even though all studies were randomized controlled trials, the overall quality of the 
evidence for both efficacy and safety outcomes was very low (Table 2). The summary of 
the within-study risk of bias assessment can be found in Supplemental Table 5, 6, and 
7A-7H.
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Beneficial treatment effects
An overview of reported efficacy and safety outcomes is presented in Table 3. For 
all efficacy outcomes, it was feasible to pool the results, except for Patient’s Global 
Impression of Improvement (Supplemental Table 8). 
Given the presence of mostly unclear risk of bias in the blinding domains, we sought to 
pool the results of the efficacy outcomes as described in the Methods section. Pooled 
efficacy analyses included all available studies, except Goldfischer, 2011, owing to its 
deviating ‘withdrawal’ study design. The Alternate Dose Study compared 50mg twice 
daily to placebo; all other included studies used the 100mg once daily at bedtime dosing 
regimen. 
The pooled mean difference for change in mean SSE from baseline was 0.49 (95% CI, 0.32 
to 0.67) between 100mg flibanserin and placebo (Figure 1A). In premenopausal women 
only, this was 0.65 (95% CI, 0.38 to 0.92) (Supplemental Table 9), and in studies using the 
FDA-approved 100mg once daily dose this was 0.54 (95% CI, 0.35 to 0.73) (Supplemental 
Table 10). For published studies, the mean difference for SSE was 0.58 (95% CI, 0.37 to 
0.80) and for unpublished studies this was 0.31 (95% CI, 0.00 to 0.62)(Supplemental Table 
11). The mean difference for e-Diary desire score mean change from baseline, which 
was only measured in studies with premenopausal women, was 1.63 (95% CI, 0.45 to 
2.82) (Figure 1B). For FSFI desire, this was 0.27 (95% CI, 0.17 to 0.38) in all women (Figure 
1C). All primary and secondary efficacy outcomes (Supplemental Figure 2A-D) showed 
a statistically significant difference between 100mg flibanserin vs placebo (p<0.001) in 
main analyses. An overview of the meta-analysis results for the efficacy outcomes in 
flibanserin and placebo groups separately can be found in Supplemental Table 12. 
Harmful treatment effects
All except two safety outcomes were feasible to pool, and all studies assessed the effect 
of 100mg flibanserin once daily versus placebo. The risk for any AEs, which also included 
non-drug related side-effects such as common cold, was 1.29 (95% CI, 1.15 to 1.45) times 
higher for flibanserin than for placebo (Supplemental Figure 3A). Investigator-defined 
drug-related AEs were reported by 2 studies and ranged from 29.9 to 36.5% for flibanserin 
and from 12.7 to 15.8% for placebo. The risk for study discontinuation owing to AEs was 
2.19 (95% CI, 1.50 to 3.20) times higher for flibanserin than for placebo, but this outcome 
was only reported in 4 studies (Supplemental Figure 3B).
The risk of dizziness was 4.00 (95% CI, 2.56 to 6.27) times higher with flibanserin than 
with placebo; for somnolence, 3.97 (95% CI, 3.01 to 5.24) times higher with flibanserin; for 
nausea, 2.35 (95% CI, 1.85 to 2.98) times higher with flibanserin; and for fatigue, 1.64 (95% 
CI, 1.27 to 2.13) times higher with flibanserin (Figure 2). The overall risk ratio for the 4 most 
common AEs was 2.86 (95% CI, 2.32 to 3.52). Severe AEs, defined as being incapacitating or 
causing inability to work or undertake activity, such as syncope, hypotension, injury, and 
severe manifestations of side-effects such as somnolence and dizziness, were reported 
by 2 studies; in flibanserin users, the percentages were 4.2 and 6.0%, and 3.5% in controls. 
Serious AEs were defined as those resulting in death, those that were immediately life 
threatening, those that required longer lasting hospitalization, or those that were deemed 
serious for any other reason; these included, among others, appendicitis, cholelithiasis, and 
concussion.29 The absolute number of serious AEs was small and the risk ratio did not differ 
between flibanserin and placebo users (1.48 (95%CI, 0.91 to 2.41)) (Supplemental Figure 
3C). All safety outcomes, except serious AEs, showed a statistically significant difference 
between 100mg flibanserin vs placebo (p<0.001) in main analyses.
None of the studies was found to be too influential on the overall effect size when 
Figure 1. Mean differences in 3 measures of sexual desire, 100mg flibanserin vs placebo. 
A: Monthly number of sexually satisfying events (SSEs). B: e-Diary desire (scale 0-84). C: Female Sexual Function 
Index (FSFI) desire (scale 1.2-6.0). Menopausal status: 1 indicates premenopause; 0 indicates postmenopause. 
CI=confidence interval, ES=effect size, I-V=inverse-variance, No=number, NR=not reported.
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omitted 1 by 1. The direction, size, and significance of the associations remained the 
same in the sensitivity analyses performed based on the assumptions made regarding 
the imputation process detailed in the Methods section (Supplemental Table 13).
Figure 2. Risk ratios (RRs) for the 4 most common adverse events, for 100mg flibanserin vs placebo. 
Menopausal status: 1 indicates premenopause; 0 indicates postmenopause. CI=confidence interval, I-V=inverse-
variance.
DISCUSSION
This systematic review and meta-analysis summarizes 5 published and 3 unpublished 
studies investigating efficacy and safety of flibanserin for the treatment of HSDD in 
nearly 6000 women. Treatment with flibanserin, on average, resulted in half of one 
additional satisfying sexual event per month, while substantially increasing the risk 
of dizziness, somnolence, nausea, and fatigue. Overall, the quality of the evidence was 
graded as very low for efficacy and safety outcomes, particularly due to limitations in 
design, indirectness of evidence, and more favorable efficacy outcomes in published 
compared to unpublished studies.
To our knowledge, this is the first systematic review and meta-analysis addressing the 
impact of flibanserin treatment in women with HSDD. The most important question 
concerns the clinical relevance of the statistically significant efficacy outcomes,30 
particularly considering side-effects that could worsen with concurrent alcohol intake or 
CYP3A4 inhibitors, including oral contraceptives and fluconazole.7 31 Clinical significance 
was evaluated by assessing the magnitude of effect sizes, and by patient reported 
minimum relevant difference and self-perceived meaningful benefit.30 32 
The data presented in this review suggest that the meaningful change caused by 
flibanserin is minimal. Firstly, for the range of 0.5-1.0 increase in SSEs reported by the 
FDA,33 frequently referenced by scientific articles and mass media, the difference in SSEs 
change per month in our review was at the lower end of this range in main, subgroup, 
and sensitivity analyses (Supplemental Table 9-11, 13). Secondly, the perceived minimum 
important difference for the SSE e-Diary in postmenopausal women ranged from 0.16-
1.84 per month.34 Hence, the mean difference for change in SSE per month in this study 
was also at the lower end of this spectrum (Figure 1A). Patient Benefit Evaluation and 
Patient’s Global Impression of Improvement measured overall subjectively experienced 
improvement. The difference in experienced meaningful benefit between flibanserin 
users and controls was small, ranging from ‘minimal improvement’ to ‘no change’ 
(Supplemental Table 8 and Supplemental Figure 2D).
The most common reported side-effects were of mild and moderate intensity, and serious 
side-effects were equally low in flibanserin and placebo users. This reflects positively on 
flibanserin’s safety, but the conclusion that flibanserin is safe is premature. Investigator-
defined drug-related AEs and severe AEs were underreported (2 studies each). Severe 
AEs included, among others, syncope and hypotension. Both can occur with flibanserin 
use alone but are amplified with concurrent alcohol use and were labelled by the FDA 
as serious safety concerns.33 In an open-label extension study with a median follow-
up time of 1 year, including 1.723 women, 723 (43%) reported investigator-defined drug-
related AEs and 143 (8.3%) reported severe AEs.35 The continued safety (and efficacy) of 
flibanserin with long-term use remains to be established. 
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The strengths and limitations of our work merit careful consideration. The systematic 
search for eligible studies in numerous medical databases, trial registries, and reference 
lists using broad search terms, and the inclusion of published and unpublished work, 
allowed us to provide a comprehensive overview of the evidence for the efficacy and 
safety of flibanserin for the treatment of women with HSDD. The inclusion of studies 
focusing on postmenopausal women took into account the potential off-label use. 
Furthermore, the extensive quality evaluation may facilitate the discussion of not only 
efficacy and safety of flibanserin, but also of reliability of the evidence put forward by the 
studies included in this review. 
A limitation was the fact that the studies were light on details. This affected the 
accuracy of the quality evaluation (many within-study risk of bias domains remained 
with unclear risk) and the completeness of the meta-analyses (some outcomes were 
not feasible to meta-analyze and some meta-analyses did not include all studies). 
Therefore, some caution is required with interpreting the results of these assessments. 
The most important lacking data included blinding ascertainment, number in analyses, 
and completeness (effect and precision estimate) of every outcome. Contacting study 
investigators and study sponsor did not generate additional information. Therefore, given 
the unclear risk of bias for blinding, results were pooled via 2 different approaches, and 
yielded comparable findings, which generates confidence with regard to the reliability of 
the findings. Also, missing values were imputed to limit introduction of bias and proved 
robust in sensitivity analyses.
As women with a wide range of medication uses, diseases (including psychological 
comorbidities), and women not in a stable, communicative, heterosexual relationship 
were excluded from participation, the generalizability of the findings may be limited.36 
Because overall, study participants were overweight, results may not be generalizable to 
women in other BMI categories. Additionally, it is unclear to what extent they represent 
typical women HSDD, given that they had baseline 2.5 SSEs per month and had to be 
willing to engage in sexual activity once a month to be eligible to participate. Because the 
actual base rate of SSE’s in women with HSDD is unknown, it is possible that the included 
women represent a higher functioning group, and conclusions may not be valid for all 
women suffering from HSDD.22
CONCLUSIONS 
With nearly 90% of American physicians indicating that they would prescribe an approved 
HSDD pharmacological product over available non-pharmacological treatments37, the 
need for sound evidence on the efficacy and safety profile of flibanserin is evident. 
The findings of this review suggest that the benefits of flibanserin treatment are 
marginal, particularly when taking into account the concurrent occurrence of side-
effects. It has been suggested that women with HSDD would benefit most from an 
integrative approach, including, medical, psychiatric, psychological, couple relationship, 
and sociocultural domains: the biopsychosocial model.11 17 Before flibanserin can be 
recommended in guidelines and clinical practice, future studies should include women 
from diverse populations, particularly women with (a history of) somatic and psychological 
comorbidities, medication use, and surgical menopause. 
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The appreciation of a health-focused approach is increasingly gaining attention. This 
is reflected in the expanding number of contemporary definitions of health, which are 
available today. Within these definitions, different body systems could be considered 
subdomains of health, such as cardiovascular health or sexual health. The complex 
physiological mechanisms within these subdomains, which can interact with both 
psychological as well as social functioning, can differ between men and women and 
across stages of life. 
To date, it remains to be elucidated how concepts of health apply to men and women, 
populations, and across stages of life and how health measurement should be 
operationalized. Therefore, the aim of this thesis was to study health and ageing in 
older adults from a gender-specific and life-course perspective. A better understanding 
of the patterns and determinants of health has the potential to aid women and 
men, professionals, and policy makers in their efforts towards obtaining, recovering, 
maintaining, and improving health in our ageing populations.
In this general discussion, the principal findings of this thesis will be summarized, after 
which the methodological considerations will be discussed. Thereafter, the findings and 
implications of this thesis will be reflected on from different perspectives, the population, 
clinical, and policy perspective. The discussion will be concluded with a section that 
reflects upon potential directions for future research.
PRINCIPAL FINDINGS
Economic impact of non-communicable diseases
In Chapter 2 we studied the economic impact of six non-communicable diseases (NCDs), 
including coronary heart disease, stroke, type 2 diabetes, cancer (lung, colon, cervical, and 
breast), chronic obstructive pulmonary disorder, and chronic kidney disease, at different 
levels of society, from the household to the governmental level. In a systematic review of 
64 studies including more than 835 million individuals, NCDs imposed a large and growing 
global economic impact on households and impoverishment, in all continents and at all 
levels of income (Chapter 2.1). Financial catastrophe was often used as an outcome, and 
was defined as a scenario in which out-of-pocket expenditures for health care exceeded a 
certain percentage of the household income, varying from 10-40%. Financial catastrophe 
due to the selected NCDs occurred globally and ranged from 6-84% of the households 
depending on the chosen catastrophe threshold. 
In total, 153 studies focused on the economic impact of NCDs at the macro-economic 
level, and suggested a steady global increase in healthcare expenditure over the years as 
well as excessive losses in national income, hampering economic development (Chapter 
2.2). The costs varied across countries, regions, NCD type, severity of disease, and years 
lived with disease. In both Chapters 2.1 and 2.2, studies from low and middle income 
countries were underrepresented. Furthermore, heterogeneity in sample selection 
procedures, ascertainment of chronic disease, and in the definitions and measurement of 
the outcome (i.e. economic burden) made it difficult to draw definite conclusions. However, 
it is likely that the impact exerted by NCDs is underestimated, since important economic 
domains, such as coping strategies and inclusion of marginalized and vulnerable people 
who do not seek health care, are under highlighted in literature.
Healthy ageing and cardiovascular health
In Chapter 3.1 we developed a comprehensive healthy ageing score in the population-
based Rotterdam Study and explored age and gender differences in great detail. The 
healthy ageing score included 7 biopsychosocial domains: chronic diseases, mental 
health, cognitive function, physical function, pain, social support, and quality of life. 
Overall, we found that levels of healthy ageing score in this population were lower in 
women compared to men, in all age categories. Fewer women had multimorbidity (i.e. 
more than 1 chronic disease) compared to men. However, women had poorer mental 
health, worse physical function, more pain, and lower quality of life compared to men. 
The healthy ageing score declined with increasing age, albeit slightly steeper in women. 
Additionally, a higher healthy ageing score was strongly associated with lower mortality 
in both genders. 
In Chapter 3.2 we explored the association between healthy ageing score with markers 
of biological ageing, including with predicted transcriptomic age (PTA), predicted DNA 
methylation age (PDMA), and with leucocyte telomere length (TL). PTA was predicted with 
a leave-one-out-prediction meta-analysis, using whole-blood gene expression levels for 
half of the genes of the human genome. PDMA and TL were measured in the genomic 
DNA, which was extracted from peripheral venous blood. PDMA was calculated with a 
DNA methylation age calculator using penalized regression models. TL was measured 
using qPCR as the ratio of telomere repeat length to the copy number of the single-
copy gene 36B4. Overall, we found that a higher healthy ageing score was associated 
with lower PTA and PDMA, and with longer TL in both genders, which could be mostly 
explained by chronological age. 
Adopting a life-course approach in Chapter 3.3, we assessed whether established and 
previously unexplored characteristics of women’s fertile life period and sex steroids were 
related to the healthy ageing score in postmenopausal women of the Rotterdam Study. 
We found that the healthy ageing score improved for women who had experienced 
menarche at an older age, were older at the time they went through menopause, had 
a longer fertile lifespan, or had more children, particularly living children, irrespective 
of socio-economic and lifestyle factors. Moreover, with increasing estradiol levels, 
healthy ageing score significantly worsened, whereas no associations were found for 
testosterone, free androgen index (FAI), and sex hormone-binding globulin (SHBG).
The counterintuitive direction of effect of estradiol in Chapter 3.2, was also found in 
Chapter 3.4. In this chapter, we were interested in the association between estradiol, 
testosterone, FAI, and SHBG with cardiovascular health in men and women of the 
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Rotterdam Study. The concept of cardiovascular health was introduced by the American 
Heart Association in 2010 and consists of 7 metrics including 3 health factors (total 
cholesterol, fasting glucose, and blood pressure) and 4 health behaviours (physical 
activity at goal, non-smoking, normal body mass index, and a healthy diet).1 Ideal 
cardiovascular health has been associated with less severe subclinical atherosclerosis,2-4 
lower incidence of cardiovascular morbidity and mortality,4-8 better cognition9, better 
psychological status10, lower cancer risk 11, more favourable overall functional status 
12, and lower all-cause mortality.7 8 In our study, higher levels of SHBG were associated 
with better cardiovascular health in men. Among women, lower levels of testosterone 
and FAI and higher levels of SHBG were associated with better cardiovascular health. 
Furthermore, women with higher levels of estradiol tended to have worse cardiovascular 
health, although this effect attenuated after adjustment for covariates.
Women’s sexual, reproductive, and menopausal health
We observed that although many studies focus on menopausal health or elements 
hereof in literature, such studies lack consensus of what menopausal health actually 
is. Therefore, we sought to conceptualize healthy menopause and aimed to incorporate 
biological as well as psychosocial aspects of health into the framework. We organized 
an expert panel meeting, inviting among others, gynaecologists, cardiologists, and 
epidemiologists, to develop a user-based conceptual framework for healthy menopause. 
We proposed healthy menopause as “a dynamic state, following the permanent loss 
of ovarian function, which is characterized by self-perceived satisfactory physical, 
psychological, and social functioning, incorporating disease and disability, allowing the 
attainment of a women’s desired ability to adapt and capacity the self-manage”. Such a 
multidimensional concept asks for multidimensional measurements. Therefore, in this 
chapter we provided an overview of measurement tools that could be used to measure 
menopausal health.
In Chapter 4.2 we explored whether differences occurred in androgen levels between 
women with various forms of ovarian (dys)function and whether or not androgens in 
these women were associated with cardiometabolic features, such as blood pressure, 
glucose and cholesterol levels. Firstly, androgen levels were compared between 4 distinct 
groups of women: regular cycling women (i.e. healthy premenopausal women), women 
with polycystic ovary syndrome (PCOS, associated with hyperandrogenism), women 
with premature ovarian insufficiency (POI, associated with hypoandrogenism), and 
healthy postmenopausal women. As expected, women with PCOS were hyperandrogenic 
and women with POI were hypoandrogenic compared to regular cycling women. After 
adjusting for age, no differences were found between women with POI and healthy 
postmenopausal women and regular cycling and healthy postmenopausal women. 
Secondly, the association between androgens with cardiometabolic features 
was assessed in these women. A higher FAI was associated with worse levels of 
cardiovascular risk factors in all groups of women, including elevated triglycerides, insulin, 
homeostasis model assessment-insulin resistance (HOMA-IR), and blood pressure. 
These associations were strongest in women with PCOS. Although the strength of the 
associations attenuated after adjusting for body mass index (BMI), most associations in 
PCOS and healthy postmenopausal women remained statistically significant.
In Chapter 4.3 we assessed the association between established and previously 
unexplored fertile lifespan characteristics, such as timing of childbirth and menopause, 
with all-cause and cause-specific mortality in postmenopausal women of the Rotterdam 
Study. We found that late first and last reproduction were protective for all-cause 
mortality, whereas a longer maternal lifespan (i.e. interval between birth of first and last 
child), post-maternal fertile lifespan (i.e. interval between birth of last child and age of 
menopause), and cumulative estrogen exposure were harmful for all-cause mortality. 
Moreover, the associations for late last reproduction, post-maternal fertile lifespan and 
cumulative estrogen exposure were strongest and most significant in 1-child mothers. 
In addition, the findings differed with regard to direction, size, and significant when 
stratifying the analyses for cardiovascular (CVD), cancer, and other mortality.
In August 2015, the US Food and Drug Administration (FDA) approved flibanserin as 
a medical treatment for women with hypoactive sexual desire disorder (HSDD). The 
approval of flibanserin at the intersection of science, policy, and advocacy received 
considerable attention in the public domain, and was accompanied by debates about 
the risk-benefit trade-off among stakeholders and health institutions. The systematic 
review and meta-analysis presented in Chapter 4.4 summarized 5 published and 3 
unpublished studies investigating the efficacy and safety of flibanserin for the treatment 
of HSDD in a little under 6000 women. Treatment with flibanserin resulted in one-half 
additional sexual satisfying event (SSE) per month while significantly increasing the risk 
of 4 common side-effects (dizziness, somnolence, nausea, and fatigue). Moreover, the 
quality of the studies was graded as very low, according to the applied Cochrane Grades 
of Recommendation, Assessment, Development and Evaluation (GRADE) Working Group 
approach.
METHODOLOGICAL CONSIDERATIONS
Systematic reviews, an exhaustive and reproducible approach 
Three of the studies in this thesis were systematic reviews and meta-analyses. This study 
design is considered high quality evidence for several reasons. As opposed to narrative 
reviews, systematic reviews have a focused research question for which a specific search 
strategy is developed (Table 1), in our case by a medical information specialist. The design 
of a systematic review is reproducible and exhaustive. Reproducible in the sense that 
any other person should be able to reproduce the search and retrieve the same results. 
Exhaustive in the sense that all literature that fulfils the in- and exclusion criteria of 
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the research question is included. If literature is missing, authors of missing studies are 
asked to provide their study results and experts in the field are consulted to suggest any 
missing work. Moreover, grey literature can be searched for example via Google and trial 
registries can be consulted to retrieve unpublished results from intervention studies. The 
standardized approach for identification, selection, and appraisal of the studies allows 
scientists to synthesize all research objectively, without bias. We followed this approach 
for all three of the systematic reviews presented in this thesis.
The power of a prospective cohort design
Most of the studies in this thesis were performed in the Rotterdam Study, a prospective 
population-based cohort study.14 A prospective cohort is a powerful study design to 
identify determinants of common health outcomes at the population level. One of the 
strengths of a prospective study design, such as the Rotterdam Study, is that information 
on determinants (i.e. sex steroids or fertile lifespan characteristics) can be collected 
before outcomes (i.e. cardiovascular health, healthy ageing score, or mortality) occur. 
This can reduce the extent of recall bias and it provides an opportunity to measure the 
temporality of a relation, in such that the determinant precedes the outcome. Another 
strength of the Rotterdam Study is that extensive information was available both for the 
exposures studied in this thesis as well as for the outcomes. This allowed us to study 
health and ageing from a gender-specific and life-course perspective in great detail. 
Healthy, healthier, healthiest
The Rotterdam Study recruited individuals living in the well-defined Ommoord district 
of Rotterdam.14 The overall response rate for inclusion at baseline was 72% (14.926 of 
20.744 participants). Although these response rates are quite good, one could wonder 
how representative the participants of the Rotterdam Study are for the general 
Feature Narrative review Systematic review
Question Broad in scope Focused question
Sources and search Not usually specified, potentially 
biased
Comprehensive sources and explicit 
search strategy
Selection Not usually specified, potentially 
biased
Criterion-based selection, uniformly 
applied
Appraisal Variable Rigorous critical appraisal
Synthesis Mostly a qualitative summary Qualitative of quantitative summary
Inferences Sometimes evidence-based Usually evidence-based
Table 1. Comparison of main features between narrative and systematic reviews.13
population. Population-based cohort studies tend to represent a more healthy and 
affluent population than the underlying general population eligible for inclusion in the 
study.15 Rotterdam Study participants had a slightly lower cardiovascular risk compared 
to the total group of invitees, and nonparticipation was associated with mortality.15 
Therefore, in our studies, selective participation at baseline of healthier individuals could 
have resulted in more optimal levels of healthy ageing score (Chapter 3.1 and 3.2) and 
cardiovascular health (Chapter 3.3) among the included participants as compared to 
the general population. Hence, the findings may not be generalizable to less healthy 
populations.
Furthermore, selection bias can occur as a result of selective loss to follow-up, such as 
selective drop-out or selective inclusion. This could have occurred in our studies. For 
example, the healthy ageing score was constructed at the fourth visit of the first cohort, 
given that measurements of quality of life and social support were introduced at that 
time. Furthermore, we excluded participants who had missing data in more than 5 of the 
7 healthy ageing score domains. It is likely that less healthy participants died before they 
were able to participate in our studies and that the less healthy had more missing data 
than the healthier participants, and were therefore more likely to have been excluded. In 
all of the studies we observed that the included population was younger, higher educated 
and suffered less from prevalent chronic disease compared to the total population at 
baseline, though the differences were minor. Although in our studies multiple procedures 
were used to reduce selective dropout of unhealthier participants to a minimum, selection 
bias due to this reason still might have remained. 
Women are not small men
Too often in biomedical research, the effect of gender is not adequately considered, or not 
taken into account at all. This is also referred to as gender blindness.16 Historically, women 
were excluded from study to prevent biases due to hormonal differences between men 
and women. Then, the findings from men were extrapolated back to women. At present, 
a prominent approach in biomedical research is to group men and women together, while 
adjusting the analyses for gender. A substantial pitfall of such an approach is that the 
effect of gender is considered a confounding effect, which is an effect that you want to 
get rid of. 
The default of research analyses ought to be changed. Rather than adjusting for gender 
and analysing men and women together, by default research questions should be 
evaluated by gender. Reporting findings by gender has the potential to teach us more 
about the biological differences that occur naturally between men and women. Therefore, 
for all studies reported in this thesis, the analyses were performed in a gender-specific 
manner. 
Measurement of women’s fertile lifespan characteristics
Fertile lifespan characteristics, including age at menarche, menopause, and timing 
of childbirth, were assessed when women already reached menopause. Therefore, 
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retrospective recall could have occurred. One study assessed the validity of self-reported 
age at menarche in adulthood, and concluded that the correctness of the recall was 
moderate.17 For age of menopause, such studies have shown that the recall is precise close 
to menopause, and starts to show more variance the larger the time since menopause 
interval is.18 19 In our population the measurement of fertile lifespan characteristics 
were collected before the assessment of the outcomes (such as mortality). Moreover, 
the women of the Rotterdam Study and interviewers administering the women’s health 
questionnaire were unaware of the research questions under study. We therefore 
reasonably expect that any misclassification of the exposure would be non-differential, 
and if any, would provide a conservative approach given that the effect estimates would 
be less strong than if no misclassification would have occurred. 
Natural postmenopausal women
By design, there is a risk of confounding in cohort studies. Confounding can be defined 
as ‘the confusion of effects’.20 Restricting the analyses to a particular subgroup of the 
population is an example of a way to control for confounding during the study design stage 
of a study. In our studies including women, analyses were restricted to postmenopausal 
women with a natural menopause. This was done because health status’ can differ greatly 
between pre, peri and postmenopausal women, given that the menopausal transition 
is characterized by significant changes at the hormonal, physiological, and metabolic 
level.21 22 To what extent these changes affect later life health further differs according 
to menopausal type (i.e. natural vs. surgical menopause). Furthermore, in the analyses 
where sex steroids were the exposure of interest, the population was further restricted 
to women who never used estrogenic hormone replacement therapy. These restrictions 
were applied to reduce the amount of bias in our effect estimates, since menopausal 
status, menopausal type, and hormone replacement therapy are considered factors that 
are associated with both the exposures and the outcomes under study in this thesis.
Adjustment for confounders
A second way to deal with confounding is by adjusting the analyses for factors that are 
associated with both the exposure and the outcome under study. In this thesis, these 
factors included socio-economic status (e.g. level of education, income, marital status) 
and lifestyle variables (e.g. smoking, body composition, alcohol, physical activity, diet). 
For women, the variable years since menopause was additionally included, which was 
defined as the interval between a woman’s age of menopause and her actual age. Women 
of the same age can have different ages of menopause. Given that timing of menopause 
is associated with sex steroid levels, fertile lifespan characteristics and postmenopausal 
health, years since menopause was included as a covariate in the statistical models. 
Although we did our best to rule out as much confounding as possible via complementary 
approaches, residual confounding can never be completely ruled out in cohort studies. 
FINDINGS IN PERSPECTIVE
An extensive discussion of the findings for each separate chapter can be found in the 
discussion sections of the separate manuscripts included in this thesis. In this general 
discussion, we will reflect on the findings and implications of our work from different 
perspectives: the population, the clinical, and the policy perspective.
Population perspective
Financial hardship
In most studies of this thesis, we incorporated the population’s perspective. This 
perspective could be described as the way people perceive a situation through their own 
eyes. High proportions (up to 90%) of individuals and households perceived changes for 
the worse and worried about their financial situation (e.g. financial hardship) due to the 
impact of non-communicable diseases in their families. Economic consequences of non-
communicable diseases are preceded by self-perceived illness and treatment seeking 
behaviour, according to a theoretical framework presented by McIntyre and colleagues.23 
People may avoid seeking health care when ill, ignore being ill, or not perceive themselves 
as being ill altogether.23 These factors together could have led to an underestimation of 
the true economic burden that NCDs impose on households and on the impoverishment 
of people. In order to constrain this burden, country and even region specific financial 
protection should be put into place. Significantly fewer households would become 
impoverished when out-of-pocket spending is reduced to less than 15% of total health 
spending.24 Other promising approaches include subsidized or free hospital services and 
the provision of certain health services to the poor.24 
Disability paradox
Considering self-perceived health is essential for both men and women and for all age 
groups. This is particularly true in the elderly for whom subjectively experienced health 
can differ substantially from what is measured objectively.25 This is referred to as the 
disability paradox: individuals suffering from disease or disability often concurrently 
report high levels of quality of life.26 27 In this thesis we observed this trend: of the people 
with multimorbidity (i.e. suffering from more than 1 chronic disease), 43% reported 
moderate and 45% reported good quality of life. Of people with severe disability, these 
percentages were 49% and 15%, respectively. These numbers were similar in men and 
women. Notably, the thresholds used for good and moderate quality of life in this 
population were stringent, because most of the participants reported high levels of 
quality of life. Hence, when studying health in older populations, combining measures of 
self-perceived health with more objective measures may better reflect the health status 
of individuals. 
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Consequences of complete 
Ideal cardiovascular health was defined by de American Heart Association as having 
ideal levels of 3 health factors (such as blood pressure < 120/80 mmHg) and 4 health 
behaviors (such as BMI < 25 kg/m2).1 The cutoffs for ideal levels originated from 
established guidelines and were literature-based.1 In Chapter 3.3 we found that none 
of the participants adhered to the definition of ideal cardiovascular health, a finding that 
has been found consistently in other populations.4-8 Should the conclusion therefore be 
that our entire populations are unhealthy, at least from a cardiovascular point of view? 
Or are the thresholds to define ideal cardiovascular health too stringent? Although the 
first may be true, one could reason in favor of the second. The approach used to define 
ideal cardiovascular health shows some similarity with the definition of health from the 
World Health Organization (WHO) from 1948: “a state of complete physical, mental and 
social well-being and not merely the absence of disease or infirmity”.28 The definition 
has been criticized, since complete implies that most of us would be unhealthy for most 
of the time.29 Although complete well-being is a desirable goal, it is hard to achieve and 
challenging to operationalize. When criteria for health are set at too stringent levels, the 
study of its determinants and consequences is hampered. 
Satisfactory and dynamic health
Living with chronic disease and disability is becoming more and more common. This is 
a second reason why the previously mentioned WHO definition has become outdated: 
its static nature makes an increasing number of people definitely ill.30 In a recent paper 
published by a group of international health experts, health is defined as ‘the ability to adapt 
and the capacity to self-manage’, herein moving from a static definition toward a more 
dynamic formulation of health.30 In the conceptual framework for healthy menopause, 
we took the dynamicity of health as a starting point, and further incorporated a people 
perspective by emphasizing self-perceived satisfactory functioning and a woman’s 
desired ability to adapt and capacity to self-manage, hereby allowing women to gain 
more control over their health. By doing so, we anticipated on the previously described 
disability paradox: disease and disability do not necessarily affect an individual’s sense of 
well-being or quality of life. Disease, disability and health can coexist at different degrees, 
changing dynamically over time, differing between men and women and within the same 
individual across different stages of life.
Clinical perspective
Healthy vs successful ageing. A semantic discussion? 
Ageing in an optimal manner is described with many different words, two of which 
are the terms healthy ageing and successful ageing. Are they two terms for the same 
thing, or do they reflect distinct phenotypes? The term successful ageing seems to be 
predominantly popular in American settings, whereas healthy ageing is more commonly 
used in European settings. To date, many different definitions of healthy or successful 
ageing exist, and many frameworks have been proposed by groups across the globe.31-37 
To some extent the frameworks show overlap, but they also include distinct features 
depending on the region or context in which they are developed. Concerns have been 
raised as to the term ‘successful’, which may stretch beyond the semantic preference 
of the users.38 Successful ageing could be problematic in the sense that it suggests 
inappropriate ideas of failure and unattainable ideals for success.38 It ignores the fact 
that decline is inevitable while ageing and it places the responsibility to delay decline 
primordially on the individual. However, most environmental challenges that people 
encounter during life, lie outside of their reach. In our developed healthy ageing score, 
we accommodated objective measures of health as well as measures of self-perceived 
health and created a continuum-based score, ranging from 0-14. A continuum-based 
score makes it easier to detect changes in healthy ageing over time, compared to the 
more conventional successful vs non-successful ageing approach.
Sex steroids & sex differences  
The more testosterone, the better it is for men. The more estradiol, the better it is for 
women. These are two expressions that still resonate in science and practice today. The 
pivotal role of sex steroids in bodily systems, such as the cardiovascular system, makes 
them a promising interventional target. This has led to the roll-out of intervention studies, 
such as the Women’s Health Initiative, which hypothesized that estrogenic hormone 
replacement therapy in women would lower cardiovascular disease risk.39 Yet, both 
testosterone treatment in men and estrogenic hormone replacement therapy in women 
have not lived up to their expectations thus far, at least with regard to benefits for the 
cardiovascular system.40-43 In this thesis, we found that higher levels of testosterone did 
not remain significantly associated with better cardiovascular health after adjustment 
for confounders in men. Higher testosterone and FAI were associated with worse 
cardiovascular health and cardiovascular risk factors in both pre- and postmenopausal 
women. Moreover, higher levels of estradiol were associated with worse cardiovascular 
health in postmenopausal women, a counterintuitive finding. The same direction of 
effect was also found for the association between estradiol with healthy ageing score. In 
line with our findings, an increasing number of studies is finding the same unfavourable 
effect of higher levels of estradiol in women.44-52 These findings imply that the effects of 
sex steroids in bodily systems are complex and differ between men and women. More 
research is needed to confirm our findings and identify specific mechanisms behind these 
findings. Several potential explanations have been discussed in the separate chapters of 
this thesis, particularly Chapters 3.2 and 3.3.
Biopsychosocial model 
One of the pillars of clinical practice is the biopsychosocial model. This model systematically 
considers biological, psychological, and social factors and their interactions to understand 
health and disease (Figure 1). 53 Practical issues, such as lack of time or budget, could 
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have led to different disciplines, including medical doctors, psychologists, and social 
workers emphasizing one specific domain of the model more than the others. The 
biopsychosocial model provided the basis for the studies on healthy ageing and healthy 
menopause in this thesis. The multidimensional healthy ageing score consisted of, among 
others, measures of physical functioning, cognitive functioning, mental health, and self-
perceived social support. While conceptualizing healthy menopause, the complementary 
relation between physical, psychological, and social functioning shaped the framework. 
These papers may be useful for clinical practice, in the sense that they could facilitate the 
implementation of sustainable biopsychosocial healthcare in clinical, public health, and 
research settings and aid health care workers to monitor healthy ageing of their patients 
over time. In fact, the public health department of the municipality of Utrecht is exploring 
whether they can implement the healthy ageing score, or an adapted version hereof, in 
the periodic health measurements that they perform among their community-dwelling 
older adults.
   
Sexual desire: spontaneous or contextual? 
The biopsychosocial model may also provide some explanation for the low efficacy of 
flibanserin found for women with HSDD, among other reasons. Eminently, sexology is 
a field of wherein biological, psychological, and social domains go hand in hand. Let’s 
assume for a moment that the suggested physiological mechanism of action for 
flibanserin is sound, and that this drug can restore the balance between excitatory and 
inhibitory activity of the brain by reducing levels of serotonin and increasing levels of 
dopamine and norepinephrine.54 This mechanism of action is founded on the (abandoned) 
Figure 1. The biopsychosocial model, incorporating disease and disability.
conception that sexual desire occurs spontaneously from an internal sexual drive.55 
Research suggests that the nature of sexual desire and arousal are conditioned upon 
an arousable system and the presence of sexually rewarding stimuli in an appropriate 
context: the incentive motivation model.56 57 Hence, it could have been expected that solely 
treating women with HSDD with flibanserin would yield little or no effect, because this 
approach is too unidimensional. Women with HSDD may benefit most from approaches 
integrating medical, psychological, couple-relationship, and sociocultural domains.58 59 
Reasonably, this also applies to patients with divergent health problems, hereby further 
emphasizing the importance of biopsychosocial thinking in clinical care, research, and 
public health settings.
Windows of opportunity in women’s life
The importance of a life-course approach in women’s health has only recently been 
adopted in guidelines for women’s health,60 61 but studies are still scarce. There is growing 
support that functioning, disease, and health in older adults share common pathways 
with accumulative life experiences, which can start as early as in utero.33 62 The work 
presented in this thesis is novel in such that we assessed how female-specific life course 
determinants impacted later life health both independently and cumulatively. We found 
that different measures of reproductive performance, such as pregnancy, reproductive 
disorders, and timing of menopause, were related to later life health. Therefore, 
reproductive performance in women could be considered an important marker of general 
health and health in later life. The identification of women with deviating reproductive 
performance earlier in life could facilitate the development of adequate preventive 
strategies to keep this women healthy until old age. 
To implement such strategies, several windows of opportunity in women are available. 
The average age of menarche in our population was 13 years. The average age at first 
birth was 25 years, and the average age of menopause was 50 years. These natural 
life stages are specific to women and can affect women’s lives beyond the ovaries and 
reproductive performance. Moreover, the time window that occurs when transitioning 
from one life phase to another, for instance the onset of puberty, the maternal period 
or the menopausal transition, provides a unique opportunity for education, evaluation 
of signs and symptoms, promotion of healthy lifestyle, personalized counseling, and 
recognition and potential treatment of modifiable risk factors. 
Policy perspective 
Population strategies for health
In Chapter 2 of this thesis, we showed that NCDs have an impact at the microeconomic as 
well as the macroeconomic level. Three factors precede catastrophic health expenditure 
of households and encompass the availability of health services requiring payment, a 
low capacity to pay, and the presence of risk pooling mechanisms. Therefore, reducing 
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the microeconomic impact of NCDs on households requires a macroeconomic health 
systems approach that is not reliant on out-of-pocket payments for treatment and 
provides financial risk protection.24 Although investing manpower and money into 
curative health care is essential, there is another promising side to the same medal: 
public health. Illustratively, Statistics Netherlands recently released a report in which 
they stated that cancer mortality among men reduced by 30% in the past 30 years.63 A 
large part of this decrease was attributable to the reduction in lung cancer mortality. 
Although advances in medical treatment claimed a 10-20% share, the largest reduction 
was due to anti-smoking regulatory mechanisms and smoking cessation campaigns.64 
Population strategies to facilitate a healthier lifestyle have several important advantages 
in the sense that they radically attempt to diminish the underlying causes of disease, 
they can benefit entire populations, and they are behaviourally appropriate.65 The latter 
is illustrated in the non-smoking example. When non-smoking becomes the social norm, 
for instance because it is prohibited in public places, it results in adapted non-smoking 
behavioural habits among the population. 
However, population strategies are plagued by the Prevention Paradox.65 How large 
the benefits of a healthy lifestyle are at the population level, how small they tend to 
be at the individual level, particularly when it comes to short term successes. Lifestyle 
measures are not only important to prevent disease, but even more so to maintain and 
facilitate health. Ageing healthily enhances the lives of individuals. Moreover, it has social 
and economic implications in ageing populations and can relieve the pressure on public 
spending. This is an important insight that is increasingly recognized and anticipated on 
by policy makers around the globe.66 67 
From binary to continuum-based health approaches 
The tendency in our societies is to think about health and disease in a binary fashion, 
in such that an individual could be either healthy or diseased. This way of dealing with 
health and disease may not reflect its true nature, although dichotomization may be 
necessary for practical reasons.68 Decades ago, the British medical doctor George 
Pickering described this phenomenon as follows: “the sharp distinction between health 
and disease is a medical artefact for which nature, if consulted, provides no support. This 
is difficult for doctors to understand, because this is a departure from binary thought. 
Medicine can count up to two, not beyond.” 
Binary thinking is also found in definitions and operationalizations of healthy ageing, 
or successful ageing. Rowe and Kahn described successful ageing as the absence of 
disease and disability, high cognitive and physical functioning, and active engagement 
with life. If you have all, then you are a successful ager.34 35 In line with George Pickerings’ 
proposed way of thinking, it has been suggested that more lenient and continuum-based 
measures for healthy ageing may better capture the heterogeneity of the phenotype.69 70 
This approach was adopted whilst developing the healthy ageing score in this thesis. 
Moreover, we incorporated disease and disability into the conceptual framework of 
healthy menopause. Moving from a binary health vs. disease towards a more integrated 
way of thinking, where even the diseased could be healthy to some extent, may aid health 
professionals and policy makers in facilitating the dynamic balance between every day 
opportunities and challenges in ageing populations. 
Evaluating research questions by gender 
In this thesis, we found gender differences in healthy ageing score and for the 
association between sex steroids with cardiovascular health. Moreover, women specific 
factors affected healthy ageing and mortality. However, by default, women and men 
are combined in the analyses and reporting of research findings. In clinical practice, 
symptoms reported by women are mostly considered atypical to those in men, instead 
of different. Furthermore, earlier life experiences, such as reproductive performance and 
pregnancy-related disorders, are often not adequately considered in later life health. 
Although there is still a long way to go, examples of good practice, that incorporate a 
gender-specific and life-course approach do exist. One such example is the Alliance of 
Gender and Health in the Netherlands, a collaboration between researchers, clinicians, 
and policy makers that emphasizes a gender-specific approach in research, training of 
doctors and psychologists, and awareness of the general public.71 Also, the first guideline 
on cardiovascular risk management after reproductive and pregnancy-related disorders 
in the Netherlands is now a fact.60 At the European level, most, but not all, EU grant 
applications include the following question: “Where relevant, describe how sex and/or 
gender analysis is taken into account in the project’s content”.72 These examples are a 
good start, although more of such measures and efforts are needed at the national and 
international level, to sustain a gender-specific and life-course approach.
Science and politics: a daring affair? 
In August 2015, flibanserin was approved by the US Food and Drug Administration (FDA) 
for the treatment of women with HSDD. The approval of flibanserin at the intersection 
of science, advocacy, and policy was controversial, of which I would like to provide a short 
history in this general discussion.73 In 2009, flibanserin was submitted to the FDA for 
approval for the first time. The committee unanimously voted against, given that the 
observed side-effects did not outweigh the still unclear benefits. They expressed the 
need for a third trial, with less restrictive inclusion criteria, and for studies focusing on the 
interaction between flibanserin, drugs, and alcohol. In 2013, the drug was resubmitted for 
approval, now including this third trial, though the inclusion criteria were still stringent. 
An alcohol interaction study was performed in 25 people, of which 23 were men. The 
study showed that concurrent intake of flibanserin with small amounts of alcohol 
substantially increased the risk of hypotension and fainting. Therefore, the FDA rejected 
approval once more. Then, in 2015, flibanserin was resubmitted for the final time and it 
got approved. The risk/benefit ratio was still the same. So if the science didn’t change, 
what did? In the meanwhile, the pharmaceutical company that owned flibanserin helped 
launch an advocacy platform called ‘Even the Score’, which framed a strong promotional 
campaign directed at all levels of society.74 Also, the FDA got accused of sexism, because 
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medications approved for men’s sexual dysfunction are many whereas women have 
none. From this example can be taken that politics, advocacy and science interact closely, 
and that it can be difficult to disentangle to what extent different factors influence 
decision-making processes.
DIRECTIONS FOR FUTURE RESEARCH
In this thesis we started out studying the economic impact of NCDs. Thereafter, we 
looked at gender differences in cardiovascular health and in the newly developed healthy 
ageing score. Furthermore, we assessed whether women’s fertile lifespan characteristics 
and sex steroids influenced postmenopausal health. Based on the findings and 
methodological considerations of our work, several potential directions for future 
research can be highlighted. As a starting point, future research should consider studying 
men and women in a gender-specific manner and adopting a life-course approach.
Economic impact of NCDs
For all studies in this thesis where men and women were involved, we stratified the 
analyses by gender from the start. Although we anticipated to do the same for the economic 
impact reviews, this was infeasible given that the individual studies mostly reported their 
findings for men and women together. Future studies focusing on the economic impact 
of NCDs should consider studying the impact by gender. Furthermore, there is a need for 
cost-effectiveness studies that can show which strategies are promising to reduce the 
economic impact of NCDs in different contexts. These studies should consider including 
the less studied indirect financial burden of NCDs on households, such as lost earnings, 
cost of premature death, and educational dropout among children. Besides focusing on 
the effect of strategies on long term outcomes (such as reductions in national health 
care spending), such studies would benefit from the additional inclusion of short term 
outcomes (such as coverage and adherence to interventions) in order to adequately 
inform politicians and decision makers. 
Healthy ageing research
Consensus & criteria
Measurement of healthy ageing is still in its infancy, although more and more research 
groups are working on operationalizing it in their populations. Therefore, several 
directions for future research could be suggested (Figure 2). The healthy ageing field 
could benefit greatly from establishing international consensus as to how healthy 
ageing should be measured and which gold standard measures could be acceptable to 
represent the underlying construct that is being measured. Moreover, there is a need for 
explicit and testable criteria for the development of healthy ageing measurement tools. 
A good example of such an approach was published by Searle and colleagues for the 
development of frailty indeces.75 Frailty is defined as the accumulation of deficits. Criteria 
for the inclusion of deficits were, among others, that the deficit should be associated 
with the health status, that it should be associated with age (p-value < 0.1), that the 
deficit does not saturate too early, and that it should be measured in at least 70% of the 
participants. Reaching consensus on such criteria for healthy ageing measurement tools 
will make judgment of the quality of the tools easier and will facilitate better comparisons 
of healthy ageing between different populations across the globe.
Optimizing and improving healthy ageing measurement 
It is possible that certain healthy ageing domains are more important than others. 
Furthermore, how healthy ageing should be measured can differ between men and 
women, in different age groups, and between populations (such as between countries or 
ethnic groups). For example, cultural beliefs and attitudes towards health and differences 
in social networks may require different approaches to healthy ageing measurement. In 
the development of the healthy ageing score in this thesis we deliberately chose to give all 
domains the same weight to make the score easy to interpret and more feasible to apply 
in other populations. The relative importance of certain healthy ageing domains could be 
assessed by creating a multivariable prediction rule. However, before such an approach 
can be implemented, outcomes that can serve as adequate gold standard measures for 
healthy ageing need to be established via the consensus mentioned above. New gender-
Figure 2. Graphical representation of potential directions for future healthy ageing research. Healthy 
ageing could be studied at the individual and population level. Furthermore, research could focus on 
determinants and potential beneficial outcomes related to healthy ageing, and on the four topics 
mentioned at the bottom of the figure.
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specific or country-specific health markers and measures could be added to such models 
in order to assess how healthy ageing measurement tools could be improved.
Monitoring and intervening on healthy ageing 
Measuring and monitoring healthy ageing could allow for a better understanding of 
patterns and trajectories of healthy ageing, how healthy ageing changes over time, 
and how it differs between individuals and populations at different levels of society. 
Moreover, there is a paucity of research that focuses on determinants of healthy ageing. 
Determinants that are of particular interest include, among others, lifestyle factors, 
gender-specific factors, and environmental factors. Furthermore, it remains unclear which 
interventions are effective with regard to obtaining, maintaining and improving healthy 
ageing. Therefore, a potential direction for future research includes the assessment 
of interventions which could be beneficial for different (sub)-groups of the population. 
Intervention studies could be implemented at the individual or population level. An 
example of an intervention directed at maintaining healthy ageing at the individual level 
could be to educate women in perimenopause about the physiology of menopause and 
the symptoms and symptom relief options of menopausal symptoms at the general 
practitioner’s office. An example of an intervention at the population level to improve 
healthy ageing could be to study the effect of taxing products containing sugar or fat and 
increasing the availability of more inexpensive healthy food choices. Finally, cost-benefit 
studies could provide a valuable insight as to which interventions are the most promising 
to invest in with regard to enhancing the lives of individuals and populations.
Women’s health research
From in utero to postmenopause 
We studied the impact of women’s fertile lifespan characteristics on mortality and 
healthy ageing. We were able to go back to the timing of menarche, but did not have 
information on early childhood or in utero exposures, both of which have been suggested 
to affect later life health.33 62 Moreover, we might have not measured characteristics of 
the fertile life that may affect the health status of older women. Such characteristics 
could include pregnancy complications, stillbirths, and abortions. It was outside the 
scope of this thesis to study the effect of earlier life experiences specific to men in more 
detail. It needs no further explanation that such studies could provide valuable insights 
for men’s later life health. Furthermore, the women included in our studies were mostly 
postmenopausal and we were not able to compare women across stages of menopause 
in detail. It would be of interest to repeat some of our work in populations where women 
can be stratified for menopausal stage, in order to assess the timeliness and durability 
of the associations under study. 
Paradigm shift 
Reproductive success and delayed ovarian ageing, which could be measured with proxies 
as late age of menopause, late last reproduction and number of living children, could 
be viewed as early markers of women’s general health in later life.76-80 Reproductive 
success and delayed ovarian ageing are linked to longevity via common genetic factors 
related to DNA repair and maintenance, and immune and mitochondrial function.77 80 81 
Therefore, it could be that the occurrence of menopause is a consequence of the ageing 
of the soma that results from the deterioration of these functions. In our studies we 
found a protective effect of late menopause and more living children on healthy ageing 
in postmenopausal women, though no association was found for late last reproduction. 
The age of last reproduction was not extreme enough in our population. Therefore, more 
studies are needed assessing the impact of these early life markers on health in later life 
in contemporary populations with more extreme ages of birth. Moreover, genetic studies 
are needed to further explore the genetic link between reproductive success, longevity, 
and health. 
CONCLUSIONS
In our modern societies, where we have the prospect of living over 100, it is becoming 
increasingly meaningful to study health and ageing from an integrated, gender-specific, 
and life-course perspective. This is true for men, and even more so for women, who tend 
to spend have of their life in postmenopause. Although the appreciation of a health-
focused approach is increasingly gaining attention, it remains under highlighted how 
concepts of health apply to men and women, populations, and across stages of life and 
how health measurement should be operationalized. 
In this thesis we conceptualized, developed, and reflected on different definitions of 
health and subdomains of health, and applied these definitions to the population-based 
Rotterdam Study. All research questions involving men and women were stratified by 
gender, and considerable differences between men and women were observed and 
discussed. Moreover, we specifically focused on women’s sexual, reproductive and 
menopausal health, and found that female factors such as pregnancy and timing of 
menopause impacted women’s later life health. 
A better understanding of gender-specific and life-course determinants of health 
has the potential of promoting and sustaining health in men and women. Moreover, 
improvements in measuring and monitoring health can contribute to a better aligning of 
health systems with the needs of ageing populations and could facilitate the development 
of age-friendly environments.
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Summary
Our population is ageing. While people are living longer in all parts of the world, evidence 
suggests that these years are spent with more disease and disability. This is observed 
in both men and women, although gender differences do occur. Worldwide, men are 
outlived by women by 6 to 8 years. However, women generally spend these additional 
years in less health: ‘men die quicker, women get sicker’. Furthermore, it has been shown 
that life events specific to women, such as pregnancy and timing of menopause, can 
greatly affect women’s health later in life. 
To date, past and current health research mostly focuses on individual risk factors, 
diseases, and mortality, and only marginally focuses on health. This approach may limit 
our overall understanding of health and the factors that are associated with obtaining, 
maintaining, and improving health. A better understanding of ageing healthily has 
the potential to enhance the lives of individuals and can facilitate the development 
of adequate strategies with regard to the economic and social implications of ageing 
populations. The benefits of a health-focused approach extend beyond the individual, 
and can impact all levels of society, ranging from the household to the governmental 
level.
In this thesis we aimed to provide insights in health and ageing of older adults whilst 
adopting an integrated, gender-specific, and life-course approach. As a first step we 
studied the global micro-economi¬¬c and macro-economic impact of NCDs in societies. 
Thereafter, we developed a healthy ageing score and applied the new concept of 
cardiovascular health to the population-based Rotterdam Study, after which we assessed 
age and gender differences and the role of sex steroids. Furthermore, because women 
encounter experiences throughout their lives that are exclusive to them, in this thesis 
we specifically focused on conceptualizing healthy menopause and on the role of fertile 
lifespan characteristics and different types of ovarian dysfunction in cardiometabolic and 
overall health. 
In Chapter 2 of this thesis, we studied the economic impact of non-communicable 
diseases (NCDs) on households, impoverishment, health care spending, and national 
income. This was done by performing 2 systematic reviews. The NCDs included were 
coronary heart disease, stroke, cancer, type 2 diabetes mellitus, chronic obstructive 
pulmonary disorder, and chronic kidney disease. 
The first systematic review is presented in Chapter 2.1, and focused on the economic 
impact of NCDs on households and impoverishment. We identified 64 articles that fulfilled 
the pre-specified inclusion criteria, which included more than 835 million individuals. 
The findings of this study showed that NCDs imposed a large and growing impact on 
households and impoverishment, in all continents and at all levels of income. 
In Chapter 2.2, we took a macro-economic approach, and observed a steady global increase 
in health care expenditure as well as excessive losses in national income due to NCDs. 
For both systematic reviews, we found little to no data for the regions Africa, South-
America, and the Middle-East. Also, most studies did not separate men and women in 
the presentation of their results. Therefore, in Chapters 2.1 and 2.2 we suggested that 
more research is needed particularly in these continents while presenting the results for 
men and women separately.
Considering the ageing of our population, healthy ageing is a priority public health challenge 
of growing importance. Therefore, in Chapter 3.1 we developed a healthy ageing score 
in the population-based Rotterdam Study, assessed age and gender differences, and 
evaluated the association of healthy ageing score with mortality. In the Rotterdam Study, 
comprehensive and detailed information on subjective and objective measures, which 
are necessary to construct a healthy ageing score, are available. The Rotterdam Study is 
a prospective, population-based cohort of individuals aged 45 years and older who reside 
in the well-defined suburb of Ommoord in the city of Rotterdam, the Netherlands. The 
healthy ageing score included a total of 7 biological, psychological, and social domains, 
most of which were easy and inexpensive to measure with questionnaires. Overall, 
we found that levels of healthy ageing score in this population were lower in women 
compared to men, in all age categories. Fewer women had multimorbidity compared to 
men. However, women had poorer mental health, worse physical function, more pain, and 
lower quality of life compared to men. The healthy ageing score declined with increasing 
age, albeit slightly steeper in women. Additionally, a higher healthy ageing score was 
strongly associated with lower mortality in both genders. 
In Chapter 3.2 we explored the association between healthy ageing score with markers 
of biological
ageing, including with predicted transcriptomic age (PTA), predicted DNA methylation 
age (PDMA), and with leucocyte telomere length (TL). Overall, we found that a higher 
healthy ageing score was associated with lower PTA and PDMA, and with longer TL in 
both genders, which could be mostly explained by chronological age.
In Chapter 3.3 we studied the association between women’s fertile lifespan characteristics 
and sex steroids with the healthy ageing score in the Rotterdam Study. We found that 
women with a later menarche, a later menopause, a longer fertile lifespan, and women 
with more children, particularly living children, had more favourable healthy ageing 
score levels. These findings remained significant after adjustment for various socio-
economic and lifestyle factors. Moreover, with increasing estradiol levels, healthy ageing 
score significantly worsened, whereas no associations were found for testosterone, free 
androgen index, and sex hormone binding globulin. 
In Chapter 3.4 we studied the association between sex steroids and sex hormone binding 
globulin with cardiovascular health in men and women of the Rotterdam Study. The 
concept of cardiovascular health was introduced by the American Heart Association in 
2010 to facilitate both clinical and public health programs for concurrent health promotion 
and disease prevention. Cardiovascular health includes ideal levels of 7 metrics, 3 of which 
are health factors (total cholesterol, fasting glucose, and blood pressure) and 4 of which 
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are health behaviours (physical activity at goal, non-smoking, normal body mass index, 
and a healthy diet). In our study, sex steroids, and particularly SHBG, were associated 
with cardiovascular health in both men and women.
In Chapter 4 we focused more specifically on women’s sexual, reproductive, and 
menopausal health.
In Chapter 4.1 we present the results of an expert meeting that we commenced to 
conceptualize healthy menopause. We proposed health menopause as “a dynamic 
state, following the permanent loss of ovarian function, which is characterized by self-
perceived satisfactory physical, psychological, and social functioning, incorporating 
disease and disability, allowing the attainment of a women’s desired ability to adapt 
and capacity the self-manage”. Adopting such a unifying conceptual framework could 
facilitate the improvement of adequate preventative and treatment strategies, guide 
scientific efforts, and aid education and communication to health professionals and the 
public with regard to women’s health in and around the menopausal transition and at 
different postmenopausal stages.
In Chapter 4.2 we studied androgens and cardiometabolic factors (e.g. blood pressure, 
cholesterol levels, glucose, and more) in 4 distinct groups of women: regular cycling 
women (e.g. healthy premenopausal women), women with polycystic ovary syndrome 
(PCOS, associated with hyperandrogenism), women with premature ovarian insufficiency 
(POI, associated with hypoandrogenism), and healthy postmenopausal women. 
Hyperandrogenism is characterized by an excess of androgens (such as testosterone) 
whereas hypoandrogenism denotes a lack of androgens in the body. Both states have 
been associated with a higher risk of cardiovascular disease. We found that increased 
levels of androgens were associated with a worse cardiometabolic profile in all 4 groups 
of women. These associations were strongest in women with PCOS. This study suggests 
that androgens could be important factors in women’s cardiometabolic health. 
In Chapter 4.3 we found that certain characteristics of women’s fertile lifespan were 
associated with all-cause mortality and that the findings differed when stratifying the 
analyses for cardiovascular, cancer, and other mortality. More specifically we found that 
late first and last reproduction were protective for all-cause mortality, whereas a longer 
maternal lifespan (e.g. interval between birth of first and last child), post-maternal fertile 
lifespan (e.g. interval between birth of last child and age of menopause), and cumulative 
estrogen exposure were harmful for all-cause mortality. Interestingly, the findings were 
merely evident in 1-child mothers, whereas no associations were found in mothers 
with more children. This study emphasizes the importance of fertility characteristics for 
longevity, and underscores the need of taking into account different aspects of the fertile 
life with regard to women’s later life health.
The final study presented in this thesis (Chapter 4.4) is a systematic review and meta-
analysis of the efficacy and safety of flibanserin as a medical treatment for women 
with hypoactive sexual desire disorder. In total, 5 published and 3 unpublished studies 
including nearly 6.000 women fulfilled the inclusion criteria. The inclusion of published 
and unpublished studies allowed us to capture a complete overview of the benefits and 
risks of flibanserin, without bias. We found that treatment with flibanserin resulted in 
one-half additional sexual satisfying event per month while significantly increasing the 
risk of 4 common side-effects (dizziness, somnolence, nausea, and fatigue). Additionally, 
we found that the quality of the evidence was very low. 
Lastly, Chapter 5 provides a general discussion of the work presented in this thesis. The 
principal findings were summarized, after which we discussed the main methodological 
considerations. Thereafter, the findings and implications of this thesis were reflected on 
from different perspectives, the population, clinical, and policy perspective. The general 
discussion was concluded with a section that delineates several potential directions for 
future research.
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Samenvatting
Achtergrond en doel van dit proefschrift
Het aandeel van ouderen in de bevolking stijgt, een fenomeen dat ook wel vergrijzing wordt 
genoemd. Mensen worden heden ten dage steeds ouder. Dit is een trend die wereldwijd 
te zien is en onder andere verklaard kan worden door toegenomen welvaart, betere 
hygiënische voorzieningen en verbeteringen in de gezondheidszorg. De extra levensjaren 
worden niet per definitie in goede gezondheid doorgebracht. Integendeel, veroudering 
gaat vaak gepaard gaat met meer ziektes en beperkingen in het dagelijks functioneren. 
Dit geldt voor mannen, maar nog meer voor vrouwen. Ook al leven vrouwen gemiddeld 
genomen 6 tot 8 jaar langer dan mannen, doorgaans worden deze extra jaren in een 
slechtere gezondheid doorgebracht. In het Engels wordt dit uitgedrukt met het gezegde 
‘men die quicker, women get sicker’. Voorts zijn er factoren waar vrouwen gedurende hun 
leven mee te maken krijgen die specifiek voor hen zijn. Hierbij valt bijvoorbeeld te denken 
aan zwangerschap en de menopauze. Deze gebeurtenissen kunnen zelfs op oudere 
leeftijd de gezondheid van vrouwen blijven beïnvloeden.
Gezondheidsonderzoek focust zich doorgaans op losse risicofactoren (zoals roken of 
hoge bloeddruk) en op ziekten en mortaliteit. In feite focust slechts een klein gedeelte 
van gezondheidsonderzoek zich op het daadwerkelijke gezondheidsaspect. Deze 
benadering beperkt het begrip dat wij hebben van gezonde veroudering en de factoren 
die gepaard gaan met het verwerven, behouden en verbeteren van onze gezondheid. 
Het verleggen van de focus van een ziekte-gecentreerde naar een gezondheids-
gecentreerde benadering sluit beter aan bij onze verouderende populatie, waarin het 
lijden aan chronische ziekten of beperkingen eerder regel dan uitzondering is. Zonder 
meer reiken de voordelen van een gezondheidsbenadering verder dan het bevorderen 
van gezondheid van het individu. Zo kan een gezondheidsbenadering een positief effect 
hebben op verschillende niveaus in de samenleving, variërend van het huishouden tot 
het bestuurlijke niveau.
Het doel van dit proefschrift is om vanuit een geïntegreerde, genderspecifieke 
levensloopbenadering inzicht te verkrijgen in gezondheid en veroudering van mannen 
en vrouwen van middelbare en oudere leeftijd. De meeste studies die beschreven 
staan in dit proefschrift, zijn onderdeel van de Rotterdam Studie. Dit is een groot 
bevolkingsonderzoek onder 15.000 mensen van 45 jaar en ouder uit de Rotterdamse wijk 
Ommoord. De overige studies die beschreven staan in dit proefschrift, zijn systematische 
literatuuronderzoeken.
Als eerste stap is getracht door middel van systematisch literatuuronderzoek vast te 
stellen wat wereldwijd de micro- en macro-economische impact is van chronische ziekten 
in de maatschappij. Daarna werd een instrument ontwikkeld om gezonde veroudering in 
de Rotterdam Studie te meten. Daarbij is specifiek gekeken naar verschillen in gezonde 
veroudering tussen mannen en vrouwen in verschillende leeftijdsgroepen. Ook is het 
door de Amerikaanse hartstichting ontwikkelde concept van cardiovasculaire gezondheid 
toegepast op de deelnemers van de Rotterdam Studie. Specifiek is gekeken naar het 
verband tussen geslachtshormonen, waaronder oestrogenen en testosteron, met 
cardiovasculaire gezondheid. In het slothoofdstuk is de aandacht specifiek gericht op 
de gezondheid van vrouwen. Zo is er een definitie voor gezonde menopauze ontwikkeld 
en is het belang van vrouwspecifieke kenmerken van de reproductieve levensfase, zoals 
zwangerschap en timing van de menopauze, voor gezondheid bij vrouwen op latere 
leeftijd in kaart gebracht.
Bevindingen per hoofdstuk
In hoofdstuk 1 wordt de achtergrond van dit proefschrift beschreven. Hoofdstuk 2 
beschrijft de economische impact van chronische ziekten op huishoudens, op armoede, 
gezondheidsuitgaven en inkomen op nationaal niveau. Hiervoor werden 2 systematische 
literatuuronderzoeken gedaan. Als chronische ziekten werden hart- en vaatziekten, 
kanker, diabetes mellitus (suikerziekte), chronisch obstructief longlijden en chronisch 
nierfalen gekozen. 
Het eerste literatuuronderzoek staat in hoofdstuk 2.1 en had als focus de economische 
impact op het niveau van huishoudens en armoede. In totaal voldeden 64 studies aan de 
inclusiecriteria die vooraf gesteld waren. Deze studies bevatten gezamenlijk meer dan 
835 miljoen mensen. De conclusie uit het literatuuronderzoek was dat chronische ziekten 
in toenemende mate een belasting vormen voor de financiële situatie van huishoudens 
en dat wereldwijd steeds meer huishoudens in armoede geraken door de korte en lange 
termijn gevolgen van deze ziekten. 
In hoofdstuk 2.2 werd ten aanzien van de macro-economische impact van chronische 
ziekten een geleidelijke en wereldwijde stijging in uitgaven aan de gezondheidszorg en 
grote verliezen op het gebied van nationaal inkomen geobserveerd. Voorts bleek uit 
beide literatuuronderzoeken dat de economische impact van chronische ziekten in de 
gebieden Afrika, Zuid-Amerika en het Midden-Oosten sterk onderbelicht is en dat maar 
weinig studies de impact voor mannen en vrouwen apart bekeken. Op basis van deze 
bevindingen deden wij de aanbeveling dat toekomstig onderzoek zich specifiek op deze 
regio’s zou moeten richten en daarin onderscheid zou moeten maken tussen de impact 
die chronische ziekten op mannen en vrouwen afzonderlijk kunnen hebben.
Hoofdstuk 3.1 gaat over de ontwikkeling van een maat om gezonde veroudering bij 
individuen en populaties te meten. Daarbij werd gekeken naar verschillen in leeftijd 
en geslacht en werd onderzoek gedaan naar de relatie tussen gezonde veroudering 
en mortaliteit. In de Rotterdam Studie was gedetailleerde informatie beschikbaar, die 
nodig was om een dergelijk meetinstrument te ontwikkelen. In totaal bevatte de maat 
voor gezonde veroudering 7 verschillende biopsychosociale domeinen, die allemaal 
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gemakkelijk te meten waren met behulp van vragenlijsten. Mannen hadden optimalere 
gezonde verouderingsscores dan vrouwen. Dit was het geval in alle leeftijdsgroepen 
(65-69 jaar, 70-74 jaar, 75-79 jaar, 80-84 jaar, en ≥85 jaar). Mannen hadden vaker dan 
vrouwen meer dan één chronische ziekte. Echter, vrouwen hadden in vergelijking met 
mannen een slechtere geestelijke gezondheid, een slechter fysiek functioneren, meer 
pijn en een lagere kwaliteit van leven. Mannen en vrouwen lieten beiden een daling in 
de gezonde verouderingsscore zien bij het ouder worden en deze daling was sterker bij 
vrouwen. Tot slot was bij mannen en vrouwen gezonde veroudering gerelateerd aan een 
lager risico op overlijden.
Hoofdstuk 3.2 gaat over de relatie tussen de gezonde verouderingsscore en verschillende 
markers van biologische veroudering. Biologische veroudering werd gemeten met een 
aantal afgeleiden van het genetische profiel van mensen. De gezonde verouderingsscore 
bleek sterk geassocieerd te zijn met deze markers van biologische veroudering in mannen 
en vrouwen, maar een groot deel van het effect werd verklaard door leeftijd. 
Hoofdstuk 3.3 beschrijft de studie van het verband tussen vrouwspecifieke kenmerken 
van de reproductieve levensfase, geslachtshormonen (zoals estradiol en androgenen) 
en gezonde veroudering in postmenopauzale vrouwen van de Rotterdam Studie. 
Hieruit bleek dat vrouwen met een latere eerste menstruatie, een latere menopauze, 
een langere reproductieve levensperiode (leeftijd van menopauze minus leeftijd van 
menarche) en vrouwen met meer kinderen, betere gezonde verouderingsscores hadden. 
Ook hadden vrouwen met hogere estradiolwaarden, lagere en dus minder optimale 
gezonde verouderingsscores. Er werd geen verband gevonden met androgenen.
Hoofdstuk 3.4 gaat over het verband tussen estradiol, testosteron, de vrije androgeen 
index en het geslachtshormoon bindende eiwit SHBG met het door de Amerikaanse 
hartstichting ontwikkelde concept van cardiovasculaire gezondheid. Cardiovasculaire 
gezondheid werd door hen in 2010 gedefinieerd als het gelijktijdig hebben van normale 
waarden voor cholesterol, bloeddruk en glucose alsmede het hebben van optimaal 
gezond gedrag (niet roken, voldoende bewegen, gezond eten en geen overgewicht). In 
deze studie werd gevonden dat vooral SHBG gerelateerd was aan cardiovasculaire 
gezondheid bij zowel mannen als vrouwen.
In hoofdstuk 4 ligt de focus specifieker op de seksuele, reproductieve en menopauze 
gezondheid van vrouwen. 
Hoofdstuk 4.1 beschrijft de uitkomsten van een expertmeeting die werd georganiseerd 
om het concept van gezonde menopauze vorm te geven. In de expertmeeting werd 
vastgesteld dat de gezonde menopauze een dynamische staat van zijn is waarbij de 
ervaren tevredenheid ten aanzien van het biopsychosociale functioneren van de vrouw 
centraal moet staan.
Hoofdstuk 4.2 beschrijft de studie van androgenen en cardiometabole factoren (zoals 
bloeddruk, cholesterol en glucosewaarden) in vier groepen vrouwen: vrouwen met 
een regelmatige menstruatiecyclus (gezonde premenopauzale vrouwen), vrouwen 
met het polycysteus ovarium syndroom (PCOS, een hyperandrogene staat), vrouwen 
met premature ovariële insufficiëntie (POI, een hypoandrogene staat) en gezonde 
postmenopauzale vrouwen. In de literatuur wordt zowel hyperandrogenisme (teveel 
androgenen) als hypoandrogenisme (te weinig androgenen) in verband gebracht met 
een verhoogd risico op hart- en vaatziekten. Uit deze studie kwam in alle vier de groepen 
vrouwen naar voren dat hogere androgeenwaarden verband hielden met een slechter 
cardiometabool profiel. De verbanden waren het sterkst voor vrouwen met PCOS. Deze 
bevindingen impliceren dat androgenen met betrekking tot het ontwikkelen van hart- en 
vaatziekten een rol kunnen spelen. 
In hoofdstuk 4.3 staat beschreven dat vrouwspecifieke kenmerken van de reproductieve 
levensfase gerelateerd zijn aan mortaliteit en dat de bevindingen veranderen wanneer 
de doodsoorzaken onderverdeeld worden in drie groepen (cardiovasculair, oncologisch 
en overige mortaliteit). Bijzonder was dat vrouwen die hun eerste of hun laatste kind 
op oudere leeftijd kregen een lager risico op overlijden hadden. Verder bleek ook dat 
vrouwen met een langer interval tussen het eerst en laatstgeboren kind, vrouwen met 
een langer interval tussen laatstgeboren kind en de start van de menopauze en vrouwen 
met een hogere blootstelling aan oestrogenen gedurende het leven een hoger risico 
hadden op overlijden. Deze studie onderstreept het belang om rekening te houden met 
eerdere levensfasen t.a.v. gezondheid bij vrouwen op latere leeftijd. 
De laatste studie van dit proefschrift (hoofdstuk 4.4) is een systematische review en meta-
analyse naar de effectiviteit en veiligheid van flibanserin als medicamenteuze behandeling 
voor vrouwen met verminderd seksueel verlangen. In totaal werden 5 gepubliceerde en 3 
ongepubliceerde studies met in totaal bijna 6.000 vrouwen geïncludeerd. Het meenemen 
van zowel gepubliceerd als ongepubliceerd werk stelden ons in de gelegenheid om een 
compleet overzicht van de gunstige effecten en bijwerkingen van flibanserin te verkrijgen. 
Eén van de uitkomsten was dat flibanserin-gebruiksters een half keer per maand vaker 
seksuele activiteit rapporteerden waar ze tevreden over waren dan placebo-gebruiksters. 
Het risico op bijwerkingen was hoger in de flibanserin groep. De meest voorkomende 
bijwerkingen waren duizeligheid, slaperigheid (somnolentie), misselijkheid en moeheid. 
Voorts bleek dat de kwaliteit van de onderzochte studies laag was. 
Tot slot staat in hoofdstuk 5 de beschouwing van de bevindingen van dit proefschrift. 
Als eerste staat er een samenvatting van alle bevindingen, waarna de belangrijkste 
methodologische overwegingen worden bediscussieerd. Daarna volgt een reflectie 
op de bevindingen en implicaties vanuit 3 verschillende perspectieven: het populatie 
perspectief, de klinische praktijk, en het beleidsmatige perspectief. Het hoofdstuk wordt 
afgesloten met aanbevelingen voor toekomstig onderzoek.
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